Page last updated: 2024-11-04

capsaicin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Capsaicin is a pungent compound found in chili peppers, responsible for their heat. It is synthesized in plants through a complex pathway involving the amino acid L-phenylalanine and vanillylamine. Capsaicin acts on the TRPV1 receptor, a sensory neuron receptor that responds to heat, causing the burning sensation associated with spicy foods. It also has various pharmacological effects, including pain relief, anti-inflammatory properties, and potential benefits for weight management. Capsaicin is studied for its potential applications in medicine, food science, and other fields. The compound's unique ability to activate TRPV1 receptors makes it a valuable tool for understanding pain mechanisms and developing new pain therapies. Capsaicin's role in plant defense against herbivores and its potential impact on human health have led to ongoing research on its biosynthesis, effects, and applications.'

ALGRX-4975: an injectable capsaicin (TRPV1 receptor agonist) formulation for longlasting pain relief [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

capsaicinoid : A family of aromatic fatty amides produced as secondary metabolites by chilli peppers. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
CapsicumgenusA plant genus of the family SOLANACEAE. The hot peppers yield CAPSAICIN, which activates VANILLOID RECEPTORS. Several varieties have sweet or pungent edible fruits that are used as vegetables when fresh and spices when the pods are dried.[MeSH]SolanaceaeA plant family of the order SOLANALES, class MAGNOLIOPSIDA. Among the most noted are POTATOES; TOMATOES; CAPSICUM (green and red peppers); TOBACCO; and BELLADONNA.[MeSH]
CapsicumgenusA plant genus of the family SOLANACEAE. The hot peppers yield CAPSAICIN, which activates VANILLOID RECEPTORS. Several varieties have sweet or pungent edible fruits that are used as vegetables when fresh and spices when the pods are dried.[MeSH]SolanaceaeA plant family of the order SOLANALES, class MAGNOLIOPSIDA. Among the most noted are POTATOES; TOMATOES; CAPSICUM (green and red peppers); TOBACCO; and BELLADONNA.[MeSH]
CapsicumgenusA plant genus of the family SOLANACEAE. The hot peppers yield CAPSAICIN, which activates VANILLOID RECEPTORS. Several varieties have sweet or pungent edible fruits that are used as vegetables when fresh and spices when the pods are dried.[MeSH]SolanaceaeA plant family of the order SOLANALES, class MAGNOLIOPSIDA. Among the most noted are POTATOES; TOMATOES; CAPSICUM (green and red peppers); TOBACCO; and BELLADONNA.[MeSH]

Cross-References

ID SourceID
PubMed CID1548943
CHEMBL ID294199
CHEBI ID3374
CHEBI ID94524
SCHEMBL ID8086
SCHEMBL ID8085
MeSH IDM0003308
PubMed CID555056
CHEMBL ID84735
SCHEMBL ID1157926
MeSH IDM0003308
PubMed CID2548
CHEMBL ID3187928
MeSH IDM0003308

Synonyms (451)

Synonym
capsaicin, natural
LS-14673
MLS002154049
smr000718774
BRD-K50590187-001-06-6
BRD-K37056290-001-01-1
(e)-8-methyl-n-vanillyl-6-nonenamide
trans-8-methyl-n-vanillyl-6-nonenamide
ngx-7325
zostrix hp
mr3h3
ngx-4010
transacin
trans-capsaicin
SDCCGMLS-0066678.P001
(e)-capsaicin
tq-1018
zostrix
ngx-1998
axsain
ngx-3781
qutenza
(6e)-n-{[4-hydroxy-3-(methyloxy)phenyl]methyl}-8-methylnon-6-enamide
6-nonenamide, n-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methyl-, (e)-
einecs 206-969-8
brn 2816484
n-(4-hydroxy-3-methoxybenzyl)-8-methylnon-trans-6-enamide
6-nonenamide, 8-methyl-n-vanillyl-, (e)-
capsaicin [in oleoresin of capsicum]
8-methyl-n-vanillyl-6-nonenamide, (e)-
nsc 56353
n-((4-hydroxy-3-methoxyphenyl)methyl)-8-methyl-6-nonenamide, (e)-
capsaicin [usan]
ccris 1588
n-(4-hydroxy-3-methoxybenzyl)-8-methylnon-6-enamide
fema no. 3404
capsaicin patch
6-nonenamide, n-((4-hydroxy-3-methoxyphenyl)methyl)-8-methyl-, (e)-
6-nonenamide, n-((4-hydroxy-3-methoxyphenyl)methyl)-8-methyl-, (6e)-
caswell no. 158
epa pesticide chemical code 070701
styptysat
hsdb 954
nci-c56564
(e)-n-((4-hydroxy-3-methoxyphenyl)-methyl)-8-methyl-6-nonenamide
6-nonenamide, (e)-n-((4-hydroxy-3-methoxy-phenyl)methyl)-8-methyl
c18h27no3
6-nonenamide, (e)-
capsaicine
capsaicin (in oleoresin of capsicum)
nsc56353
nsc-56353
neurotoxic
depletes substance p
PRESTWICK_204
e-capsaicin
IDI1_034018
PRESTWICK2_000879
IDI1_000354
BPBIO1_001053
SMP2_000337
PRESTWICK3_000879
BSPBIO_000957
BSPBIO_002917
NCGC00090853-01
UPCMLD-DP092:001
bdbm20461
(6e)-n-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methylnon-6-enamide
chembl294199 ,
(e)-n-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methylnon-6-enamide
404-86-4
C06866
capsaicin ,
capsaicin, >=95%, from capsicum sp.
UPCMLD-DP092
capsaicin (jan/usp)
zostrix (tn)
D00250
SPECTRUM5_000538
UPCMLD-DP092:002
NCGC00090853-07
NCGC00090853-02
CHEBI:3374 ,
NCGC00090853-06
(6e)-n-(4-hydroxy-3-methoxybenzyl)-8-methylnon-6-enamide
NCGC00090853-08
NCGC00090853-03
isodecenoic acid vanillylamide
SPECTRUM1501128
BSPBIO_001548
MEGXP0_001448
NCGC00090853-09
NCGC00090853-04
ngx 4010
8-methyl-n-vanillyl-trans-6-nonenamide
gtpl2486
zacin
C-1700
capsaicin, from capsicum sp., >=50% (hplc)
HMS2092D21
HMS1989N10
HMS2089N11
ausanil
capzasin-hp
mioton
dolenon
algrx-4975
ratden pe 40
togarashi orenji
ovocap
cntx-4975
algrx 4975
HMS501B16
HMS1791N10
HMS1361N10
capsaicin (natural)
M1149
HMS1570P19
HMS1921H11
NCGC00017337-02
NCGC00090853-10
NCGC00090853-11
NCGC00090853-12
HMS2097P19
8-methyl-n-vanillyl-6e-nonenamide
LMFA08020085
AKOS007930159
capsaicin [usp:inn]
s07o44r1zm ,
unii-s07o44r1zm
tox21_200315
NCGC00257869-01
pharmakon1600-01501128
nsc-757844
nsc757844
dtxsid9020241 ,
dtxcid30241
tox21_110817
cas_404-86-4
nsc_2548
bdbm86537
HMS2230O23
CCG-39908
CCG-39657
NCGC00017337-05
NCGC00017337-04
NCGC00017337-03
NCGC00017337-13
NCGC00017337-10
NCGC00017337-09
NCGC00017337-08
NCGC00017337-07
NCGC00017337-11
NCGC00017337-06
NCGC00017337-12
vanilloid
capsicine
7553-53-9
6-nonenamide, n-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methyl-
STL372889
S1990
trans-capsaicin-d3
capsaicin [usp-rs]
capsaicin [who-dd]
capsaicin (constituent of capsicum) [dsc]
capsaicin [mart.]
capsaicin [vandf]
n-(4-hydroxy-3-methoxybenzyl)-8-methyl-6-nonenamide [fhfi]
capsaicin [mi]
capsaicin [ema epar]
capsaicin [jan]
capsaicin [inn]
capsaicin [hsdb]
capsaicin [orange book]
capsaicin [usp monograph]
capsaicin [inci]
EI-125
HY-10448
CS-1518
BBL027836
SCHEMBL8086
SCHEMBL8085
KS-5181
AB00053098-11
(e)-n-[(4-hydroxy-3-methoxy-phenyl)methyl]-8-methyl-non-6-enamide
(e)-n-(4-hydroxy-3-methoxybenzyl)-8-methylnon-6-enamide
trans-n-((4-hydroxy-3-methoxyphenyl)methyl)-8-methyl-6-nonenamide
(6e)-n-(4-hydroxy-3-methoxybenzyl)-8-methyl-6-nonenamide #
(e)-n-[(4-hydroxy-3-methoxyphenyl)-methyl]-8-methyl-6-nonenamide
n-((4-hydroxy-3-methoxyphenyl)methyl)-8-methyl-6-nonenamide
adlea
AC-10114
n-[(4-hydroxy-3-methoxyphenyl)methyl]-6e-8-methyl-nonenamide
(e)-n-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methyl-6-nonenamide
HB1179
HMS3649N15
HMS3402N10
AB00053098_12
mfcd00017259
4dy ,
SR-05000001861-6
sr-05000001861
capsaicin, united states pharmacopeia (usp) reference standard
capsaicin, analytical standard
CHEBI:94524
epsilon-capsaicin
isodecenoate
(e)8-methyl-n-vanillyl-6-nonenamide
(e)-8-methyl-n-vanillyl-6-nonenamide(8cl)
SR-05000001861-1
SR-05000001861-5
SR-05000001861-4
capsaicin, european pharmacopoeia (ep) reference standard
capsaicin, pharmaceutical secondary standard; certified reference material
6-nonenamide, n-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methyl-, (6e)-
capsaicin, certified reference material, tracecert(r)
SBI-0052593.P002
NCGC00017337-18
1217899-52-9
DB06774
capsaicin; 8-methyl-n-vanillyl-trans-6-nonenamide; ngx-4010
qutenza;vanilloid
capsacin(e)
isoamyl4-methoxycinnamate
methyl-n-vanillyl-6-noneneamide
CS-0181240
HMS3678F11
capsaicin,(s)
6-nonenamide,n-((4-hydroxy-3-methoxyphenyl)methyl)-8-methyl-,(6e)-
SR-05000001861-9
HMS3414F11
Q273169
AMY25669
NCGC00017337-17
8-methyl-n-vanillyl-(trans)-6-nonenamide
capsaicin 10 microg/ml in acetonitrile
HY-10448A
capsaicinoid
STARBLD0019180
bronson soothe pain relief
capsaicin (mart.)
capsaicina
sherman and clark pain relieving
neuritrx
avon hexashield arthritis pain reliefcream capsaisin
leader capsaicin pain relief cream
coralite medicated heat
ageranium patch
capzix
capzasin hp arthritis pain relief
astrapharm chilli brand external medicated
guardania pain
wellness products victorx
capsaicin 0.25%
good neighbor capsaicin heat patch for back
nufabrx neck wrap
hot spotpoint relief
capsaicinexternal analgesic
awaye
capsaicin 0.075 percent
fyzical sports pain relief 2 mild
flavor and extract manufacturers' association no. 3404
nufabrx back wrap
nufabrx arm sleeve
astrapharm chilli brand
capsaicin (usp:inn)
capsaicin 0.1 percent
capsaicin 0.025% topical patch
painbloc24
capsaicin 0.05%
rite aid capsicum hot
hot pain relief
capsimide
capsaicinum
beerx muscle and joint pain relief
capsaisin 0.1%
rugby arthritis pain relieving
fyzical sports pain relief
nufabrx medicine infused ankle sleeve
nobleaid capsaid
castiva warming
usepa/opp pesticide code: 070701
equi-blockdt formula
cvs roll-on
miracle plus overnightpain relieving
frankie avalons zero pain roll on
zostrix high potency foot pain relief
equate capsaicin pain relieving
satogesic hot
(6e)-n-
painazin cp
avon hexashield arthritis pain relief
capsaisin
nufabrx medicine infused socks
capsaicin (usp monograph)
2-count heat patches
screamin hot toast
revlex arthritis pain relief
dch arthritis pain relief roll-on
capsaicin 0.15
nufabrx calf sleeve
medicated heat
capsaicin 0.15%
leader capsaicin
family care arthritis pain relief
red hot
penetrex(r) arthritis pain relief
omega 3
nufabrx foot/ankle sleeve
nufabrx lower leg sleeve xs/s
careall arthritis and muscle
dr. harveys herbal motion pain formula
medicated compression sock
capsaicin cream
nufabrx hand/wrist sleeve
qc arthritis pain relief
rugby arthritis pain relievingtopical analgesic
rugby capsaicin
equi-blockoriginal
sure result sr relief
livreliefpain relief
nufabrx ankle sleeve
rugby capsaicin cream
biomega
zostrix original strength
wellpatch warming pain relief
nufabrx lower leg sleeve m/l
good neighbor pharmacy capsaicin
capsaicin heat patches back and large areas
campo pharma muscle hot
nufabrx knee sleeve
walgreens arthritis pain relief capsaicin analgesic
capsaicin extract
solstice capsaicin patch hot
cvs capsaicin
capsaicin hp arthritis pain relief
dusel warm arthritis dead sea salt therapy
toplast hot capsaicin 0.025percent
gellert joint care
fast arthritis aidpain relieving
nufabrx lower leg sleeve xl/xxl
capsaicin (usp-rs)
rezil
neuriterx
hempvana ultra strength pain relief cream-deep heat
better nature pain relief balmx
earths care arthritis
capsaicin heat patches pain relief
medirelief hot
flexxsonicpain relief
capsaicintopical analgesic
a2a arthritis
rugby capsaicinexternal analgesic
cvs medicated heat 1 ct
capsaicin pain relief
capsaicin heat
sinsinpas hot large
nufabrx lower leg sleeve
walgreens capsaicin hot
bio-sorb
spraypain away
nufabrx wrist sleeve
capsaicin hot patches
pure reliefpenetrating pain relief
wellness products j-flex
melt pain away
capsaicin 0.075%
retadolorpain relief
capsaicin (constituent of capsicum)
capsacin
cannavera pain relief
pure relief
hurt blocker propain relief
sure relief sr relief
cvs capsaicin arthritis pain relief
meijer capsaicin
EN300-7544118
826 - capsaicin and heat units in chilli powder
CHEMBL84735
1,3,4,6-tetrathiapentalene-2,5-dione, 98%
SR-01000636303-1
[1,3]dithiolo[4,5-d][1,3]dithiole-2,5-dione
1,3,4,6-tetrathiapentalene-2,5-dione
64394-45-2
T1132
[1,3]dithiolo[4,5-d]-1,3-dithiole-2,5-dione
CCG-46617
FT-0606492
AKOS015856645
thiapendione
TD8105
SCHEMBL1157926
[1,3]dithiolo[4,5-d][1,3]dithiole-2,5-dione #
XMQJUIFJLYEFQR-UHFFFAOYSA-N
AC-28116
CS-W006396
mfcd00010403
DS-7375
1,3,4,6-terathiapentalene-2,5-dione
A853807
c4o2s4
HMS3393O07
HMS3266C10
KBIO1_000354
DIVK1C_000354
brn 4261852
SPECTRUM4_001739
SPECTRUM_000303
BIO1_000957
BIO2_000268
BIO1_000468
BIO1_001446
BIO2_000748
KBIO2_003351
KBIO3_002417
KBIO2_002836
KBIOGR_002158
KBIOSS_000268
KBIOSS_000783
KBIO2_000783
KBIOGR_000268
KBIO2_005919
KBIO2_005404
KBIO2_000268
KBIO3_000536
KBIO3_000535
SPBIO_002878
SPBIO_000820
SPECTRUM2_000770
SPECTRUM3_001449
PRESTWICK1_000879
NINDS_000354
PRESTWICK0_000879
8-methyl-n-vanillyl-6-nonenamide
n-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methylnon-6-enamide
FT-0664231
n-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methyl-6-nonenamide
FT-0638549
FT-0600038
NCGC00017337-15
HMS3369I19
HMS3369C16
CHEMBL3187928
AKOS028109365
mfcd00209942
n-vanillyl-8-methyl-6-nonenamide
BCP10026
Q27166370
zucapsaicin;civamide;cis-capsaicin
DTXSID40859357
SY103308

Research Excerpts

Toxicity

Capsaicin inhalation cough provocation test by dosimeter method is a safe and specific tool for measuring cough reflex sensitivity. TQ and capsaicin have shown efficacy in alleviating all of the acrylamide's toxic insults in the current treatment regime.

ExcerptReferenceRelevance
"We examined the mechanism by which capsaicin produces its toxic effects on cultures of rat sensory neurons."( Capsaicin-induced neurotoxicity in cultured dorsal root ganglion neurons: involvement of calcium-activated proteases.
Bleakman, D; Chard, PS; Miller, RJ; Savidge, JR, 1995
)
0.29
" While covalent modification of protein and nucleic acids leads to toxicity including necrosis, mutagenesis, and carcinogenesis, suicidal inhibition of microsomal cytochrome P450 may prohibit further activation of capsaicin and also of other toxic xenobiotics."( Capsaicin, a double-edged sword: toxicity, metabolism, and chemopreventive potential.
Lee, SS; Surh, YJ, 1995
)
0.29
" While no patients had adverse outcomes attributed to OC exposure, practitioners assessing exposure should consider the potential for pulmonary and ocular toxicity."( Oleoresin capsicum (Cap-Stun) toxicity from aerosol exposure.
Stremel, KR; Watson, WA; Westdorp, EJ,
)
0.13
" Oral LD50 values were 118."( Acute oral toxicity of capsaicin in mice and rats.
Saito, A; Yamamoto, M, 1996
)
0.29
" Toxic effects were assessed by incorporation of [3H]L-leucine into cellular proteins in the presence of capsazepine, the VR1 vanilloid receptor antagonist and Ruthenium red or tyrosine or calcium."( Cytotoxicity of capsaicin in monkey kidney cells: lack of antagonistic effects of capsazepine and Ruthenium red.
Carratú, MR; Cochereau, C; Creppy, EE; Cuomo, V; Ennamany, R; Richeux, F; Saboureau, D, 2000
)
0.31
"The beneficial and adverse effects of some chemopreventive agents, such as Vitamins A, C, E, beta-carotene, indole-3-carbinol, capsaicin, garlic, and aloe are reviewed."( Beneficial and adverse effects of chemopreventive agents.
Lee, BM; Park, KK,
)
0.13
" In the Ames assay, pure trans-capsaicin was not mutagenic to Salmonella typhimurium or Escherichia coli when dissolved in dimethylsulfoxide and tested at concentrations extending into the toxic range."( Genotoxicity studies with pure trans-capsaicin.
Bley, K; Chanda, S; Erexson, G; Innes, D; Murli, H; Riach, C; Stevenson, F, 2004
)
0.32
" Although > 2 decades of experience has led investigators to consider capsaicin cough challenge testing a safe diagnostic modality, this issue has not been specifically addressed in the literature."( Safety of capsaicin cough challenge testing.
Alva, RV; Dicpinigaitis, PV, 2005
)
0.33
"One hundred twenty-two published studies since 1984 described 4,833 subjects (4,374 adults, 459 children) undergoing capsaicin cough challenge, with no serious adverse events reported."( Safety of capsaicin cough challenge testing.
Alva, RV; Dicpinigaitis, PV, 2005
)
0.33
"A review of the 20-year clinical experience has failed to uncover a single serious adverse event associated with capsaicin cough challenge testing in humans."( Safety of capsaicin cough challenge testing.
Alva, RV; Dicpinigaitis, PV, 2005
)
0.33
"There was no serious side effect of the test in all subjects; two subjects complained of slight nausea; one of heartburn, and three of hoarseness."( [The development and safety of cough provocation test by capsaicin inhalation].
Chen, RC; Lai, KF; Liu, CL; Luo, W; Zheng, JP; Zhong, NS, 2005
)
0.33
"Capsaicin inhalation cough provocation test by dosimeter method is a safe and specific tool for measuring cough reflex sensitivity."( [The development and safety of cough provocation test by capsaicin inhalation].
Chen, RC; Lai, KF; Liu, CL; Luo, W; Zheng, JP; Zhong, NS, 2005
)
0.33
" Natural henna leaves did not show toxic effects, whereas two out of four samples of marketed henna products were shown toxicity effects."( Cytotoxicity of lawsone and cytoprotective activity of antioxidants in catalase mutant Escherichia coli.
Horita, M; Masuoka, N; Ogino, K; Sano, K; Sauriasari, R; Takemura, Y; Tsutsui, K; Wang, BL; Wang, DH, 2007
)
0.34
" As clinicians face a broader spectrum of efficacious treatments, side-effect profiles play an increasingly important role in the development of a pain management regimen."( Safety profile of treatment in diabetic peripheral neuropathic pain.
Robinson-Papp, J; Simpson, DM, 2007
)
0.34
" For these agents, normal dietary intake, doses used in clinical trials, efficacious doses in rodents, and where available, toxic doses are compared."( Putative cancer chemopreventive agents of dietary origin-how safe are they?
Gescher, AJ; Steward, WP; Verschoyle, RD, 2007
)
0.34
" Adverse test article-related changes were only observed in males, not in females, and within the males, only at the high dose (5."( Studies of the toxicological potential of capsinoids: II. A 26-week daily gavage dosing toxicity study of CH-19 Sweet extract in rats.
Bernard, BK; Kodama, T; Masuyama, T; Mochizuki, M; Otabe, A; Tsubuku, S; Watanabe, E, 2008
)
0.35
" It was concluded that the no observed adverse effect level (NOAEL) of dihydrocapsiate was 1000 mg/kg/day for both male and female rats in this 13-week gavage study."( Studies of the toxicological potential of capsinoids: VII. A 13-week toxicity study of dihydrocapsiate in rats.
Bernard, BK; Kodama, T; Masuyama, T; Mochizuki, M; Otabe, A; Tsubuku, S; Watanabe, E, 2008
)
0.35
" It was concluded that the no observed adverse effect level (NOAEL) of dihydrocapsiate was 300 mg/kg/day for male rats and 1000 mg/kg/day for female rats in this 13 week gavage study."( Studies of the toxicological potential of capsinoids: VIII. A 13-week toxicity study of commercial-grade dihydrocapsiate in rats.
Bernard, BK; Kodama, T; Masuyama, T; Mochizuki, M; Otabe, A; Tsubuku, S; Watanabe, E, 2008
)
0.35
"A single, clinically relevant application of instilled or injected 4975 has no observable adverse effect on wound and bone healing after osteotomy or on the structural integrity of exposed muscle and nerve."( Instilled or injected purified natural capsaicin has no adverse effects on rat hindlimb sensory-motor behavior or osteotomy repair.
Boyer, M; Chouinard, L; Doyle, N; Kramer, SM; Longstaff, E; May, JR; Patrick, DJ; Smith, SY; Varela, A, 2009
)
0.35
"Pungent transient receptor potential vanilloid (TRPV1) channel activators have been shown to have broad inhibitory anti-emetic activity against centrally- and peripherally acting challenges but only at doses that have adverse effects on the cardiovascular system and on temperature homeostasis."( Olvanil, a non-pungent vanilloid enhances the gastrointestinal toxicity of cisplatin in the ferret.
Andrews, PL; Chu, KM; Lin, G; Ngan, MP; Percie du Sert, N; Rudd, JA; Wai, MK; Yeung, CK, 2010
)
0.36
" There were no adverse or toxicological changes observed in clinical signs, body weight, food consumption, water intake, ophthalmology, urinalysis, hematology, blood chemistry, organ weights, or histopathology."( Studies of the toxicological potential of capsinoids XIV: a 26-week gavage toxicity study of dihydrocapsiate in rats.
Bernard, BK; Kayahara, T; Kodama, T; Masuyama, T; Ohishi, T; Tsubuku, S; Wagner, BM, 2010
)
0.36
" The most frequently reported treatment-emergent adverse events were transient, mild-to-moderate application site erythema, pain, edema, and papules."( Long-term safety of NGX-4010, a high-concentration capsaicin patch, in patients with peripheral neuropathic pain.
Brown, S; Gazda, S; Lu, SP; Simpson, DM; Tobias, JK; Vanhove, GF; Webster, LR, 2010
)
0.36
"It is concluded that repeated treatments with NGX-4010 administered over a one-year period are generally safe and well tolerated."( Long-term safety of NGX-4010, a high-concentration capsaicin patch, in patients with peripheral neuropathic pain.
Brown, S; Gazda, S; Lu, SP; Simpson, DM; Tobias, JK; Vanhove, GF; Webster, LR, 2010
)
0.36
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
" More adverse events occurred in the capsicum group (n = 13) than in the placebo group (n = 6)."( Effectiveness and safety of topical capsaicin cream in the treatment of chronic soft tissue pain.
Beime, B; Chrubasik, S; Weiser, T, 2010
)
0.36
" Adverse events (AEs), laboratory parameters, vital signs, neurosensory examinations, dermal assessments, treatment-related pain scores, and medication use for treatment-related pain were collected."( Efficacy, safety, and tolerability of NGX-4010, capsaicin 8% patch, in an open-label study of patients with peripheral neuropathic pain.
Lu, B; Murphy, FT; Peppin, JF; Tobias, JK; Vanhove, GF; Webster, LR, 2011
)
0.37
"NGX-4010 in conjunction with any of the three topical anesthetics tested was generally safe and well tolerated and reduced pain over a 12-week period in patients with PDN and PHN."( Efficacy, safety, and tolerability of NGX-4010, capsaicin 8% patch, in an open-label study of patients with peripheral neuropathic pain.
Lu, B; Murphy, FT; Peppin, JF; Tobias, JK; Vanhove, GF; Webster, LR, 2011
)
0.37
" Primary outcomes of interest were patient-reported pain relief of 30% or greater and withdrawals due to adverse events."( Efficacy and safety of neuromodulators in inflammatory arthritis: a Cochrane systematic review.
Buchbinder, R; Richards, BL; van der Heijde, DM; Whittle, SL, 2012
)
0.38
"Based on 3 small trials, which were all at high risk of bias, there is weak evidence that nefopam and capsaicin are superior to placebo in reducing pain in patients with RA, but both are associated with a significant side effect profile."( Efficacy and safety of neuromodulators in inflammatory arthritis: a Cochrane systematic review.
Buchbinder, R; Richards, BL; van der Heijde, DM; Whittle, SL, 2012
)
0.38
"We have formulated a safe and effective, omega-3 rich polyunsaturated fatty acid containing oil-in-water nanoemulsion formulation, for encapsulating and delivering chemically-modified DALDA, a potent mu-opioid peptide analogue, to the CNS."( Analgesic efficacy and safety of DALDA peptide analog delivery to the brain using oil-in-water nanoemulsion formulation.
Amiji, MM; Ferris, C; Kulkarni, P; Shah, L, 2014
)
0.4
" TrkA is a key target in pruritus, and CT327 has potential to become an effective and safe first-in-class treatment."( Topical TrkA Kinase Inhibitor CT327 is an Effective, Novel Therapy for the Treatment of Pruritus due to Psoriasis: Results from Experimental Studies, and Efficacy and Safety of CT327 in a Phase 2b Clinical Trial in Patients with Psoriasis.
Anand, P; Anand, U; Boyce, B; Mainero, V; Robinson, J; Roblin, D; Sandy, J; Wickramasinghe, R; Yosipovitch, G, 2015
)
0.42
" Apart from being valuable in drug development programs, the outlined approach can be used to determine the choice of drug and dose in the treatment of pain in patients with potent and toxic analgesics."( Pharmacotherapy for pain: efficacy and safety issues examined by subgroup analyses.
Dahan, A; Niesters, M; Olofsen, E, 2015
)
0.42
"Topical treatments have gained popularity for general use as an adjunct to systemic drugs in neuropathic pain, but their use produces variable clinical results and local adverse events."( Liposomal topical capsaicin in post-herpetic neuralgia: a safety pilot study.
Andrade, DC; Duarte, KP; Galhardoni, R; Menezes, LM; Okada, M; Sasson, J; Silva, V; Teixeira, MJ; Yeng, LT, 2015
)
0.42
" LC was safe and well tolerated."( Liposomal topical capsaicin in post-herpetic neuralgia: a safety pilot study.
Andrade, DC; Duarte, KP; Galhardoni, R; Menezes, LM; Okada, M; Sasson, J; Silva, V; Teixeira, MJ; Yeng, LT, 2015
)
0.42
" No treatment-related serious adverse events were reported."( Efficacy and safety of nicoboxil/nonivamide ointment for the treatment of acute pain in the low back - A randomized, controlled trial.
Gaubitz, M; Holm, C; Pisternick-Ruf, W; Richter, E; Schiffer, T; Weiser, T, 2016
)
0.43
" Capsaicin treatment was well tolerated and the most frequent treatment-emergent adverse events were application site pain (30 min, 28."( Capsaicin 8% patch repeat treatment plus standard of care (SOC) versus SOC alone in painful diabetic peripheral neuropathy: a randomised, 52-week, open-label, safety study.
Jacobs, H; Katz, N; Long, SK; Ortega, E; Pazdera, L; Perrot, S; Snijder, RJ; Stoker, M; van der Stoep, M; Vinik, AI; Vinik, EJ, 2016
)
0.43
"625% CP may prove to be an effective and safe alternative with which to treat patients with peripheral neuropathy and could replace the high concentration (8%) CP."( Efficacy and Safety of 0.625% and 1.25% Capsaicin Patch in Peripheral Neuropathic Pain: Multi-Center, Randomized, and Semi-Double Blind Controlled Study.
Choi, E; Kim, YC; Lee, PB; Lee, SC; Moon, JY; Nahm, FS, 2017
)
0.46
"Most previous transient receptor potential vanilloid subtype 1 (TRPV1) antagonist programs have been put on hold, mainly because of on-target adverse events: hyperthermia and impaired noxious heat sensation."( Safety, Pharmacokinetics, and Pharmacodynamics Study in Healthy Subjects of Oral NEO6860, a Modality Selective Transient Receptor Potential Vanilloid Subtype 1 Antagonist.
Aubray, R; Brown, W; Chiche, DA; Griffin, A; Hossack, S; Leff, RL; Walker, P, 2017
)
0.46
" Treatment-emergent adverse events (TEAEs) and drug-related TEAEs were reported by 252 (82."( Capsaicin 8% Patch Repeat Treatment in Nondiabetic Peripheral Neuropathic Pain: A 52-Week, Open-Label, Single-Arm, Safety Study.
Attal, N; Ernault, E; Gálvez, R; Maihöfner, C; Moyle, G; Navez, ML; Nurmikko, TJ; Stoker, M, 2017
)
0.46
" All JNJ-39439335-treated participants reported ≥1 treatment-emergent adverse events (TEAE); most common (≥50% incidence) TEAEs in part 1 were feeling hot (79%), thermohypoesthesia (71%), paresthesia (58%) and feeling cold (50%), and in part 2, were minor thermal burns (50%)."( A multiple-dose double-blind randomized study to evaluate the safety, pharmacokinetics, pharmacodynamics and analgesic efficacy of the TRPV1 antagonist JNJ-39439335 (mavatrep).
Flores, CM; Hutchison, JS; Manitpisitkul, P; Mayorga, AJ; Moyer, JA; Romano, G; Shalayda, K; Tatikola, K, 2018
)
0.48
" Analgesic efficacy of lower doses administered over a longer period of time and improved patient counseling techniques to reduce the minor thermal burns can be explored to minimize the adverse events."( A multiple-dose double-blind randomized study to evaluate the safety, pharmacokinetics, pharmacodynamics and analgesic efficacy of the TRPV1 antagonist JNJ-39439335 (mavatrep).
Flores, CM; Hutchison, JS; Manitpisitkul, P; Mayorga, AJ; Moyer, JA; Romano, G; Shalayda, K; Tatikola, K, 2018
)
0.48
" Lip volume and adverse event were assessed by two clinicians at various time points: 15 minutes, 1 hour, 2 hours, 3 hours, and 4 hours."( A Single Site, Open Label Clinical Trial, Evaluating the Duration, Efficacy, and Safety of a Novel Lip Plumper.
Alhaddad, M; Boen, M; Goldman, MP; Guiha, I; Wu, DP, 2018
)
0.48
" TQ and capsaicin have shown efficacy in alleviating all of the acrylamide's toxic insults in the current reproductive toxicity model."( Therapeutic effects of thymoquinone or capsaicin on acrylamide-induced reproductive toxicity in rats mediated by their effect on oxidative stress, inflammation, and tight junction integrity.
Abd Al Haleem, EN; Arafa, HMM; Hasan, WYS, 2022
)
0.72

Pharmacokinetics

Capsaicin levels declined very rapidly, with a mean population elimination half-life of 1. This is consistent with a prolongation in the elimination of capsaicin.

ExcerptReferenceRelevance
"Nonanoyl vanillylamide (nonivamide NVA) was compared with trans-8-methyl-N-vanillyl-nonenamide (capsaicin, CAP) with regard to their pharmacokinetic properties, their potency in stimulating primary afferent neurons and depleting them of substance P and somatostatin in rats."( Comparison of nonivamide and capsaicin with regard to their pharmacokinetics and effects on sensory neurons.
Donnerer, J; Lembeck, F; Skofitsch, G, 1984
)
0.27
" This is consistent with a prolongation in the elimination half-life of antipyrine in animals pretreated with capsaicin (2."( Effects of capsaicin on the pharmacokinetics of antipyrine, theophylline and quinine in rats.
Clark, CR; Ferry, DG; Kepple, M; Nyika, S; Wanwimolruk, S, 1993
)
0.29
" administration of DA-5018, 1, 2, and 5 mg kg-1, the pharmacokinetic parameters of DA-5018 were independent of the dose ranges studied."( Pharmacokinetics of a non-narcotic analgesic, DA-5018, in rats.
Kim, SH; Kim, WB; Lee, JJ; Lee, MG; Lee, SD; Shim, HJ; Yang, J, 1998
)
0.3
" The purposes of this study were to explore the in vivo pharmacodynamic responses of nonivamide in hydrogels using Wistar rat as an animal model and to correlate the in vivo results with in vitro topical application."( In vitro topical application and in vivo pharmacodynamic evaluation of nonivamide hydrogels using Wistar rat as an animal model.
Fang, JY; Leu, YL; Tsai, YH; Wang, YY, 2002
)
0.31
") on hyperalgesia and pain after a tissue injury in human volunteers, and to describe the relationship between pharmacokinetic and pharmacodynamic data."( Intravenous dextromethorphan to human volunteers: relationship between pharmacokinetics and anti-hyperalgesic effect.
Dahl, JB; Dirks, J; Duedahl, TH; Larsen, NE; Petersen, KB; Romsing, J, 2005
)
0.33
" In this report, we describe a noninvasive pharmacodynamic model in which topical application of capsaicin is utilized to induce the release of endogenous CGRP and a vasodilatory response which can be measured using laser Doppler imaging."( Investigation of the species selectivity of a nonpeptide CGRP receptor antagonist using a novel pharmacodynamic assay.
Baskin, EP; Corcoran, HA; Hargreaves, RJ; Hershey, JC; Kane, SA; Koblan, KS; Mosser, S; Salvatore, CA; Williams, TM, 2005
)
0.33
"The purpose of this study was to identify the mediators involved in capsaicin-induced vasodilation in the human skin and to evaluate a pharmacodynamic model for the early clinical evaluation of calcitonin gene-related peptide (CGRP) receptor antagonists."( Calcitonin gene-related peptide8-37 antagonizes capsaicin-induced vasodilation in the skin: evaluation of a human in vivo pharmacodynamic model.
de Hoon, JN; De Lepeleire, I; Depré, M; Kane, SA; Rogiers, A; Sinclair, SR; Van der Schueren, BJ; Van Hecken, A; Vanmolkot, FH, 2008
)
0.35
"The present research was conducted to study the effect of capsicum on plasma glucose level and to correlate its action with the pharmacokinetic properties of capsaicin in capsicum."( Pharmacokinetic and the effect of capsaicin in Capsicum frutescens on decreasing plasma glucose level.
Chaiyasit, K; Khovidhunkit, W; Wittayalertpanya, S, 2009
)
0.35
"Oxycodone blood concentrations could be described by a one-compartment model but, given the necessarily short timescale of the study, the concentrations were represented by linear interpolation for subsequent pharmacodynamic models."( A pharmacokinetic and pharmacodynamic study of oral oxycodone in a human experimental pain model of hyperalgesia.
Arendt-Nielsen, L; Christrup, LL; Drewes, AM; Foster, DJ; Olesen, AE; Staahl, C; Upton, R, 2010
)
0.36
"This study describes the development of a rapid and sensitive high-performance liquid chromatography-electrospray ionization tandem mass spectrometry (LC-MS/MS) assay for the quantification of [6]-gingerol in mouse plasma and application to a pharmacokinetic study after dose ranging in mice."( Determination and pharmacokinetics of [6]-gingerol in mouse plasma by liquid chromatography-tandem mass spectrometry.
Choi, Y; Choo, HW; Kim, MG; Ryu, JK; Shin, BS; Shin, SW; Yoo, SD, 2012
)
0.38
" This study aimed to examine the pharmacokinetic properties of the formulated capsaicin-loaded nanoemulsions."( Pharmacokinetic characteristics of capsaicin-loaded nanoemulsions fabricated with alginate and chitosan.
Choi, AY; Gwak, HS; Kim, CT; Kim, HO; Lee, KE; Lee, NR; Park, HY, 2013
)
0.39
" Similarly, the in vivo pharmacokinetics parameters also increased, Cmax (from 737."( Preparation, characterization, and pharmacokinetics study of capsaicin via hydroxypropyl-beta-cyclodextrin encapsulation.
Firempong, CK; Shi, F; Sun, C; Xu, X; Yu, J; Zhang, W; Zhao, Y, 2016
)
0.43
" Utilization of this pharmacodynamic biomarker with pharmacokinetic data collected in phase I studies provided the dose-response relationship that assisted in dose selection for the phase II clinical development of LY2951742."( Translational Pharmacodynamics of Calcitonin Gene-Related Peptide Monoclonal Antibody LY2951742 in a Capsaicin-Induced Dermal Blood Flow Model.
Benschop, RJ; Collins, EC; de Hoon, J; Grayzel, D; Monteith, D; Van Hecken, A; Vermeersch, S; Wroblewski, VJ, 2015
)
0.42
" The mean apparent plasma terminal elimination half-life was between 4 and 8 hours."( Safety, Pharmacokinetics, and Pharmacodynamics Study in Healthy Subjects of Oral NEO6860, a Modality Selective Transient Receptor Potential Vanilloid Subtype 1 Antagonist.
Aubray, R; Brown, W; Chiche, DA; Griffin, A; Hossack, S; Leff, RL; Walker, P, 2017
)
0.46
"This work describes an intradermal microdosing approach in humans for pharmacodynamic deductions and pharmacological profiling of compounds."( Clinical testing of three novel transient receptor potential cation channel subfamily V member 1 antagonists in a pharmacodynamic intradermal capsaicin model.
Halldin, MM; Jonzon, B; Kullenberg, T; Segerdahl, M; Sjögren, E; Stålberg, O; Sundgren-Andersson, AK, 2018
)
0.48
"With careful design of a pharmacodynamic translational human pain model, it was possible to rank order TRPV1 efficacy among three investigational TRPV1 antagonists, and to estimate human efficacious concentrations."( Clinical testing of three novel transient receptor potential cation channel subfamily V member 1 antagonists in a pharmacodynamic intradermal capsaicin model.
Halldin, MM; Jonzon, B; Kullenberg, T; Segerdahl, M; Sjögren, E; Stålberg, O; Sundgren-Andersson, AK, 2018
)
0.48
" Marked dose-related increases in pharmacodynamic heat pain assessments were observed in JNJ-39439335-treated participants, which persisted throughout the treatment with no signs of tolerance with repeated dosing."( A multiple-dose double-blind randomized study to evaluate the safety, pharmacokinetics, pharmacodynamics and analgesic efficacy of the TRPV1 antagonist JNJ-39439335 (mavatrep).
Flores, CM; Hutchison, JS; Manitpisitkul, P; Mayorga, AJ; Moyer, JA; Romano, G; Shalayda, K; Tatikola, K, 2018
)
0.48
"JNJ-39439335 (doses 2-50 mg) was well-tolerated, and associated with acceptable multiple-dose pharmacokinetic profile."( A multiple-dose double-blind randomized study to evaluate the safety, pharmacokinetics, pharmacodynamics and analgesic efficacy of the TRPV1 antagonist JNJ-39439335 (mavatrep).
Flores, CM; Hutchison, JS; Manitpisitkul, P; Mayorga, AJ; Moyer, JA; Romano, G; Shalayda, K; Tatikola, K, 2018
)
0.48

Compound-Compound Interactions

Capsaicin was preparatively separated and purified from capsicum oleoresin. Study compared the therapeutic effect of monotherapy with a nonsteroidal anti-inflammatory drug (NSAID) patch vs an NSAID patch combined with transcutaneous electric nerve stimulation.

ExcerptReferenceRelevance
" In this in vivo study, the mammary glands of mature female rats were treated with TPA, and then the effects of genistein alone or in combination with capsaicin on suppression of inflammatory responses were examined."( Anti-inflammatory and anticarcinogenic effect of genistein alone or in combination with capsaicin in TPA-treated rat mammary glands or mammary cancer cell line.
Hwang, JT; Lee, YK; Park, OJ; Shin, JI, 2009
)
0.35
"The present study examined the effects of the mGluR1 antagonist JNJ16259685 (JNJ) and the mGluR5 antagonist 2-methyl-6-phenylethynylpyridine (MPEP) alone and in combination with morphine in two acute pain models (hotplate, warm water tail-withdrawal), and a persistent, inflammatory pain model (capsaicin)."( Metabotropic glutamate antagonists alone and in combination with morphine: comparison across two models of acute pain and a model of persistent, inflammatory pain.
Daugherty, D; Dykstra, LA; Henry, FE; Miller, LL; Picker, MJ, 2011
)
0.37
"Capsaicin was preparatively separated and purified from capsicum oleoresin with a new method combined with aqueous two-phase extraction (ATPE) and chromatography."( Aqueous two-phase extraction combined with chromatography: new strategies for preparative separation and purification of capsaicin from capsicum oleoresin.
Cui, B; Liang, Y; Lu, YM; Tan, CP; Zhao, PP, 2015
)
0.42
"This study compared the therapeutic effect of monotherapy with a nonsteroidal anti-inflammatory drug (NSAID) patch vs an NSAID patch combined with transcutaneous electric nerve stimulation (TENS), a heating pad, or topical capsaicin in the treatment of patients with myofascial pain syndrome (MPS) of the upper trapezius."( Comparison of NSAID patch given as monotherapy and NSAID patch in combination with transcutaneous electric nerve stimulation, a heating pad, or topical capsaicin in the treatment of patients with myofascial pain syndrome of the upper trapezius: a pilot st
An, YJ; Jin, TE; Kim, DH; Park, S; Schepis, EA; Yoon, DM; Yoon, KB, 2014
)
0.4
" The objective of our study was to analyze the potential synergistic anti-tumor effects of BSN combined with CAP on prostate cancer PC-3 cells."( Brassinin Combined with Capsaicin Enhances Apoptotic and Anti-metastatic Effects in PC-3 Human Prostate Cancer Cells.
Ahn, KS; Kim, SH; Kim, SM; Lee, J; Lee, JH; Lee, SG; Nam, D; Oh, EY; Shim, BS, 2015
)
0.42
" With the idea that the difference may translate into an altered spectrum of activity, monofunctional planaramineplatinum(II) complex tris(quinoline)monochloro-platinum chloride (coded as LH5) was synthesized and investigated for its activity against human ovarian A2780, cisplatin-resistant A2780 (A2780(cisR)) and ZD0473-resistnat A2780 (A2780(ZD0473R)) cancer cell lines alone and in combination with the phytochemicals capsaicin (Caps) and curcumin (Cur) as a function of concentration and sequence of administration."( Synthesis of tris(quinoline)monochloroplatinum(II) Chloride and its Activity Alone and in Combination with Capsaicin and Curcumin in Human Ovarian Cancer Cell Lines.
Arzuman, L; Beale, P; Huq, F; Yu, JQ, 2016
)
0.43
"Capsaicin per se or its combination with moderate exercise could be a useful therapy against complications linked to obesity-IR in HE females."( Effects of topical capsaicin combined with moderate exercise on insulin resistance, body weight and oxidative stress in hypoestrogenic obese rats.
Aranda-Fraustro, A; Bravo, G; Carvajal, K; Colado-Velázquez, J; Gómez-Viquez, NL; Mailloux-Salinas, P; Medina-Contreras, JML; Pérez-Torres, I, 2017
)
0.46
" We aimed to evaluate the effects and safety of capsaicin combined with ice stimulation in patients with dysphagia after stroke."( Capsaicin combined with ice stimulation improves swallowing function in patients with dysphagia after stroke: A randomised controlled trial.
Cui, F; Ma, C; Shen, F; Shen, M; Wu, C; Yin, Q; Zhang, H; Zhang, Y, 2020
)
0.56

Bioavailability

Capsaicin has demonstrated effectiveness as an anticancer agent. A restraining factor is its pungency. Nanotechnologies are being employed to enhance the stability and oral bioavailability of lipophilic substances, such as capsaicin.

ExcerptReferenceRelevance
" Previous work has shown that this molecule can sequester nerve growth factor and reduce its bioavailability both in vitro and in vivo."( The role of nerve growth factor in a model of visceral inflammation.
Dmitrieva, N; McMahon, SB; Rice, AS; Shelton, D, 1997
)
0.3
" These data suggest that an orally bioavailable capsaicin analogue, civamide, possessed analgesic activity with respect to several noxious stimuli, including inflammation-induced hyperalgesia, noxious thermal stimulation and nerve injury-induced tactile allodynia."( Antinociception induced by civamide, an orally active capsaicin analogue.
Chen, P; Hua, XY; Hwang, J; Yaksh, TL, 1997
)
0.3
" After oral administration of DA-5018, absorption of the drug from gastrointestinal (GI) tract was fast, but the extent of absolute bioavailability (F) was low; the values were 23."( Pharmacokinetics of a non-narcotic analgesic, DA-5018, in rats.
Kim, SH; Kim, WB; Lee, JJ; Lee, MG; Lee, SD; Shim, HJ; Yang, J, 1998
)
0.3
" Thus, alterations in both plasma extravasation and tissue pH seem to be relevant factors regulating the delivery and bioavailability of this nonsteroidal anti-inflammatory drug to dental pulp."( Effect of inflammation on the delivery of drugs to dental pulp.
Bunczak-Reeh, MA; Hargreaves, KM, 1998
)
0.3
" Also, some nasal preparations have significant adverse effects or are not well absorbed and therefore do not work consistently; others are more challenging to administer as a result of their delivery apparatus."( Intranasal medications for the treatment of migraine and cluster headache.
Bigal, ME; Rapoport, AM; Sheftell, FD; Tepper, SJ, 2004
)
0.32
" In this report, we describe the synthesis and structure-activity relationship of a series of N-aryl cinnamides, the most potent of which (49a and 49b) exhibit good oral bioavailability in rats (F(oral) = 39% and 17%, respectively)."( Discovery of potent, orally available vanilloid receptor-1 antagonists. Structure-activity relationship of N-aryl cinnamides.
Bo, Y; Chakrabarti, PP; Chen, N; Doherty, EM; Fotsch, C; Gavva, N; Han, N; Kelly, MG; Kincaid, J; Klionsky, L; Liu, Q; Norman, MH; Ognyanov, VI; Tamir, R; Treanor, JJ; Wang, X; Zhu, J, 2005
)
0.33
" Exploration of the structure-activity relationships by parallel synthesis identified the essential pharmacophoric elements for antagonism that permitted further optimization via targeted synthesis to provide a potent orally bioavailable and selective TRPV1 modulator 41 active in several in vivo models."( Identification and biological evaluation of 4-(3-trifluoromethylpyridin-2-yl)piperazine-1-carboxylic acid (5-trifluoromethylpyridin-2-yl)amide, a high affinity TRPV1 (VR1) vanilloid receptor antagonist.
Bogenstaetter, M; Breitenbucher, JG; Carruthers, NI; Chang, L; Chaplan, SR; Codd, EE; Dax, SL; Dubin, AE; Gonzales, L; Hoey, K; Jetter, M; Lee, DH; Liu, C; Lord, B; Mazur, C; Nasser, N; Rizzolio, M; Shah, C; Swanson, DM; Zhang, SP, 2005
)
0.33
" Critical areas of future investigation include: (1) identification of the direct molecular target(s) of EGCG and related polyphenolic compounds in cells; (2) the in vivo metabolism and bioavailability of these compounds; (3) the ancillary effects of these compounds on tumor-stromal interactions; (4) the development of synergistic combinations with other antitumor agents to enhance efficacy in cancer prevention and therapy, and also minimize potential toxicities."( Modulation of signal transduction by tea catechins and related phytochemicals.
Shimizu, M; Weinstein, IB, 2005
)
0.33
" In particular, the oral bioavailability of these drugs may be influenced by the P-gp status of populations that rely heavily on hot chilli in their diets."( Effects of capsaicin on P-gp function and expression in Caco-2 cells.
Han, Y; Lim, LY; Tan, TM, 2006
)
0.33
" This compound was orally bioavailable in rats and was efficacious in blocking capsaicin-induced flinch in rats in a dose-dependent manner."( Design of potent, orally available antagonists of the transient receptor potential vanilloid 1. Structure-activity relationships of 2-piperazin-1-yl-1H-benzimidazoles.
Balan, C; Bannon, AW; Bo, Y; Dominguez, C; Fotsch, C; Gavva, NR; Gore, VK; Klionsky, L; Ma, VV; Norman, MH; Ognyanov, VI; Qian, YX; Tamir, R; Treanor, JJ; Wang, X; Xi, N; Xu, S; Zhu, D, 2006
)
0.33
" In addition, compound 26 was found to be orally bioavailable (rat F(oral)=24%) and had potent TRPV1 antagonist activity (capsaicin IC(50)=1."( Trisubstituted pyrimidines as transient receptor potential vanilloid 1 (TRPV1) antagonists with improved solubility.
Chakrabarti, PP; Gavva, NR; Norman, MH; Ognyanov, VI; Pettus, LH; Tamir, R; Tan, H; Tang, P; Treanor, JJ; Wang, X, 2007
)
0.34
"1 min and high clearance values suggesting that drug bioavailability will be considerably reduced, consequently affecting drug response and efficacy."( Quantitative determination of capsaicin, a transient receptor potential channel vanilloid 1 agonist, by liquid chromatography quadrupole ion trap mass spectrometry: evaluation of in vitro metabolic stability.
Beaudry, F; Vachon, P, 2009
)
0.35
"To evaluate inhibition of capsaicin-induced increase in dermal blood flow (DBF) following telcagepant (MK-0974), a potent and selective orally bioavailable calcitonin gene-related peptide (CGRP) receptor antagonist being developed for the acute treatment of migraine."( Inhibition of capsaicin-induced increase in dermal blood flow by the oral CGRP receptor antagonist, telcagepant (MK-0974).
Boyle, J; de Hoon, JN; de Lepeleire, I; Denney, WS; Depré, M; Hickey, L; Ho, TW; Kane, SA; Li, CC; Murphy, MG; Palcza, J; Sinclair, SR; Van der Schueren, BJ; Van Hecken, A; Vanmolkot, FH; Willson, KJ; Xiao, A; Xu, Y, 2010
)
0.36
" Scanning electronic microscopy of the intestinal villi in these spice treatments revealed alterations in the ultrastructure, especially an increase in microvilli length and perimeter which would mean a beneficial increase in the absorptive surface of the small intestine, providing for an increased bioavailability of micronutrients."( Beneficial influence of dietary spices on the ultrastructure and fluidity of the intestinal brush border in rats.
Prakash, UN; Srinivasan, K, 2010
)
0.36
" For example, the 1,8-naphthyridine 52 was characterized as an orally bioavailable and brain penetrant TRPV1 antagonist."( Discovery of novel 6,6-heterocycles as transient receptor potential vanilloid (TRPV1) antagonists.
Bakthavatchalam, R; Blum, CA; Boyce, S; Brielmann, H; Burnaby-Davies, N; Caldwell, T; Capitosti, S; Chenard, BL; Conley, R; Cortright, D; Crandall, M; De Lombaert, S; Hodgetts, KJ; Jones, AB; Kershaw, MT; Krause, JE; Martin, WJ; Mason, G; Matson, D; Murphy, BA; Perrett, H; Rycroft, W; Zheng, X, 2010
)
0.36
" Enhanced bioavailability of curcumin was evidenced when the same was orally administered concomitant with piperine."( Tissue distribution & elimination of capsaicin, piperine & curcumin following oral intake in rats.
Srinivasan, K; Suresh, D, 2010
)
0.36
"Considerable difference exists in the bioavailability of the three test compounds."( Tissue distribution & elimination of capsaicin, piperine & curcumin following oral intake in rats.
Srinivasan, K; Suresh, D, 2010
)
0.36
"3 min and a high clearance, suggesting that drug bioavailability is considerably reduced following extravascular administrations, consequently affecting drug response."( Characterization of in vitro metabolism of capsazepine, a vanilloid transient receptor potential channel antagonist, by liquid chromatography quadrupole ion trap mass spectrometry.
Beaudry, F; Douat, J; Vachon, P, 2011
)
0.37
"To increase the aqueous solubility and poor bioavailability of capsaicin (CAS 404-86-4), in this paper, the effects of hydroxypropyl-beta-cyclodextrin (HP-beta-CD) on the aqueous solubility and the pharmacokinetic characteristics of capsaicin were investigated."( Enhanced aqueous solubility and bioavailability of capsaicin by the preparation of an inclusion complex.
Chen, X; Gong, T; Ren, K; Sun, X; Zhang, X; Zhang, Z, 2010
)
0.36
" AS1928370 showed good oral bioavailability and high penetration into the brain and spinal cord in mice."( Intrathecal administration of AS1928370, a transient receptor potential vanilloid 1 antagonist, attenuates mechanical allodynia in a mouse model of neuropathic pain.
Aoki, T; Kiso, T; Matsuoka, N; Tsukamoto, M; Watabiki, T, 2011
)
0.37
" The bioavailability of digoxin in LPS group was higher than that in the LPS + Cap group."( Influence of capsaicin on fluctuation of digoxin pharmacokinetics in lipopolysaccharide-treated rats.
Hayashi, T; Higashitani, A; Ijiri, Y; Irie, T; Kato, R; Kusukawa, Y; Nagata, M; Nakagawa, M; Tanaka, K; Urashima, Y; Yamamoto, Y, 2012
)
0.38
" These results demonstrate that the chronic ingestion of high doses of CAP will decrease the bioavailability of galantamine to a significant extent in rats."( Food-drug interactions: effect of capsaicin on the pharmacokinetics of galantamine in rats.
Lu, YN; Zhai, XJ, 2012
)
0.38
" The results demonstrate that chronic ingestion of high doses of CAP will decrease the bioavailability of SV to a significant extent in rats."( Food-drug interactions: effect of capsaicin on the pharmacokinetics of simvastatin and its active metabolite in rats.
Chen, JG; Liu, JM; Lu, YN; Shi, F; Zhai, XJ, 2013
)
0.39
"In view of the wide-spread deficiency of iron and zinc in populations dependent on plant foods, it is desirable to improve the bioavailability of the same."( Enhanced intestinal uptake of iron, zinc and calcium in rats fed pungent spice principles--piperine, capsaicin and ginger (Zingiber officinale).
Prakash, UN; Srinivasan, K, 2013
)
0.39
"Nanotechnologies are being employed to enhance the stability and oral bioavailability of lipophilic substances, such as capsaicin."( Pharmacokinetic characteristics of capsaicin-loaded nanoemulsions fabricated with alginate and chitosan.
Choi, AY; Gwak, HS; Kim, CT; Kim, HO; Lee, KE; Lee, NR; Park, HY, 2013
)
0.39
" There are few in vivo studies on absorption, bioavailability and disposition of CAP and DHC."( A sensitive LC-MS/MS method for quantifying capsaicin and dihydrocapsaicin in rabbit plasma and tissue: application to a pharmacokinetic study.
Guo, J; Meng, F; Sun, L; Wang, D; Yu, L, 2015
)
0.42
" These results demonstrated that chronic ingestion of CAP increases the bioavailability of pitavastatin in rat and that Oatp1b2 gene expression in rat liver is hardly effected by CAP."( Effects of capsaicin on pharmacokinetics of pitavastatin in rats.
Chen, F; Lu, Y; Zhai, X; Zhu, C, 2015
)
0.42
"34-fold increase in relative bioavailability compared to free capsaicin."( Improved oral bioavailability of capsaicin via liposomal nanoformulation: preparation, in vitro drug release and pharmacokinetics in rats.
Deng, W; Firempong, CK; Peng, W; Shi, F; Wang, M; Wang, Q; Wang, S; Xu, X; Yu, J; Zhang, J; Zhang, W; Zhu, Y, 2015
)
0.42
" Under physiological temperature conditions, a sufficient bioavailability of capsaicin in the cutaneous target compartments can be found."( Cutaneous drug delivery of capsaicin after in vitro administration of the 8% capsaicin dermal patch system.
Heskamp, ML; Michael, J; Neubert, RH; Wohlrab, J, 2015
)
0.42
"After 30 min of application, a sufficient cutaneous bioavailability of capsaicin is reached in thick as well as thin skin."( Cutaneous drug delivery of capsaicin after in vitro administration of the 8% capsaicin dermal patch system.
Heskamp, ML; Michael, J; Neubert, RH; Wohlrab, J, 2015
)
0.42
" The present review describes the current knowledge involving the metabolism and bioavailability of capsaicinoids in rodents and humans."( Bioavailability of capsaicin and its implications for drug delivery.
Ball, JG; Brown, KC; Dasgupta, P; McNees, CA; Perry, HE; Rollyson, WD; Stevenson, CD; Stover, CA; Valentovic, MA, 2014
)
0.4
" Nevertheless, the limited systemic bioavailability of phytochemicals may raise questions regarding the physiological relevance of their phytochemical effects in vivo."( Oxidant-based anticancer activity of a novel synthetic analogue of capsaicin, capsaicin epoxide.
Chochrek, P; Lewinska, A; Rawska, E; Smolag, K; Wnuk, M, 2015
)
0.42
" However, poor water solubility and low bioavailability have limited its application."( In vitro and in vivo evaluation of capsaicin-loaded microemulsion for enhanced oral bioavailability.
Deng, W; Firempong, CK; Li, Q; Tong, S; Wang, M; Wang, S; Xu, X; Yu, J; Zhang, J; Zheng, Q; Zhu, Y, 2015
)
0.42
"CAP/NPs significantly enhance the bioavailability of CAP and markedly reduce gastric mucosa irritation in rats."( Oral delivery of capsaicin using MPEG-PCL nanoparticles.
Deng, WW; Jiang, XY; Omari-Siaw, E; Peng, W; Xu, XM; Yu, JN; Zhang, WM; Zhu, Y, 2015
)
0.42
"The objective of this study is to improve the solubility and oral bioavailability of CAP by reducing irritation via hydroxypropyl-β-cyclodextrin (HP-β-CD) inclusion complex formulation, in vitro and in vivo analysis."( Preparation, characterization, and pharmacokinetics study of capsaicin via hydroxypropyl-beta-cyclodextrin encapsulation.
Firempong, CK; Shi, F; Sun, C; Xu, X; Yu, J; Zhang, W; Zhao, Y, 2016
)
0.43
"8 ng × h × mL(-1)) or relative bioavailability (139."( Preparation, characterization, and pharmacokinetics study of capsaicin via hydroxypropyl-beta-cyclodextrin encapsulation.
Firempong, CK; Shi, F; Sun, C; Xu, X; Yu, J; Zhang, W; Zhao, Y, 2016
)
0.43
" Capsaicin has demonstrated effectiveness as an anticancer agent, but a restraining factor is its pungency, extremely low aqueous solubility, and poor oral bioavailability which impede its use as an anticancer agent."( Infringement of the barriers of cancer via dietary phytoconstituents capsaicin through novel drug delivery system.
Alexander, A; Barman, TK; Giri, TK; Maity, S, 2016
)
0.43
" More importantly, the relative bioavailability of the sustained-release matrix pellets was studied in fasted rabbits after oral administration using free capsaicin and solid dispersion as references."( Preparation and In Vitro-In Vivo Evaluation of Sustained-Release Matrix Pellets of Capsaicin to Enhance the Oral Bioavailability.
Huang, Z; Jiang, D; Lu, S; Omari-Siaw, E; Wang, M; Xu, X; Yu, J; Zhang, W; Zhang, Y; Zhu, Y, 2016
)
0.43
" However, the low bioavailability and irritating quality of CAP greatly limit its applications in functional foods."( Development of Organogel-Derived Capsaicin Nanoemulsion with Improved Bioaccessibility and Reduced Gastric Mucosa Irritation.
Cao, Y; Ho, CT; Huang, Q; Lu, M, 2016
)
0.43
"Capsaicin is the main pungent principle present in chili peppers has been found to possess P-glycoprotein (P-gp) inhibition activity in vitro, which may have the potential to modulate bioavailability of P-gp substrates."( Capsaicin pretreatment enhanced the bioavailability of fexofenadine in rats by P-glycoprotein modulation: in vitro, in situ and in vivo evaluation.
Appani, R; Bedada, SK; Boga, PK, 2017
)
0.46
"Capsaicin pretreatment significantly enhanced the intestinal absorption and bioavailability of fexofenadine in rats likely by inhibition of P-gp mediated cellular efflux, suggesting that the combined use of capsaicin with P-gp substrates may require close monitoring for potential drug interactions."( Capsaicin pretreatment enhanced the bioavailability of fexofenadine in rats by P-glycoprotein modulation: in vitro, in situ and in vivo evaluation.
Appani, R; Bedada, SK; Boga, PK, 2017
)
0.46
"6 days and bioavailability was 74%."( Pharmacokinetic-Pharmacodynamic Relationship of Erenumab (AMG 334) and Capsaicin-Induced Dermal Blood Flow in Healthy and Migraine Subjects.
Chen, JS; de Hoon, J; Hamilton, L; Ma, P; Van Hecken, A; Vargas, G; Vu, T; Wu, LS; Yan, L, 2017
)
0.46
" However, a key problem is their short half-life and low bioavailability under in vivo conditions."( Polyphenolic Phytochemicals in Cancer Prevention and Therapy: Bioavailability versus Bioefficacy.
Benlloch, M; Castellano, G; Dellinger, RW; Estrela, JM; Mena, S; Obrador, E; Salvador, R, 2017
)
0.46
" However, its use is limited by the low bioavailability and irritating quality."( Design, synthesis and biological evaluation of novel hydrogen sulfide releasing capsaicin derivatives.
Gao, M; Li, J; Nie, C; Qian, H; Song, B; Yan, L, 2018
)
0.48
" However, some reports have shown that anthocyanin is poorly absorbed in the small intestine."( Intestinal absorption of black chokeberry cyanidin 3-glycosides is promoted by capsaicin and capsiate in a rat ligated small intestinal loop model.
Chiji, H; Higuchi, O; Sakaguchi, H; Suzuki, T; Takahashi, A, 2019
)
0.51
" However, the poor stability, solubility, in vivo bioavailability and weak activity of CU greatly limit its clinical application."( Recent advances of analogues of curcumin for treatment of cancer.
Pi, C; Wei, Y; Ye, Y; Zhao, L; Zhao, S, 2019
)
0.51
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" Nonetheless, their low bioavailability forecasts controversy about mechanisms on their in vivo scavenging activity against reactive oxygen species (ROS)."( Antioxidant effect of phenolic compounds (PC) at different concentrations in IEC-6 cells: A spectroscopic analysis.
Alvarez-Parrilla, E; Barraza-Garza, G; Castillo-Michel, H; Cotte, M; de la Rosa, LA; Martinez-Martinez, A; Pérez-León, JA, 2020
)
0.56
" Novel delivery systems, such as liposomes, micelles, micro/nano-emulsions, colloidal capsules and solid nanoparticles, for enhancing the oral bioavailability of capsaicin are also evaluated depending on the stability, encapsulation efficiency and biological properties."( Capsaicin-the major bioactive ingredient of chili peppers: bio-efficacy and delivery systems.
Cao, Y; Chen, C; Ho, CT; Huang, J; Huang, Q; Lan, Y; Li, R; Lu, M; Xiao, J, 2020
)
0.56
"6 fold increase in bioavailability was observed after oral administration of capsaicin-SNEDDS than plain capsaicin."( Capsaicin Loaded Solid SNEDDS for Enhanced Bioavailability and Anticancer Activity: In-Vitro, In-Silico, and In-Vivo Characterization.
Bhagwat, DA; Choudhari, PB; Kawtikwar, PS; Killedar, SG; Kumbar, VM; More, HN; Nadaf, SJ; Swami, PA, 2021
)
0.62
" Thus, unlike a typical receptor antagonist, continued bioavailability at the level of the receptor is not necessary."( Injectable Capsaicin for the Management of Pain Due to Osteoarthritis.
Campbell, JN; Chung, MK; Connolly, J; Hanson, P; Lascelles, BDX; Meske, DS; Stevens, R, 2021
)
0.62
" The effect of spices on carotenoids' bioavailability is validated with active spice principles."( Turmeric, red pepper, and black pepper affect carotenoids solubilized micelles properties and bioaccessibility: Capsaicin/piperine improves and curcumin inhibits carotenoids uptake and transport in Caco-2 cells.
Ambedkar, R; Baskaran, V; Hanumanthappa, M; Lakshminarayana, R; Perumal, MK; Shilpa, S; Shwetha, HJ, 2021
)
0.62
" Despite its potent cancer-suppressing activity, the clinical applications of capsaicin as a viable anti-cancer drug have remained problematic due to its poor bioavailability and aqueous solubility properties."( Anti-cancer activity of sustained release capsaicin formulations.
Brown, KC; Cox, AJ; Dasgupta, P; Finch, PT; Hess, JA; Merritt, JC; Miles, SL; Moles, EG; Richbart, SD; Tirona, MT; Valentovic, MA, 2022
)
0.72
" The current review also discusses essential information on capsaicin, including its source, bioavailability profile, as well as treatment doses and duration, to highlight its therapeutic potential."( Capsaicin, its clinical significance in patients with painful diabetic neuropathy.
Cirilli, I; Dludla, PV; Hanser, S; Jack, B; Mabhida, SE; Marcheggiani, F; Mazibuko-Mbeje, SE; Nkambule, BB; Ntamo, Y; Nyambuya, TM; Ziqubu, K, 2022
)
0.72
" In our study, acyclic cucurbit[n]urils (ACBs, M1, M2 and M3) were rationally utilized to prepare a series of CAP inclusion complexes to improve the bioavailability and reduce stimulation."( Acyclic cucurbit[n]urils-based supramolecular encapsulation for enhancing the protective effect of capsaicin on gastric mucosa and reducing irritation.
Lv, P; Yang, B; Yang, J; Zhang, R; Zhang, S; Zhang, Y; Zhou, J, 2022
)
0.72
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Capsaicin induced cough reflex was assessed by the single breath dose-response method according to ERS 2007 guidelines. Surgical removal of the duodenum, but not the stomach, produces a marked leftward shift in the capsaicin-induced inhibition of synovial plasma extravasation induced by the potent inflammatory mediator bradykinin.

ExcerptRelevanceReference
" The dye leakage response to nasal capsaicin challenge was abolished by pretreatment with topical lidocaine, general substance P analogue, topical or general high dosage capsaicin."( Study on the dye leakage response of nasal mucosa following topical, capsaicin challenge in guinea pigs.
Asakura, K; Kataura, A; Kojima, T; Narita, S; Shirasaki, H, 1992
)
0.28
" To date, only the antidepressants and the anticonvulsants have shown any effectiveness, albeit incomplete and inconsistent, and many questions remain unanswered: What are the exact indications for the antidepressants? What component of neuropathic pain do they relieve, and through which mechanisms? Which type of antidepressants should be prescribed? A first-generation tricyclic? Or a new compound with a selective action on serotonin reuptake? What are the effective dosage and duration of the treatment? What is it mechanism of action? What other antalgic effects do carbamazepine and baclofen possess apart from their action on trigeminal neuralgia? The opiates are generally considered to be without effect, but recent clinical and experimental findings seem to point otherwise."( [Pharmacological treatment of neuropathic pain].
Ollat, H, 1992
)
0.28
" Pretreatment with aerosolized capsaicin (3 micrograms/ml for 15 to 60 s) 30 min before obtaining the dose-response to histamine significantly potentiated percent increase in RL caused by each dose of intravenously administered histamine."( Pretreatment with aerosolized capsaicin potentiates histamine-induced bronchoconstriction in guinea pigs.
Hirose, T; Nishima, S; Umeno, E, 1992
)
0.28
" In order to gain insight into the mechanisms of impaired hyperaemia, dose-response curves to intradermal substance P (25, 50, 100 pmol) and capsaicin (1."( The skin hyperaemic response to local injection of substance P and capsaicin in diabetes mellitus.
Boolell, M; Tooke, JE, 1990
)
0.28
" Phosphoramidon (10(-7) to 10(-5) M) potentiated the substance P-induced contraction in a dose-dependent fashion, and phosphoramidon shifted the dose-response curve to lower concentrations."( Enkephalinase inhibitor potentiates substance P- and capsaicin-induced bronchial smooth muscle contractions in humans.
Ando, M; Araki, S; Honda, I; Kohrogi, H; Yamaguchi, T, 1991
)
0.28
"Full methacholine dose-response curves were performed on anesthetized tracheostomized Fischer 344 adult rats treated neonatally with capsaicin (50 mg/kg) or with vehicle alone."( Neonatal capsaicin treatment alters basal pulmonary mechanics and response to methacholine in F344 rats.
App, EM; De Sanctis, GT; Green, FH; Hulbert, WC; King, M; Remmers, JE; Rubin, BK, 1991
)
0.28
" A maximally effective dose of LY53857 (1 mg/kg) produced larger shifts of the dose-response curves to serotonin, 5-methoxytryptamine and alpha-methyl-serotonin than did a maximally effective dose of ketanserin (1 mg/kg)."( A pharmacologic examination of receptors mediating serotonin-induced bronchoconstriction in the anesthetized guinea pig.
Buckner, CK; Dea, D; Krell, RD; Liberati, N, 1991
)
0.28
" Vanilloids undergo extensive first-pass metabolism when dosed orally to rats and mice."( Application of liquid chromatography with on-line radiochemical detection to metabolism studies on a novel class of analgesics.
Bowman, LA; Kasting, GB; Kuhlenbeck, DL; Powell, JH; Underwood, RA; Wehmeyer, KR, 1990
)
0.28
" At the maximal depletion dosage (173 micrograms of capsaicin/kg), SP concentration decreased 72."( Innervation of guinea pig heart by neurons sensitive to capsaicin.
Durkee, KH; Hougland, AE; Hougland, MW, 1986
)
0.27
" Cumulative dose-response studies with capsaicin revealed an enhanced contractile response after P-3 infection."( Enhancement by parainfluenza 3 infection of contractile responses to substance P and capsaicin in airway smooth muscle from the guinea pig.
Buckner, CK; Dick, EC; Fishleder, RI; Saban, R, 1987
)
0.27
"We performed three consecutive dose-response curves to rapid intravenous infusions of substance P (SP) in anesthetized, mechanically ventilated guinea pigs."( Enhanced airway responses to substance P after repeated challenge in guinea pigs.
Drazen, JM; Shore, SA, 1989
)
0.28
" Calcitonin gene-related peptide relaxed gastric smooth muscle, however, a dose-response relationship could not be established."( Effect of capsaicin on gastric corpus smooth muscle of the rat in vitro.
Holzer-Petsche, U; Lembeck, F; Seitz, H, 1989
)
0.28
" Methacholine dose-response curves (10(-11) to 10(-7) mol iv) obtained at the conclusion of the experiments were similar among capsaicin, phosphoramidon, and control groups."( Tachykinins mediate bronchoconstriction elicited by isocapnic hyperpnea in guinea pigs.
Drazen, JM; Hernandez, C; Leff, AR; Ray, DW; Solway, J, 1989
)
0.28
" Systemic dosing of opiates is therefore required to reduce the cough reflex, whereas inhaled opiates may reduce the increase in Rrs after inhaled capsaicin."( Effect of inhaled and systemic opiates on responses to inhaled capsaicin in humans.
Choudry, NB; Fuller, RW; Karlsson, JA; Pride, NB, 1988
)
0.27
" However, the dose-response curve for bombesin was bell-shaped suggesting the development of tachyphylaxis with larger doses."( Effects of neuropeptides and capsaicin on the canine tracheal vasculature in vivo.
Salonen, RO; Webber, SE; Widdicombe, JG, 1988
)
0.27
" capsaicin pretreatment on nociception, mean systemic arterial blood pressure, and dose-response curves for depressor effects of substance P (SP) and pressor effects of angiotension II (AII) and norepinephrine (NE) were examined in normotensive Wistar-Kyoto (WKY) and spontaneously hypertensive rats (SHR)."( Capsaicin treatment in adult Wistar-Kyoto and spontaneously hypertensive rats: effects on nociceptive behavior and cardiovascular regulation.
Brody, MJ; Gebhart, GF; Knuepfer, MM; McManus, DQ; Virus, RM, 1981
)
0.26
" Dose-response curves to aerosolized methacholine were performed on anesthetized and mechanically ventilated Wistar rats."( Neonatal capsaicin treatment decreases airway and pulmonary tissue responsiveness to methacholine.
do Patrocínio, M; Dolhnikoff, M; Leme, AS; Martins, MA; Pereira, PM; Sakae, RS; Saldiva, PH; Warth, TN; Zin, WA, 1994
)
0.29
" Dose-response curves to methacholine were constructed before and 1 h after intratracheal instillation of poly-L-lysine in anaesthetized spontaneously breathing rats, and the concentration of methacholine required to induce a doubling in total lung resistance was calculated."( Cationic protein-induced sensory nerve activation: role of substance P in airway hyperresponsiveness and plasma protein extravasation.
Coyle, AJ; Irvin, CG; Manzini, S; Perretti, F, 1994
)
0.29
" The amount of IV SP, IV ACh, or inhaled capsaicin necessary to increase baseline specific airway resistance by 100% (ED200ACh or ED200SP) or 35% (ED135CAP) was determined by interpolation from dose-response curves."( Dexamethasone reduces tachykinin but not ACh airway hyperreactivity after O3.
Chodimella, V; Lang, Z; Murlas, CG, 1993
)
0.29
") pretreatment shifted the bronchoconstrictor dose-response to capsaicin (0."( Evan's blue dye blocks capsaicin-induced cough and bronchospasm in the guinea pig.
Bolser, DC; Del Prado, M; Hey, JA; Mingo, G; O'Reilly, S, 1995
)
0.29
" Recently we found that spinal intrathecal administration of nicotine dose-dependently inhibits bradykinin-induced plasma extravasation (BK-induced PE) in the knee joint of the rat and that the dose-response curve for the inhibition of BK-induced PE by intrathecal nicotine is shifted to the left, by six orders of magnitude, after surgical interventions in the abdominal cavity, which might have interrupted visceral afferents to the neuraxis."( Role of vagal afferents and spinal pathways modulating inhibition of bradykinin-induced plasma extravasation by intrathecal nicotine.
Basbaum, AI; Benowitz, NL; Dallman, MF; Heller, PH; Jänig, W; Levine, JD; Miao, FJ, 1994
)
0.29
" After repeated dosing (12-15 days), moguisteine did not induce tolerance in either guinea-pigs or dogs."( Moguisteine: a novel peripheral non-narcotic antitussive drug.
Borghi, A; Ceserani, R; Dalla Rosa, C; Gallico, L; Tognella, S, 1994
)
0.29
" The dose-response curve to acrolein was also significantly inhibited by treatment with indomethacin (10 microM) and slightly affected by Hoe 140 (1 microM)."( Characterization of the capsaicin-sensitive component of cyclophosphamide-induced inflammation in the rat urinary bladder.
Ahluwalia, A; Giuliani, S; Lecci, A; Maggi, CA; Santicioli, P, 1994
)
0.29
" The dose-response and temporal analysis of CGRP effect show that the maximal activity is present at the dose of 30 pmol/ear and when administered 30 min after the irritating agent."( Effects of CGRP in different models of mouse ear inflammation.
Amico-Roxas, M; Caruso, A; Catena Cutuli, VM; Clementi, G; de Bernardis, E; Maugeri, S; Prato, A; Scapagnini, U, 1994
)
0.29
"The aim of the present study was to investigate the voluntary suppression of cough in response to capsaicin inhalation in healthy volunteers, and to determine if the dose-response curve to capsaicin was significantly altered when volunteers were asked to suppress their cough response."( Voluntary suppression of cough induced by inhalation of capsaicin in healthy volunteers.
Eccles, R; Hutchings, HA; Jawad, MS; Morris, S, 1993
)
0.29
" Capsaicin and citric acid gave comparable dose-response curves in the two species."( A comparative study of the effects of citric acid, capsaicin and resiniferatoxin on the cough challenge in guinea-pig and man.
Higgins, KS; Laude, EA; Morice, AH, 1993
)
0.29
" The NK1 antagonist (+/-)-CP96345 was found to cause, at a maximally tolerated dose of 9 mumol/kg, an approximate 10-fold rightward shift of the dose-response curves for selective NK1 agonists substance P (SP), [Sar9,Met(O2)11]SP and Ac-[Arg6,Sar9,Met(O2)11]SP6-11 without altering responses to selective NK2 agonists neurokinin A (NKA), [Nle10]NKA4-10 or [beta-Ala8]NKA4-10."( Differential blockade by tachykinin NK1 and NK2 receptor antagonists of bronchoconstriction induced by direct-acting agonists and the indirect-acting mimetics capsaicin, serotonin and 2-methyl-serotonin in the anesthetized guinea pig.
Buckner, CK; Campbell, J; Dea, D; Krell, RD; Lengel, D; Liberati, N; Miller, S; Shenvi, A; Stinson-Fisher, C, 1993
)
0.29
" Dose-response curves to intravenously infused capsaicin (1, 10, and 100 micrograms/kg) were performed (five animals for each dose, one dose per animal)."( Airway and pulmonary tissue responses to capsaicin in guinea pigs assessed with the alveolar capsule technique.
Dolhnikoff, M; Martins, MA; Saldiva, PH; Zin, WA, 1993
)
0.29
" In contrast, it was found that 13-HODE itself induced a decrease in diastolic arterial blood pressure when it was injected intravenously after either a single dose of histamine (10, 100 or 1000 micrograms kg-1) or after a dose-response curve of histamine (0."( Hypotensive effect of 13-hydroxylinoleic acid in the rat: mediation via the release of a CGRP-like mediator from capsaicin-sensitive nerves.
Buckley, TL; Engels, F; Henricks, PA; Muis, T; Nijkamp, FP; van Heuven-Nolsen, D, 1995
)
0.29
" C or D alone shifted dose-response curves to capsaicin (from 10(-7) M to 10(-3) M) to lower concentrations compared with the control, and C+D further shifted them."( Angiotensin-converting enzyme inhibitor and danazol increase sensitivity of cough reflex in female guinea pigs.
Ebihara, T; Nakazawa, H; Ohrui, T; Sasaki, H; Sekizawa, K, 1996
)
0.29
" Airway hyperresponsiveness was evidenced by significant shifts to the left of dose-response curves for intravenous acetylcholine (ACh) without a change in maximum responses to ACh."( The tachykinin NK2 receptor antagonist SR 48968 inhibits citric acid-induced airway hyperresponsiveness in guinea pigs.
Advenier, C; Emonds-Alt, X; Girard, V; Yavo, JC, 1996
)
0.29
") shifted these dose-response curves in parallel to the right."( The selective capsaicin antagonist capsazepine abolishes the antinociceptive action of eugenol and guaiacol.
Ohkubo, T; Shibata, M, 1997
)
0.3
" The ACH concentration which produced an increase of 100% in pulmonary resistance (PC100 RI) and in dynamic elastance (PC100 Edyn) was calculated from a 5-step ACH dose-response curve (0."( Role of sensory neuropeptides in PIV-3-infection-induced airway hyperresponsiveness in guinea pigs.
Benden, C; Marek, W; Philippou, S; Riedel, F; Streckert, HJ, 1997
)
0.3
" FK224 (10(-6) M and 10(-5) M, respectively) significantly inhibited NKA-induced contraction and 10(-5) M FK224 shifted the dose-response curve to more than one log unit higher concentration."( Tachykinin antagonist FK224 inhibits neurokinin A-, substance P- and capsaicin-induced human bronchial contraction.
Ando, M; Fujii, K; Goto, E; Hamamoto, J; Hirata, N; Honda, I; Iwagoe, H; Kohrogi, H; Yamaguchi, T, 1997
)
0.3
" Twenty-four sheep were actively sensitized to Ascaris suum, then challenged with nebulized Ascaris extract in a dose-response fashion."( Tachykinins contribute to the acute airways response to allergen in sheep actively sensitized to Ascaris suum.
Holmes, MD; Reynolds, AM; Reynolds, PN; Rice, AJ; Scicchitano, R; Thornton, AT, 1997
)
0.3
" Animals were placed in a bodyplethysmographic box and two procedures of chemical stimulation were used: 3-5 minutes lasting inhalation of overthreshold concentration of tussive agents, and the second procedure resided in an exposure to a dose-response study with doubled concentrations of citric acid."( [Sensitivity of the cough reflex in awake guinea pigs, rats and rabbits].
Karcolová, D; Pécová, R; Tatár, M, 1997
)
0.3
" Guinea-pigs were the species reacting most intensively to citric acid dose-response exposure."( [Sensitivity of the cough reflex in awake guinea pigs, rats and rabbits].
Karcolová, D; Pécová, R; Tatár, M, 1997
)
0.3
" Capsaicin concentrations at first cough (threshold) were recorded; concentrations at frequencies of 10 and 20 coughs/minute were interpolated from the dose-response curve."( Cough responsiveness in neurogenic dysphagia.
Smith, PE; Wiles, CM, 1998
)
0.3
" Capsaicin (10(-6) M) caused relaxation and desensitization that was overcome by long recovery periods and substance P dosing (10(-8) M)."( Activation of non-adrenergic non-cholinergic inhibitory pathways by endogenous and exogenous tachykinins in the ferret lower oesophageal sphincter.
Blackshaw, LA; Lynn, PA; Smid, SD; Templeman, R, 1998
)
0.3
" The dose-response relationship and possible tachyphylaxis were tested for each chemical."( Activation of neurons in rat trigeminal subnucleus caudalis by different irritant chemicals applied to oral or ocular mucosa.
Carstens, E; Handwerker, HO; Kuenzler, N, 1998
)
0.3
" There was a trend toward a dose-response effect of LY293558 on the area in which pinprick evoked pain after intradermal capsaicin, which did not reach statistical significance."( AMPA/kainate antagonist LY293558 reduces capsaicin-evoked hyperalgesia but not pain in normal skin in humans.
Caruso, R; Chappell, AS; Gracely, RH; Hostetter, MP; Lee, G; Max, MB; Sang, CN; Schoepp, DD; Whitcup, S, 1998
)
0.3
" The ideal dosage and treatment interval have not yet been established, and further studies are necessary to confirm our preliminary results."( Intravesical resiniferatoxin for the treatment of detrusor hyperreflexia refractory to capsaicin in patients with chronic spinal cord diseases.
Beneforti, P; Lazzeri, M; Spinelli, M; Turini, D; Zanollo, A, 1998
)
0.3
") shifted the dose-response curves to capsaicin to the right in a dose-dependent fashion."( Cholinergic influence on the sensitivity of cough reflex in awake guinea-pigs.
Jia, YX; Sasaki, H; Sekizawa, K, 1998
)
0.3
" Vagal ligation but not perivagal capsaicin treatment reduced the inhibitory effect of secretin on bethanechol-stimulated contraction of isolated forestomach muscle strips, causing a right shift in the dose-response curve."( Vagus nerve modulates secretin binding sites in the rat forestomach.
Chang, TM; Chey, WY; Kwon, HY; Lee, KY, 1999
)
0.3
" We monitored bladder activity urodynamically during infusion of high dosage of capsaicin."( Urodynamic assessment during intravesical infusion of capsaicin for the treatment of refractory detrusor hyperreflexia.
Beneforti, P; Lazzeri, M; Spinelli, M; Turini, D; Zanollo, A, 1999
)
0.3
" The ideal dosage and treatment interval are not at present established and further studies are needed to explain substantial differences in the outcome according to different urodynamic responses."( Urodynamic assessment during intravesical infusion of capsaicin for the treatment of refractory detrusor hyperreflexia.
Beneforti, P; Lazzeri, M; Spinelli, M; Turini, D; Zanollo, A, 1999
)
0.3
"Male rats were dosed with capsaicin after the administration of olive oil, and the serum was obtained for analysis of triglycerides and free fatty acids (FFAs)."( Effects of capsaicin on serum triglycerides and free fatty acid in olive oil treated rats.
Hori, Y; Nakamura, K; Saito, A; Yamamoto, M, 1999
)
0.3
" In addition, we obtained dose-response curves for possible local anesthetic effects."( The effects of intradermal fentanyl and ketamine on capsaicin-induced secondary hyperalgesia and flare reaction.
Blunk, JA; Koppert, W; Likar, R; Schmelz, M; Sittl, R; Zeck, S, 1999
)
0.3
"1-235 nmol site(-1)) injected intradermally into the rostral back elicited scratching of the injected site, with bell-shaped dose-response relationship."( Itch-associated response induced by intradermal serotonin through 5-HT2 receptors in mice.
Kuraishi, Y; Nagasawa, T; Satoh, M; Yamaguchi, T, 1999
)
0.3
" Animals were dosed 100 mg/kg capsaicin after the administration of olive oil, and the bile was obtained for 6 hours continuously after dosing with capsaicin for analysis of FFAs using HPLC methods."( Effects of capsaicin on biliary free fatty acids in rats.
Hori, Y; Nakamura, K; Saito, A; Yamamoto, M, 2000
)
0.31
" Steady-state dose-response relationships, current-voltage relationships, ionic selectivities, and single-channel properties were recorded using voltage-clamp techniques."( The activation mechanism of rat vanilloid receptor 1 by capsaicin involves the pore domain and differs from the activation by either acid or heat.
Reinhart, PH; Simon, SA; Welch, JM, 2000
)
0.31
" Dose-response relationships for evodiamine, rutaecarpine and capsaicin were obtained."( The positive inotropic and chronotropic effects of evodiamine and rutaecarpine, indoloquinazoline alkaloids isolated from the fruits of Evodia rutaecarpa, on the guinea-pig isolated right atria: possible involvement of vanilloid receptors.
Hoshikuma, K; Kamiya, T; Kobayashi, Y; Nakano, Y; Yokoo, Y, 2001
)
0.31
" Bronchial rings were incubated with normal or immune serum (100 microl ml(-1) for 2 h) and dose-response curves to TDI (0."( Serum-mediated relaxant response to toluene diisocyanate (TDI) in isolated guinea-pig bronchi.
Boschetto, P; Chitano, P; De Marzo, N; Fabbri, LM; Faggian, D; Jovine, L; Mapp, CE; Plebani, M, 2001
)
0.31
" On the other hand, although a typical bell-shaped dose-response relationship was observed with a wide range of N/OFQ doses in both peripheral and central nociception tests, N/OFQ (13-17) did not show bell-shaped dose-response relationship in the central nociception test."( Pronociceptive effects of nociceptin/orphanin FQ (13-17) at peripheral and spinal level in mice.
Inoue, M; Matsunaga, S; Mizuno, K; Rashid, MH; Sakurada, T; Takeshima, H; Ueda, H; Yoshida, A, 2001
)
0.31
" Also, in spite of the variability in perceived responses to the recalled/imagined skin sensations, statistically significant dose-response and time-response patterns were observed in chemical (lactic acid and capsaicin) challenge studies."( Evaluation of a quantitative clinical method for assessment of sensory skin irritation.
Perkins, MA; Robinson, MK, 2001
)
0.31
" The final effects of capsaicin depend on the dosage and timing."( Four response stages of capsaicin-sensitive primary afferent neurons to capsaicin and its analog: gastric acid secretion, gastric mucosal damage and protection.
Mózsik, G; Szolcsányi, J; Vincze, A, 2001
)
0.31
" Trypsin also produced a vasodilator dose-response curve that was biphasic in nature (ED(50-1)=0."( Protease-activated receptor-2 activation causes EDHF-like coronary vasodilation: selective preservation in ischemia/reperfusion injury: involvement of lipoxygenase products, VR1 receptors, and C-fibers.
Ahluwalia, A; Aston, D; McLean, PG; Sarkar, D, 2002
)
0.31
" Lauroylethanolamide (C12:0) produced a leftward shift in the dose-response curve for AEA."( 'Entourage' effects of N-acyl ethanolamines at human vanilloid receptors. Comparison of effects upon anandamide-induced vanilloid receptor activation and upon anandamide metabolism.
Fowler, CJ; Jonsson, KO; Lambert, DM; Smart, D; Vandevoorde, S, 2002
)
0.31
" After the treatment with azelastine, capsaicin-induced cough decreased significantly, and the dose-response curve to capsaicin was shifted to a higher concentration in comparison with the the controls."( Mechanism of the antitussive effect of azelastine in guinea pigs.
Ito, N; Miura, M; Sano, M; Sasaki, M; Shioya, T; Watanabe, A, 2002
)
0.31
" Precise dose-response relationships allowed current amplitudes and firing frequencies to be tuned by varying the concentration of ligand."( Photochemical gating of heterologous ion channels: remote control over genetically designated populations of neurons.
Lee, GA; Miesenbock, G; Nesnas, N; Zemelman, BV, 2003
)
0.32
" 19 and 20 produced leftward shifts in the dose-response curve for AEA activation of Ca(2+) influx into hVR1-HEK293 cells."( N-Morpholino- and N-diethyl-analogues of palmitoylethanolamide increase the sensitivity of transfected human vanilloid receptors to activation by anandamide without affecting fatty acid amidohydrolase activity.
Fowler, CJ; Jonsson, KO; Lambert, DM; Smart, D; Vandevoorde, S, 2003
)
0.32
" These results suggest that the improvement in swimming endurance with the high capsaicin dosage is caused by an increase in fatty acid utilization as the energy source, resulting in the sparing of glycogen."( Capsaicin increases endurance capacity and spares tissue glycogen through lipolytic function in swimming rats.
Oh, TW; Ohta, F, 2003
)
0.32
" Surgical removal of the duodenum, but not the stomach, produces a marked (six orders of magnitude) leftward shift in the dose-response curve for intraplantar capsaicin-induced inhibition of synovial plasma extravasation induced by the potent inflammatory mediator bradykinin, in the knee joint; this is similar in magnitude to the inhibition produced by subdiaphragmatic or by coeliac plus coeliac accessory branch vagotomy."( Mechanosensitive duodenal afferents contribute to vagal modulation of inflammation in the rat.
Green, PG; Levine, JD; Miao, FJ, 2004
)
0.32
" trans-Capsaicin did not induce micronuclei in bone marrow cells when tested to the maximum tolerated dose of 800 mg/kg per day in male and 200 mg/kg per day in female CD-1 mice using a 0 h plus 24 h oral dosing and 48 h sampling regimen."( Genotoxicity studies with pure trans-capsaicin.
Bley, K; Chanda, S; Erexson, G; Innes, D; Murli, H; Riach, C; Stevenson, F, 2004
)
0.32
" After the perivascular preinjection of 1 nmol/l L-668,169 or 1 nmol/l L-733,060 (NK1 receptor antagonists), the SP dose-response curve was shifted to the right."( Effects of neuropeptides on the sumatriptan-disturbed circulation in the optic nerve head of rabbits.
Cunha-Vaz, JG; Gaspar, MN; Macedo, TR; Ribeiro, CA, 2004
)
0.32
" Dosing with capsaicin significantly decreased the pressures and corresponding wall tensions at the discomfort threshold."( Effects of capsaicin on the sensorimotor function of the proximal stomach in humans.
Lee, KJ; Tack, J; Vos, R, 2004
)
0.32
" Subjects were then dosed with either lamotrigine (300 mg), 4030W92 (100 mg), or placebo, followed 2 h later by capsaicin (100 microg) injected intradermally on the volar aspect of the left forearm."( Lack of effect of two oral sodium channel antagonists, lamotrigine and 4030W92, on intradermal capsaicin-induced hyperalgesia model.
Quessy, S; Schulteis, G; Wallace, MS, 2004
)
0.32
" Comparative study of the pruritogenic activity revealed that histamine possessed a potent effect characterized by a dose-response relationship; however, prostaglandin D2 failed to induce this response."( Itch-scratch responses induced by lysophosphatidic acid in mice.
Hashimoto, T; Momose, K; Ohata, H, 2004
)
0.32
" This study examined the effects of gabapentin on signs of central sensitization (brush and pinprick hyperalgesia) in a human model of capsaicin-evoked pain, using a gabapentin dosing regimen similar to that used in the clinic."( Chronic oral gabapentin reduces elements of central sensitization in human experimental hyperalgesia.
Bach, FW; Brown, J; Chizh, BA; Gottrup, H; Jensen, TS; Juhl, G; Kristensen, AD; Lai, R, 2004
)
0.32
" Incubation with CGRP8-37 (10(-6) M) specifically during the 90-minute desensitization period with nitroglycerin resulted in even greater impairment in the response to nitroglycerin in tolerant rings, even though the calcitonin gene-related peptide antagonist had been washed out before completion of the nitroglycerin dose-response curve."( Nitroglycerin-induced release of calcitonin gene-related peptide from sensory nerves attenuates the development of nitrate tolerance.
Ghatta, S; O'Rourke, ST, 2006
)
0.33
"2 for (+)-AM1241 and L768242, respectively) of the dose-response curve."( CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms.
Beltramo, M; Bernardini, N; Bertorelli, R; Campanella, M; Fredduzzi, S; Nicolussi, E; Reggiani, A, 2006
)
0.33
" Further studies are required to determine the optimal dosing regimes and formulations for individual sub-populations of neurogenic bladder patients and to determine the cost-effectiveness of these interventions."( Improving the global management of the neurogenic bladder patient: part II. Future treatment strategies.
Chartier-Kastler, E; Corcos, J; Denys, P; Everaert, K; Fowler, C; Kalsi, V; Nitti, V; Schulte-Baukloh, H; Schurch, B, 2006
)
0.33
"To evaluate the effects of one week of oral dosing with capsaicin on mechanonociception and chemonociception."( Effect of repeated capsaicin ingestion on intestinal chemosensation and mechanosensation.
Hammer, J, 2006
)
0.33
" All groups were dosed once weekly, except for the TPA group, which was dosed twice per week."( 26-Week dermal oncogenicity study evaluating pure trans-capsaicin in Tg.AC hemizygous mice (FBV/N).
Babbar, S; Bley, K; Burlew, JA; Chanda, S; Erexson, G; Frost, D,
)
0.13
" Control groups were dosed with capsaicin-free, ethanol-containing or ethanol-free ciprofloxacin."( Administration of ciprofloxacin and capsaicin in rats to achieve higher maximal serum concentrations.
Aguilera-Jiménez, R; Gutiérrez-Olvera, C; Gutiérrez-Olvera, L; Jiménez-Gómez, F; Sumano-López, H, 2007
)
0.34
" Dose-response analysis of the antagonistic effect of the TRPV1 receptor antagonist, capsazepine administered peripherally, shows that the capsaicin-evoked inflammation was inhibited in a dose-dependent manner, and nearly completely abolished by capsazepine at doses between 30-150 mug."( Roles of TRPV1 and neuropeptidergic receptors in dorsal root reflex-mediated neurogenic inflammation induced by intradermal injection of capsaicin.
Fang, L; Li, D; Lin, Q; Xu, X; Zou, X, 2007
)
0.34
" Mean and log C5 dosage in current smoker and non-smoker groups and mean and log C5 dosage in current smoker according to gender were calculated by using Mann-Whitney U-test."( [Sensitivity of cough with capsaicin in smokers].
Celik, P; Coşkun, E; Dinç, G; Havlucu, Y; Sakar, A; Yildirim, CA; Yorgancioğlu, A, 2008
)
0.35
" immediately after each dosing of 5-FU significantly reversed the delay in healing by 5-FU, and this effect was attenuated by the chemical ablation of capsaicin-sensitive afferent neurons."( Impairment by 5-fluorouracil of the healing of gastric lesions in rats: effect of lafutidine, a histamine H2 receptor antagonist, mediated by capsaicin-sensitive afferent neurons.
Amagase, K; Hayashi, S; Komatsu, Y; Kotani, T; Murashima, Y; Nakagiri, A; Takeuchi, K, 2009
)
0.35
" This compound penetrates the CNS and shows potent anti-nociceptive effects in a broad range of animal pain models upon oral dosing due in part to its ability to antagonize both central and peripheral TRPV1 receptors."( Tetrahydropyridine-4-carboxamides as novel, potent transient receptor potential vanilloid 1 (TRPV1) antagonists.
Bianchi, BR; Brown, BS; Faltynek, CR; Honore, P; Jarvis, MF; Keddy, R; Koenig, JR; Lee, CH; Marsh, KC; McDonald, HA; Polakowski, JS; Schmidt, RG; Surowy, CS; Zheng, GZ, 2008
)
0.35
" In time course and dosage studies, the mitochondrial membrane potential of MCF-7 cells decreased."( Capsaicin-induced apoptosis in human breast cancer MCF-7 cells through caspase-independent pathway.
Chen, DR; Chou, CC; Chou, MJ; Kuo, SJ; Wang, YF; Wu, YC, 2009
)
0.35
"), dose-dependently produced rightward shifts of the dose-response curve of Ro 64-6198-induced antinociception."( Behavioral effects of a synthetic agonist selective for nociceptin/orphanin FQ peptide receptors in monkeys.
Fantegrossi, WE; Galuska, CM; Ko, MC; Prinssen, EP; Wichmann, J; Woods, JH, 2009
)
0.35
" Intra-cerebral administration of cannabidiol, a phytocannabinoid, or anandamide, an endocannabinoid, into the dorsolateral portion of periaqueductal gray (dlPAG) promotes anxiolytic-like effects in several animal models of anxiety with bell-shaped dose-response curves."( Evidence for a potential role for TRPV1 receptors in the dorsolateral periaqueductal gray in the attenuation of the anxiolytic effects of cannabinoids.
Campos, AC; Guimarães, FS, 2009
)
0.35
"To compare the dose-response relationships of two formulations [Tween- or hydroxypropyl-b-cyclodextrin (HP-b-CD)-based] of intradermal capsaicin in healthy volunteers and to assess the effect of potential covariates of response."( A comparison of two formulations of intradermal capsaicin as models of neuropathic pain in healthy volunteers.
Akesson, J; Gustafsson, H; Lau, CL; Miller, L; Rolan, P; Williams, D; Yap, S, 2009
)
0.35
" Given the greater ease of formulation and the superior dose-response relationship, the HP-beta-CD formulation is preferable for use in the model in future studies."( A comparison of two formulations of intradermal capsaicin as models of neuropathic pain in healthy volunteers.
Akesson, J; Gustafsson, H; Lau, CL; Miller, L; Rolan, P; Williams, D; Yap, S, 2009
)
0.35
"Geometric mean plasma concentrations after dosing with 300 mg and 800 mg telcagepant were 720 and 1146 nm, respectively, at 1 h, vs."( Inhibition of capsaicin-induced increase in dermal blood flow by the oral CGRP receptor antagonist, telcagepant (MK-0974).
Boyle, J; de Hoon, JN; de Lepeleire, I; Denney, WS; Depré, M; Hickey, L; Ho, TW; Kane, SA; Li, CC; Murphy, MG; Palcza, J; Sinclair, SR; Van der Schueren, BJ; Van Hecken, A; Vanmolkot, FH; Willson, KJ; Xiao, A; Xu, Y, 2010
)
0.36
" After the end of the dosing period, reversibility was assessed (10/sex/group for the control and 1000 mg/kg groups) following a 4-week recovery period."( Studies of the toxicological potential of capsinoids XIV: a 26-week gavage toxicity study of dihydrocapsiate in rats.
Bernard, BK; Kayahara, T; Kodama, T; Masuyama, T; Ohishi, T; Tsubuku, S; Wagner, BM, 2010
)
0.36
" A low dosage of capsaicin (5mg/kg) administered intraperitoneally desensitizes the local afferent vagal nerve endings for approximately three weeks without causing systemic desensitization or damaging the efferent fibers."( Fasting hypometabolism and refeeding hyperphagia in rats: Effects of capsaicin desensitization of the abdominal vagus.
Balaskó, M; Garami, A; Pétervári, E; Solymár, M; Székely, M, 2010
)
0.36
"RMR was similar in the 3 groups before dosing on day 1 [1714 ± 41 kcal/d (0 mg), 1760 ± 41 kcal/d (3 mg), and 1694 ± 38 kcal/d (9 mg)] and after acute dosing (41 ± 17, 55 ± 17, and 3 ± 24 kcal/d for 3-mg, 9-mg, and placebo groups, respectively)."( Effect of dihydrocapsiate on resting metabolic rate in humans.
Galgani, JE; Ravussin, E, 2010
)
0.36
"First, we screened a heterogeneous group of TRPV1 agonists and secondly we tested the hypothermic properties of a selected candidate by dose-response studies."( Drug-induced mild therapeutic hypothermia obtained by administration of a transient receptor potential vanilloid type 1 agonist.
Buus, C; Fosgerau, K; Gotfredsen, JW; Hansen, P; Jayatissa, M; Kristensen, NB; Køber, L; Raunsø, J; Schneider, A; Teschendorf, P; Torp-Pedersen, C; Vestergaard, M; Videbaek, C; Weber, UJ, 2010
)
0.36
" Dose-response experiments: In both rats and cynomologus monkeys DHC caused a dose-dependent and immediate decrease in body temperature."( Drug-induced mild therapeutic hypothermia obtained by administration of a transient receptor potential vanilloid type 1 agonist.
Buus, C; Fosgerau, K; Gotfredsen, JW; Hansen, P; Jayatissa, M; Kristensen, NB; Køber, L; Raunsø, J; Schneider, A; Teschendorf, P; Torp-Pedersen, C; Vestergaard, M; Videbaek, C; Weber, UJ, 2010
)
0.36
" For this purpose, newborn rats were injected with a single dosage of 50mg/kg capsaicin subcutaneously under the neck fold and after three months, particular eye tissues were dissected and the concentration of PE-11-like immunoreactivity was determined by radioimmunoassay."( PE-11, a peptide derived from chromogranin B, in the rat eye.
Bechrakis, N; Fischer-Colbrie, R; Gramlich, O; Grus, F; Haas, G; Hattmannstorfer, R; Joachim, S; Lorenz, K; Schmid, E; Teuchner, B; Troger, J, 2011
)
0.37
" The median dosage required to induce moderate pain for at least 5min was two capsules (interquartile range 1-3) and the median gastric pain intensity was 47 (41-53)."( Characterization of a reproducible gastric pain model using oral capsaicin titration in healthy volunteers.
Cao, Y; Hammer, J; Ho, KY; Li, XH; Wilder-Smith, CH; Wong, RK, 2011
)
0.37
" Mean TNSS and ISS were recorded after single dosing at different intervals over 60 minutes."( A randomized, double-blind, parallel trial comparing capsaicin nasal spray with placebo in subjects with a significant component of nonallergic rhinitis.
Bernstein, JA; Cooper, JP; Davis, BP; Levin, LS; Picard, JK; Zheng, S, 2011
)
0.37
" The CNS effects were assessed at baseline and up to 24 h after dosing using visual analogue mood scales for feeling 'stimulated', 'anxious', 'sedated' and 'down'."( Lack of effect of central nervous system-active doses of nabilone on capsaicin-induced pain and hyperalgesia.
Annas, P; Baxendale, J; Kalliomäki, J; Karlsten, R; Philipp, A; Segerdahl, M, 2012
)
0.38
" Trial duration, dosage and sized varied, though trials were generally of high quality with a low risk of bias."( Capsaicinoids and capsinoids. A potential role for weight management? A systematic review of the evidence.
Derbyshire, E; Tiwari, BK; Whiting, S, 2012
)
0.38
"The aim of the study was to evaluate the analgesic/antihyperalgesic efficacy and to establish the dose-response relationship of morphine immediate release (IR) and oxycodone IR in a human experimental algesimetric model."( Dose-response relationship after single oral dose administrations of morphine and oxycodone using laser-evoked potentials on UVB- and capsaicin-irritated skin in healthy male subjects.
Hoeben, E; Mangold, B; Reitmeir, P; Rusch, S; Schaffler, K; Smit, JW; Upmalis, D, 2012
)
0.38
" After exposure the capsaicin induced cough reflex was assessed by the single breath dose-response method according to ERS 2007 guidelines."( Reproducibility of sensitivity to capsaicin assessed by single breath inhalation methodology.
Berresheim, H; Brüning, T; Bünger, J; Hoffmeyer, F; Monse, C; Rosenkranz, N; Sucker, K, 2013
)
0.39
" The oral dosage versus mortality pattern of some compounds did not follow a true dose-response curve (DRC); however, following inhalation, all the compounds followed DRC."( Evaluation of oleoresin capsicum of Capsicum frutescenes var. Nagahari containing various percentages of capsaicinoids following inhalation as an active ingredient for tear gas munitions.
Deb, U; Kaushik, MP; Kumar, P, 2012
)
0.38
" Finally, the analysis of hepatic glutathione conjugates and urinary N-acetylcysteine conjugates from mice dosed with capsaicin confirmed the formation of glutathione conjugates of O-demethylated quinone methide and 5-OH-capsaicin in vivo."( Reactive intermediates produced from the metabolism of the vanilloid ring of capsaicinoids by p450 enzymes.
Bugni, TS; Ethirajan, M; Henion, F; Pramanik, KC; Reilly, CA; Srivastava, SK; Stockmann, C; Yost, GS, 2013
)
0.39
" The CNS effects were assessed at baseline and up to 24 h after dosing using a visual analogue mood scales (VAMS) for feeling 'stimulated', 'high', 'anxious', 'sedated' or 'down'."( Evaluation of the analgesic efficacy and psychoactive effects of AZD1940, a novel peripherally acting cannabinoid agonist, in human capsaicin-induced pain and hyperalgesia.
Annas, P; Clarke, C; Huizar, K; Kalliomäki, J; Karlsten, R; Segerdahl, M; Zettergren, A, 2013
)
0.39
" Ten milligram per millilitre intranasal SB-705498, dosed 24 h prior to capsaicin challenge produced a 52% reduction in secretory response."( Effect of the TRPV1 antagonist SB-705498 on the nasal parasympathetic reflex response in the ovalbumin sensitized guinea pig.
Biggadike, K; Busza, A; Campbell, S; Changani, K; Coe, D; Denyer, J; Dinnewell, L; Hotee, S; Lines, M; Pindoria, K; Saklatvala, P; Thompson, SA; Vitulli, G, 2013
)
0.39
" A nonlinear mixed-effects model compared dose-response parameters by disease group and sex."( Pharmacodynamic modeling of cough responses to capsaicin inhalation calls into question the utility of the C5 end point.
Baverel, PG; Hilton, EC; Smith, JA; Van Der Graaf, PH; Woodcock, A, 2013
)
0.39
"5 to 12 mg and of repeat dosing with 6 mg and 12 mg twice daily for 14 days and (ii) a PD efficacy study in subjects with non-allergic rhinitis (NAR) to evaluate the effect of 12 mg intranasal SB-705498 against nasal capsaicin challenge."( Inhibition of capsaicin-driven nasal hyper-reactivity by SB-705498, a TRPV1 antagonist.
Beerahee, M; Denyer, J; Fokkens, W; Holland, C; Newlands, A; Segboer, C; Smart, K; Terreehorst, I; Tsitoura, DC; van Drunen, C, 2014
)
0.4
"Single and repeat dosing with intranasal SB-705498 was safe and well tolerated."( Inhibition of capsaicin-driven nasal hyper-reactivity by SB-705498, a TRPV1 antagonist.
Beerahee, M; Denyer, J; Fokkens, W; Holland, C; Newlands, A; Segboer, C; Smart, K; Terreehorst, I; Tsitoura, DC; van Drunen, C, 2014
)
0.4
"Cough reflex thresholds reflecting C-fiber sensitivity were evaluated by capsaicin single breath dose-response method."( Relationship of pulmonary function response to ozone exposure and capsaicin cough sensitivity.
Beine, A; Berresheim, H; Brüning, T; Bünger, J; Hoffmeyer, F; Jettkant, B; Monsé, C; Rosenkranz, N; Sucker, K, 2013
)
0.39
" Dosing was set by the Dixon sequential up-down method; that is, a greater or less than 30% reduction in capsaicin pain decreased or increased the dose, respectively, by a fixed interval for the next subject."( Determination of the effective dose of pregabalin on human experimental pain using the sequential up-down method.
Wallace, MS; Wong, W, 2014
)
0.4
" The effect of enteric coated formulation variables such as content of talc (10%, 25% and 40%), plasticisers (TEC and DBS), dosage of plasticiser (10%, 20% and 30%) and coating weight (2%, 3% and 5%) were evaluated for drug release characteristics."( The preparation of capsaicin-chitosan microspheres (CCMS) enteric coated tablets.
Chen, J; Guo, J; Huang, GD; Su, ZQ; Tan, SR, 2013
)
0.39
" In vivo antiarthritic activity study shows that our formulation possesses superior inhibitory activity than the marketed Thermagel formulation at the same dosage level, which could probably be due to the lesser permeability of Thermagel across the dermal barriers compared to our specially designed transfersomal delivery system."( Potential of capsaicin-loaded transfersomes in arthritic rats.
Mazumder, B; Rudrapal, M; Sarwa, KK; Verma, VK, 2015
)
0.42
" The aim of the present study was to evaluate the ability of a single-breath, dose-response capsaicin threshold test to discriminate such patients from control subjects."( Capsaicin cough threshold test in diagnostics.
Johansson, EL; Millqvist, E; Pullerits, T; Ternesten-Hasséus, E, 2014
)
0.4
"A total of 46 patients with chronic cough and SHR who had previously shown a positive reaction in accordance with limits set for a tidal breathing capsaicin test were tested once with a single-breath, dose-response capsaicin cough threshold test, assessing capsaicin concentrations to evoke 2 (C2), 5 (C5) or 10 (C10) coughs."( Capsaicin cough threshold test in diagnostics.
Johansson, EL; Millqvist, E; Pullerits, T; Ternesten-Hasséus, E, 2014
)
0.4
"For patients with SHR and chronic cough, capsaicin cough sensitivity was once again confirmed to be increased, in this case, using the single-breath dose-response method."( Capsaicin cough threshold test in diagnostics.
Johansson, EL; Millqvist, E; Pullerits, T; Ternesten-Hasséus, E, 2014
)
0.4
" MK-3207 dose-response predictions were made based on estimated potency from the PK/PD model and mean plasma concentrations observed at the doses investigated."( Characterizing the PK/PD relationship for inhibition of capsaicin-induced dermal vasodilatation by MK-3207, an oral calcitonin gene related peptide receptor antagonist.
Blanchard, R; de Hoon, JN; De Lepeleire, I; Denney, WS; Depré, M; Gipson, A; Han, TH; Kennedy, WP; Li, CC; Murphy, MG; Palcza, J; Van Dyck, K; Vermeersch, S, 2015
)
0.42
"59 nm) would be required to attain the peripheral CIDV response at a target level that was shown previously to correlate with 2 h clinical efficacy based on phase 3 telcagepant clinical data, and that a plateau of the dose-response would be reached around 40-100 mg."( Characterizing the PK/PD relationship for inhibition of capsaicin-induced dermal vasodilatation by MK-3207, an oral calcitonin gene related peptide receptor antagonist.
Blanchard, R; de Hoon, JN; De Lepeleire, I; Denney, WS; Depré, M; Gipson, A; Han, TH; Kennedy, WP; Li, CC; Murphy, MG; Palcza, J; Van Dyck, K; Vermeersch, S, 2015
)
0.42
"The integrated CIDV PK/PD model provides a useful platform for characterization of PK/PD relationships and predictions of dose-response relationships to aid in future development of CGRP and TRPV1 receptor antagonists."( Characterizing the PK/PD relationship for inhibition of capsaicin-induced dermal vasodilatation by MK-3207, an oral calcitonin gene related peptide receptor antagonist.
Blanchard, R; de Hoon, JN; De Lepeleire, I; Denney, WS; Depré, M; Gipson, A; Han, TH; Kennedy, WP; Li, CC; Murphy, MG; Palcza, J; Van Dyck, K; Vermeersch, S, 2015
)
0.42
" As long as morphine did not cause reduced participation due to sedation, subcutaneous morphine dosing reduced the effects of capsaicin (p<0."( A novel operant-based behavioral assay of mechanical allodynia in the orofacial region of rats.
Allen, KD; Caudle, RM; Jacobs, BY; Kloefkorn, HE; Lakes, EH; Neubert, JK; Rohrs, EL, 2015
)
0.42
" Utilization of this pharmacodynamic biomarker with pharmacokinetic data collected in phase I studies provided the dose-response relationship that assisted in dose selection for the phase II clinical development of LY2951742."( Translational Pharmacodynamics of Calcitonin Gene-Related Peptide Monoclonal Antibody LY2951742 in a Capsaicin-Induced Dermal Blood Flow Model.
Benschop, RJ; Collins, EC; de Hoon, J; Grayzel, D; Monteith, D; Van Hecken, A; Vermeersch, S; Wroblewski, VJ, 2015
)
0.42
" The higher doses of capsaicin administered into the vMPFC after the ineffective dose of 6-IODO displaced the dose-response curve of the baroreflex parameters to the right, with no alteration in the maximum effect of capsaicin."( Medial prefrontal cortex TRPV1 channels modulate the baroreflex cardiac activity in rats.
Ferreira-Junior, NC; Lagatta, DC; Resstel, LB, 2015
)
0.42
" Patients entering the model received either a single application of capsaicin 8% patch or titrated daily dosing with pregabalin; after 8 weeks patients were classified as responders, non-responders, or were assumed to discontinue treatment due to intolerable adverse events."( Cost-Effectiveness of Capsaicin 8% Patch Compared with Pregabalin for the Treatment of Patients with Peripheral Neuropathic Pain in Scotland.
Bentley, A; Mankowski, C; Patel, S; Poole, C; Trueman, D, 2016
)
0.43
" In comparison to capsaicin, coadministration of 1 and capsaicin increased the half-maximal effective concentration (EC50) of capsaicin-activated TRPV1 currents as shown by a right shift in the dose-response curve, whereas coadministration of 1 with protons failed to inhibit the proton-induced current."( Partial Activation and Inhibition of TRPV1 Channels by Evodiamine and Rutaecarpine, Two Major Components of the Fruits of Evodia rutaecarpa.
Dai, Y; Kogure, Y; Noguchi, K; Wang, S; Yamamoto, S; Zhang, W, 2016
)
0.43
" In addition, the dose-response data showed that the minimal antagonist concentrations needed to inhibit TRPV1 was ≥6-7 times the equilibrium dissociation constant for each compound."( Clinical testing of three novel transient receptor potential cation channel subfamily V member 1 antagonists in a pharmacodynamic intradermal capsaicin model.
Halldin, MM; Jonzon, B; Kullenberg, T; Segerdahl, M; Sjögren, E; Stålberg, O; Sundgren-Andersson, AK, 2018
)
0.48
"We observed an immunomodulatory effect of an early preventive diet-concept, where a physiological dosage of oral capsaicin was given 10 days before immunization in EAN."( Capsaicin-enriched diet ameliorates autoimmune neuritis in rats.
Ambrosius, B; Bachir, H; Gold, R; Grüter, T; Motte, J; Pedreiturria, X; Pitarokoili, K; Sgodzai, M, 2018
)
0.48
"The presented results suggest that capsaicin is not detected in horse serum in the 24-hour-periodfollowing its last application according to the dosage regimen used by owners and veterinarians for therapy rather than doping, based on a five day gel application and a polar bandage."( The detection of capsaicin and dihydrocapsaicin in horse serum following long-term local administration.
Borowicz, H; Niedzwiedz, A; Siwinska, N; Slowikowska, M; Szpot, P; Zak, A; Zawadzki, M, 2018
)
0.48
" Caution should be taken with the use of both topical and oral NSAIDs, including close adherence to dosing regimens and monitoring, especially for patients with previous complications of NSAIDs."( Topical therapies for knee osteoarthritis.
Rodriguez-Merchan, EC, 2018
)
0.48
" It was also found that the topical gel outperforms the topical cream as dosage form for the nanoemulsion."( Enhancing analgesic and anti-inflammatory effects of capsaicin when loaded into olive oil nanoemulsion: An in vivo study.
Aghajani, M; Amani, A; Esmaeli, F; Faramarzi, MA; Ghazi-Khansari, M; Ghiasi, Z, 2019
)
0.51
" However, there is a lack of data on the dose-response for CAP to inhibit HFD-induced obesity."( Assessment of Pharmacology, Safety, and Metabolic activity of Capsaicin Feeding in Mice.
Baskaran, P; Bennis, J; Fox, J; Markert, L; Thyagarajan, B; Zimmerman, L, 2019
)
0.51
" The efficacy of MMF as an immunosuppressant and long-term safety in cats of this dosage regimen is unknown."(
Abrams, G; Adolfsson, E; Agarwal, PK; Akkan, AG; Al Alhareth, NS; Alves, VGL; Armentano, R; Bahroos, E; Baig, M; Baldridge, KK; Barman, S; Bartolucci, C; Basit, A; Bertoli, SV; Bian, L; Bigatti, G; Bobenko, AI; Boix, PP; Bokulic, T; Bolink, HJ; Borowiec, J; Bulski, W; Burciaga, J; Butt, NS; Cai, AL; Campos, AM; Cao, G; Cao, Y; Čapo, I; Caruso, ML; Chao, CT; Cheatum, CM; Chelminski, K; Chen, AJW; Chen, C; Chen, CH; Chen, D; Chen, G; Chen, H; Chen, LH; Chen, R; Chen, RX; Chen, X; Cherdtrakulkiat, R; Chirvony, VS; Cho, JG; Chu, K; Ciurlino, D; Coletta, S; Contaldo, G; Crispi, F; Cui, JF; D'Esposito, M; de Biase, S; Demir, B; Deng, W; Deng, Z; Di Pinto, F; Domenech-Ximenos, B; Dong, G; Drácz, L; Du, XJ; Duan, LJ; Duan, Y; Ekendahl, D; Fan, W; Fang, L; Feng, C; Followill, DS; Foreman, SC; Fortunato, G; Frew, R; Fu, M; Gaál, V; Ganzevoort, W; Gao, DM; Gao, X; Gao, ZW; Garcia-Alvarez, A; Garza, MS; Gauthier, L; Gazzaz, ZJ; Ge, RS; Geng, Y; Genovesi, S; Geoffroy, V; Georg, D; Gigli, GL; Gong, J; Gong, Q; Groeneveld, J; Guerra, V; Guo, Q; Guo, X; Güttinger, R; Guyo, U; Haldar, J; Han, DS; Han, S; Hao, W; Hayman, A; He, D; Heidari, A; Heller, S; Ho, CT; Ho, SL; Hong, SN; Hou, YJ; Hu, D; Hu, X; Hu, ZY; Huang, JW; Huang, KC; Huang, Q; Huang, T; Hwang, JK; Izewska, J; Jablonski, CL; Jameel, T; Jeong, HK; Ji, J; Jia, Z; Jiang, W; Jiang, Y; Kalumpha, M; Kang, JH; Kazantsev, P; Kazemier, BM; Kebede, B; Khan, SA; Kiss, J; Kohen, A; Kolbenheyer, E; Konai, MM; Koniarova, I; Kornblith, E; Krawetz, RJ; Kreouzis, T; Kry, SF; Laepple, T; Lalošević, D; Lan, Y; Lawung, R; Lechner, W; Lee, KH; Lee, YH; Leonard, C; Li, C; Li, CF; Li, CM; Li, F; Li, J; Li, L; Li, S; Li, X; Li, Y; Li, YB; Li, Z; Liang, C; Lin, J; Lin, XH; Ling, M; Link, TM; Liu, HH; Liu, J; Liu, M; Liu, W; Liu, YP; Lou, H; Lu, G; Lu, M; Lun, SM; Ma, Z; Mackensen, A; Majumdar, S; Martineau, C; Martínez-Pastor, JP; McQuaid, JR; Mehrabian, H; Meng, Y; Miao, T; Miljković, D; Mo, J; Mohamed, HSH; Mohtadi, M; Mol, BWJ; Moosavi, L; Mosdósi, B; Nabu, S; Nava, E; Ni, L; Novakovic-Agopian, T; Nyamunda, BC; Nyul, Z; Önal, B; Özen, D; Özyazgan, S; Pajkrt, E; Palazon, F; Park, HW; Patai, Á; Patai, ÁV; Patzke, GR; Payette, G; Pedoia, V; Peelen, MJCS; Pellitteri, G; Peng, J; Perea, RJ; Pérez-Del-Rey, D; Popović, DJ; Popović, JK; Popović, KJ; Posecion, L; Povall, J; Prachayasittikul, S; Prachayasittikul, V; Prat-González, S; Qi, B; Qu, B; Rakshit, S; Ravelli, ACJ; Ren, ZG; Rivera, SM; Salo, P; Samaddar, S; Samper, JLA; Samy El Gendy, NM; Schmitt, N; Sekerbayev, KS; Sepúlveda-Martínez, Á; Sessolo, M; Severi, S; Sha, Y; Shen, FF; Shen, X; Shen, Y; Singh, P; Sinthupoom, N; Siri, S; Sitges, M; Slovak, JE; Solymosi, N; Song, H; Song, J; Song, M; Spingler, B; Stewart, I; Su, BL; Su, JF; Suming, L; Sun, JX; Tantimavanich, S; Tashkandi, JM; Taurbayev, TI; Tedgren, AC; Tenhunen, M; Thwaites, DI; Tibrewala, R; Tomsejm, M; Triana, CA; Vakira, FM; Valdez, M; Valente, M; Valentini, AM; Van de Winckel, A; van der Lee, R; Varga, F; Varga, M; Villarino, NF; Villemur, R; Vinatha, SP; Vincenti, A; Voskamp, BJ; Wang, B; Wang, C; Wang, H; Wang, HT; Wang, J; Wang, M; Wang, N; Wang, NC; Wang, Q; Wang, S; Wang, X; Wang, Y; Wang, Z; Wen, N; Wesolowska, P; Willis, M; Wu, C; Wu, D; Wu, L; Wu, X; Wu, Z; Xia, JM; Xia, X; Xia, Y; Xiao, J; Xiao, Y; Xie, CL; Xie, LM; Xie, S; Xing, Z; Xu, C; Xu, J; Yan, D; Yan, K; Yang, S; Yang, X; Yang, XW; Ye, M; Yin, Z; Yoon, N; Yoon, Y; Yu, H; Yu, K; Yu, ZY; Zhang, B; Zhang, GY; Zhang, H; Zhang, J; Zhang, M; Zhang, Q; Zhang, S; Zhang, W; Zhang, X; Zhang, Y; Zhang, YW; Zhang, Z; Zhao, D; Zhao, F; Zhao, P; Zhao, W; Zhao, Z; Zheng, C; Zhi, D; Zhou, C; Zhou, FY; Zhu, D; Zhu, J; Zhu, Q; Zinyama, NP; Zou, M; Zou, Z, 2019
)
0.51
"The dose-response of cough induced by CPS inhalation was determined in 20 unselected healthy volunteers and the concentration of CPS causing two coughs (C2) was calculated."( Multiple single nucleotide polymorphisms of the transient receptor potential vanilloid 1 (TRPV1) genes associate with cough sensitivity to capsaicin in healthy subjects.
Campisi, M; Guarnieri, G; Liviero, F; Maestrelli, P; Mason, P; Pavanello, S; Scarpa, MC, 2020
)
0.56
" Discussed also are potential future directions for formulation strategies to develop efficient, safe and cost-effective dosage forms of capsiate to explore its role in various disease conditions."( Sweet pepper and its principle constituent capsiate: functional properties and health benefits.
Awasthi, A; Gulati, M; Gupta, M; Gupta, R; Kapoor, B; Kumar, B; Singh, SK, 2022
)
0.72
" Dose-response analysis reveals a significant nonlinear relationship between gastric cancer risk and capsaicin intake."( Spicy Food and Chili Peppers and Multiple Health Outcomes: Umbrella Review.
Ao, Z; Huang, Z; Liu, H, 2022
)
0.72
" Capsaicin sensitivity at the site of the cancer was evident in cancer patients by a leftward shift of the cancer site capsaicin dose-response curve compared to that of the patient's contralateral matched normal site."( Oral cancer patients experience mechanical and chemical sensitivity at the site of the cancer.
Albertson, DG; Janal, MN; Nicholson, SJ; Sawicki, CM; Schmidt, BL; Wu, AK, 2022
)
0.72
" Furthermore, the dose-response relationship of capsaicin and γ-nonalactone to TRPV1 suggests that γ-nonalactone acts as an agonist or antagonist of TRPV1, depending on its concentration."( Agonistic/antagonistic properties of lactones in food flavors on the sensory ion channels TRPV1 and TRPA1.
Kaneko, S; Kusakabe, Y; Ogawa, Y; Zhou, L, 2022
)
0.72
" Emax and ED50 were shown to be repeatable, and the dose-response method well tolerated."( Novel capsaicin cough endpoints effectively discriminate between healthy controls and patients with refractory chronic cough.
Belcher, J; Holt, KJ; Smith, JA, 2023
)
0.91
"Novel capsaicin dose-response endpoints effectively discriminate between healthy controls and refractory chronic cough patients, which may better represent pathophysiological mechanisms and show promise for development as a tool to identify patients with cough hyper-excitability."( Novel capsaicin cough endpoints effectively discriminate between healthy controls and patients with refractory chronic cough.
Belcher, J; Holt, KJ; Smith, JA, 2023
)
0.91
" The dose-response curves in citric acid and capsaicin cough challenge construction shows significantly increased cough threshold in SPF animals compared to wild-type animals of both sexes."( Cough response in specific pathogen-free guinea pig animal model.
Biringerova, Z; Brozmanova, M; Buday, T; Kopcova, L; Matloobi, A; Plevkova, J, 2023
)
0.91
" ORs for developing hypertensive ICH according to overtime working hours showed a dose-response relationship; an overtime of 100 hours/month was associated with a significantly higher OR (1."( Long working hours and risk of hypertensive intracerebral haemorrhage among Japanese workers claiming compensation for overwork-related intracerebral haemorrhage: an unmatched case-control study.
Morita, Y; Takahashi, M; Yoshikawa, T, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
non-narcotic analgesicA drug that has principally analgesic, antipyretic and anti-inflammatory actions. Non-narcotic analgesics do not bind to opioid receptors.
voltage-gated sodium channel blockerAny sodium channel blocker that interferes with the activity of voltage-gated sodium channels.
TRPV1 agonistAn agonist at the transient receptor potential vanilloid 1 (TRPV1).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
capsaicinoidA family of aromatic fatty amides produced as secondary metabolites by chilli peppers.
methoxybenzenesAny aromatic ether that consists of a benzene skeleton substituted with one or more methoxy groups.
phenolsOrganic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (3)

PathwayProteinsCompounds
capsaicin biosynthesis616
NADH to cytochrome bo oxidase electron transfer I1734
NADH to cytochrome bd oxidase electron transfer I1627

Protein Targets (75)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency7.94330.003245.467312,589.2998AID2517
Chain A, HADH2 proteinHomo sapiens (human)Potency35.71680.025120.237639.8107AID886; AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency35.71680.025120.237639.8107AID886; AID893
15-lipoxygenase, partialHomo sapiens (human)Potency31.62280.012610.691788.5700AID887
phosphopantetheinyl transferaseBacillus subtilisPotency89.12510.141337.9142100.0000AID1490
RAR-related orphan receptor gammaMus musculus (house mouse)Potency59.51780.006038.004119,952.5996AID1159523
GLS proteinHomo sapiens (human)Potency8.91250.35487.935539.8107AID624170
TDP1 proteinHomo sapiens (human)Potency23.13200.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency5.95180.000714.592883.7951AID1259392
Microtubule-associated protein tauHomo sapiens (human)Potency24.70280.180013.557439.8107AID1460; AID1468
AR proteinHomo sapiens (human)Potency30.91400.000221.22318,912.5098AID1259243; AID1259247; AID588515; AID743035; AID743036; AID743042; AID743054; AID743063
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency21.64520.011212.4002100.0000AID1030
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency11.87540.000657.913322,387.1992AID1259377
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency39.98380.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency53.04530.000417.946075.1148AID1346795
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency3.41240.003041.611522,387.1992AID1159552; AID1159555
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency59.71520.001530.607315,848.9004AID1224848; AID1224849; AID1259401; AID1259403
pregnane X nuclear receptorHomo sapiens (human)Potency32.79960.005428.02631,258.9301AID1346982; AID720659
estrogen nuclear receptor alphaHomo sapiens (human)Potency37.03520.000229.305416,493.5996AID1259244; AID1259248; AID743069; AID743075; AID743078; AID743079; AID743091
67.9K proteinVaccinia virusPotency39.81070.00018.4406100.0000AID720580
glucocerebrosidaseHomo sapiens (human)Potency17.78280.01268.156944.6684AID2101
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency15.07430.001024.504861.6448AID743212
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency55.06520.001019.414170.9645AID588536; AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency60.01180.023723.228263.5986AID743222
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency21.26560.001723.839378.1014AID743083
chromobox protein homolog 1Homo sapiens (human)Potency100.00000.006026.168889.1251AID540317
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency32.67150.000323.4451159.6830AID743065; AID743067
mitogen-activated protein kinase 1Homo sapiens (human)Potency31.62280.039816.784239.8107AID995
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency35.64500.000627.21521,122.0200AID651741; AID720636; AID743202; AID743219
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency89.12510.050127.073689.1251AID588590
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency35.48130.00798.23321,122.0200AID2551
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency9.07430.005612.367736.1254AID624032
survival motor neuron protein isoform dHomo sapiens (human)Potency22.38720.125912.234435.4813AID1458
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency2.51190.031610.279239.8107AID884; AID885
transient receptor potential cation channel subfamily V member 1Homo sapiens (human)Potency0.04330.09120.09120.0912AID623958; AID623959; AID623960
lamin isoform A-delta10Homo sapiens (human)Potency35.48130.891312.067628.1838AID1487
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency2.51191.000012.224831.6228AID885
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency59.51780.001557.789015,848.9004AID1259244
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency2.51191.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency2.51191.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency2.51191.000012.224831.6228AID885
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency59.51780.001551.739315,848.9004AID1259244
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency2.51191.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency2.51191.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency2.51191.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency2.51191.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency2.51191.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency2.51191.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency2.51191.000012.224831.6228AID885
Nuclear receptor ROR-gammaHomo sapiens (human)Potency33.49150.026622.448266.8242AID651802
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency44.66840.009610.525035.4813AID1479145
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency2.51191.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency2.51191.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency2.51191.000012.224831.6228AID885
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency2.81841.000010.475628.1838AID1457
GABA theta subunitRattus norvegicus (Norway rat)Potency2.51191.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency2.51191.000012.224831.6228AID885
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency0.75690.060110.745337.9330AID485367
EWS/FLI fusion proteinHomo sapiens (human)Potency10.99060.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Transient receptor potential cation channel subfamily V member 1Rattus norvegicus (Norway rat)IC50 (µMol)0.01900.00040.21474.0000AID538419
Transient receptor potential cation channel subfamily V member 1Rattus norvegicus (Norway rat)Ki1.77950.00010.64456.4000AID1581154; AID218324; AID218326; AID348212
Lysine-specific histone demethylase 1AHomo sapiens (human)IC50 (µMol)0.60000.00312.16029.6000AID1845955; AID1854424; AID1872409
Bile salt export pumpHomo sapiens (human)IC50 (µMol)10.00000.11007.190310.0000AID1449628
NADH-ubiquinone oxidoreductase chain 1Bos taurus (cattle)IC50 (µMol)52.48080.00300.01150.0257AID1105529
Cytochrome P450 1A2Homo sapiens (human)IC50 (µMol)3.00000.00011.774010.0000AID625245
Polyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)IC50 (µMol)56.00000.00011.68479.3200AID1603728
Cannabinoid receptor 1Homo sapiens (human)Ki8.90000.00010.50779.6000AID1727011; AID1798961; AID353802
AcetylcholinesteraseHomo sapiens (human)IC50 (µMol)200.00000.00000.933210.0000AID1707534
Prostaglandin G/H synthase 1Homo sapiens (human)IC50 (µMol)2.67550.00021.557410.0000AID403341; AID625243
Cannabinoid receptor 2 Homo sapiens (human)Ki10.00000.00000.415610.0000AID1798961; AID353803
Corticotropin-releasing factor receptor 2Homo sapiens (human)Ki10.00000.16800.16800.1680AID353803
Transient receptor potential cation channel subfamily V member 1Homo sapiens (human)IC50 (µMol)0.00800.00020.606010.0000AID1191866; AID1700045
Transient receptor potential cation channel subfamily V member 1Homo sapiens (human)Ki1.18650.00010.67956.4000AID1451859; AID1451870; AID1581152; AID538418
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Transient receptor potential cation channel subfamily V member 1Rattus norvegicus (Norway rat)EC50 (µMol)0.40940.00050.43182.3800AID1537419; AID1581155; AID175476; AID175668; AID175848; AID218163; AID218314; AID345832
D(2) dopamine receptorRattus norvegicus (Norway rat)EC50 (µMol)0.30000.00040.32993.9100AID175476
Transient receptor potential cation channel subfamily V member 1Homo sapiens (human)EC50 (µMol)1.84630.00051.06746.3096AID1191865; AID1390827; AID1392619; AID1581153; AID1590170; AID1700044; AID1727013; AID1744407; AID1797975; AID1798962; AID1875054; AID229033; AID292699; AID353804; AID452447; AID478379; AID644962
Transient receptor potential cation channel subfamily V member 4Rattus norvegicus (Norway rat)EC50 (µMol)0.24600.03000.33150.9000AID175476; AID175668; AID175848; AID218163
Transient receptor potential cation channel subfamily V member 2Rattus norvegicus (Norway rat)EC50 (µMol)0.24600.03000.45071.7000AID175476; AID175668; AID175848; AID218163
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Transient receptor potential cation channel subfamily V member 1Homo sapiens (human)Activity0.01000.01003.519810.0000AID500214
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (229)

Processvia Protein(s)Taxonomy
regulation of double-strand break repair via homologous recombinationLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of protein ubiquitinationLysine-specific histone demethylase 1AHomo sapiens (human)
regulation of protein localizationLysine-specific histone demethylase 1AHomo sapiens (human)
cellular response to UVLysine-specific histone demethylase 1AHomo sapiens (human)
cellular response to gamma radiationLysine-specific histone demethylase 1AHomo sapiens (human)
DNA repair-dependent chromatin remodelingLysine-specific histone demethylase 1AHomo sapiens (human)
negative regulation of transcription by RNA polymerase IILysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of neuroblast proliferationLysine-specific histone demethylase 1AHomo sapiens (human)
regulation of transcription by RNA polymerase IILysine-specific histone demethylase 1AHomo sapiens (human)
protein demethylationLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of epithelial to mesenchymal transitionLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of neuron projection developmentLysine-specific histone demethylase 1AHomo sapiens (human)
cerebral cortex developmentLysine-specific histone demethylase 1AHomo sapiens (human)
negative regulation of protein bindingLysine-specific histone demethylase 1AHomo sapiens (human)
neuron maturationLysine-specific histone demethylase 1AHomo sapiens (human)
negative regulation of DNA bindingLysine-specific histone demethylase 1AHomo sapiens (human)
negative regulation of DNA-binding transcription factor activityLysine-specific histone demethylase 1AHomo sapiens (human)
negative regulation of DNA damage response, signal transduction by p53 class mediatorLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of cell sizeLysine-specific histone demethylase 1AHomo sapiens (human)
negative regulation of DNA-templated transcriptionLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of transcription by RNA polymerase IILysine-specific histone demethylase 1AHomo sapiens (human)
guanine metabolic processLysine-specific histone demethylase 1AHomo sapiens (human)
muscle cell developmentLysine-specific histone demethylase 1AHomo sapiens (human)
regulation of androgen receptor signaling pathwayLysine-specific histone demethylase 1AHomo sapiens (human)
response to fungicideLysine-specific histone demethylase 1AHomo sapiens (human)
cellular response to cAMPLysine-specific histone demethylase 1AHomo sapiens (human)
regulation of DNA methylation-dependent heterochromatin formationLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of cold-induced thermogenesisLysine-specific histone demethylase 1AHomo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of neural precursor cell proliferationLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of stem cell proliferationLysine-specific histone demethylase 1AHomo sapiens (human)
chromatin remodelingLysine-specific histone demethylase 1AHomo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
mitochondrial respiratory chain complex I assemblyNADH-ubiquinone oxidoreductase chain 1Bos taurus (cattle)
transmembrane transportNADH-ubiquinone oxidoreductase chain 1Bos taurus (cattle)
steroid catabolic processCytochrome P450 1A2Homo sapiens (human)
porphyrin-containing compound metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1A2Homo sapiens (human)
cholesterol metabolic processCytochrome P450 1A2Homo sapiens (human)
estrogen metabolic processCytochrome P450 1A2Homo sapiens (human)
toxin biosynthetic processCytochrome P450 1A2Homo sapiens (human)
post-embryonic developmentCytochrome P450 1A2Homo sapiens (human)
alkaloid metabolic processCytochrome P450 1A2Homo sapiens (human)
regulation of gene expressionCytochrome P450 1A2Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 1A2Homo sapiens (human)
dibenzo-p-dioxin metabolic processCytochrome P450 1A2Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
lung developmentCytochrome P450 1A2Homo sapiens (human)
methylationCytochrome P450 1A2Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 1A2Homo sapiens (human)
retinol metabolic processCytochrome P450 1A2Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 1A2Homo sapiens (human)
cellular respirationCytochrome P450 1A2Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 1A2Homo sapiens (human)
hydrogen peroxide biosynthetic processCytochrome P450 1A2Homo sapiens (human)
oxidative demethylationCytochrome P450 1A2Homo sapiens (human)
cellular response to cadmium ionCytochrome P450 1A2Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
negative regulation of endothelial cell proliferationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukocyte chemotaxis involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukocyte migration involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene production involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene metabolic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
humoral immune responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of angiogenesisPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
positive regulation of bone mineralizationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
dendritic cell migrationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
glucose homeostasisPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
long-chain fatty acid biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of fat cell differentiationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of insulin secretionPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of vascular wound healingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of wound healingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of inflammatory response to woundingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of cytokine production involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of cellular response to oxidative stressPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene A4 biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of reactive oxygen species biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of response to endoplasmic reticulum stressPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of sprouting angiogenesisPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
positive regulation of leukocyte adhesion to arterial endothelial cellPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
lipoxin biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
positive regulation of acute inflammatory response to antigenic stimulusCannabinoid receptor 1Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerCannabinoid receptor 1Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayCannabinoid receptor 1Homo sapiens (human)
spermatogenesisCannabinoid receptor 1Homo sapiens (human)
axonal fasciculationCannabinoid receptor 1Homo sapiens (human)
response to nutrientCannabinoid receptor 1Homo sapiens (human)
memoryCannabinoid receptor 1Homo sapiens (human)
positive regulation of neuron projection developmentCannabinoid receptor 1Homo sapiens (human)
negative regulation of serotonin secretionCannabinoid receptor 1Homo sapiens (human)
positive regulation of fever generationCannabinoid receptor 1Homo sapiens (human)
negative regulation of fatty acid beta-oxidationCannabinoid receptor 1Homo sapiens (human)
regulation of synaptic transmission, GABAergicCannabinoid receptor 1Homo sapiens (human)
response to lipopolysaccharideCannabinoid receptor 1Homo sapiens (human)
negative regulation of mast cell activationCannabinoid receptor 1Homo sapiens (human)
negative regulation of dopamine secretionCannabinoid receptor 1Homo sapiens (human)
response to nicotineCannabinoid receptor 1Homo sapiens (human)
cannabinoid signaling pathwayCannabinoid receptor 1Homo sapiens (human)
response to cocaineCannabinoid receptor 1Homo sapiens (human)
glucose homeostasisCannabinoid receptor 1Homo sapiens (human)
positive regulation of apoptotic processCannabinoid receptor 1Homo sapiens (human)
response to ethanolCannabinoid receptor 1Homo sapiens (human)
negative regulation of action potentialCannabinoid receptor 1Homo sapiens (human)
negative regulation of blood pressureCannabinoid receptor 1Homo sapiens (human)
positive regulation of blood pressureCannabinoid receptor 1Homo sapiens (human)
regulation of insulin secretionCannabinoid receptor 1Homo sapiens (human)
regulation of synaptic transmission, glutamatergicCannabinoid receptor 1Homo sapiens (human)
maternal process involved in female pregnancyCannabinoid receptor 1Homo sapiens (human)
regulation of feeding behaviorCannabinoid receptor 1Homo sapiens (human)
regulation of penile erectionCannabinoid receptor 1Homo sapiens (human)
retrograde trans-synaptic signaling by endocannabinoidCannabinoid receptor 1Homo sapiens (human)
regulation of presynaptic cytosolic calcium ion concentrationCannabinoid receptor 1Homo sapiens (human)
trans-synaptic signaling by endocannabinoid, modulating synaptic transmissionCannabinoid receptor 1Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayCannabinoid receptor 1Homo sapiens (human)
regulation of metabolic processCannabinoid receptor 1Homo sapiens (human)
acetylcholine catabolic process in synaptic cleftAcetylcholinesteraseHomo sapiens (human)
regulation of receptor recyclingAcetylcholinesteraseHomo sapiens (human)
osteoblast developmentAcetylcholinesteraseHomo sapiens (human)
acetylcholine catabolic processAcetylcholinesteraseHomo sapiens (human)
cell adhesionAcetylcholinesteraseHomo sapiens (human)
nervous system developmentAcetylcholinesteraseHomo sapiens (human)
synapse assemblyAcetylcholinesteraseHomo sapiens (human)
receptor internalizationAcetylcholinesteraseHomo sapiens (human)
negative regulation of synaptic transmission, cholinergicAcetylcholinesteraseHomo sapiens (human)
amyloid precursor protein metabolic processAcetylcholinesteraseHomo sapiens (human)
positive regulation of protein secretionAcetylcholinesteraseHomo sapiens (human)
retina development in camera-type eyeAcetylcholinesteraseHomo sapiens (human)
acetylcholine receptor signaling pathwayAcetylcholinesteraseHomo sapiens (human)
positive regulation of cold-induced thermogenesisAcetylcholinesteraseHomo sapiens (human)
prostaglandin biosynthetic processProstaglandin G/H synthase 1Homo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 1Homo sapiens (human)
regulation of blood pressureProstaglandin G/H synthase 1Homo sapiens (human)
cyclooxygenase pathwayProstaglandin G/H synthase 1Homo sapiens (human)
regulation of cell population proliferationProstaglandin G/H synthase 1Homo sapiens (human)
cellular oxidant detoxificationProstaglandin G/H synthase 1Homo sapiens (human)
response to amphetamineCannabinoid receptor 2 Homo sapiens (human)
inflammatory responseCannabinoid receptor 2 Homo sapiens (human)
immune responseCannabinoid receptor 2 Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerCannabinoid receptor 2 Homo sapiens (human)
leukocyte chemotaxisCannabinoid receptor 2 Homo sapiens (human)
negative regulation of synaptic transmission, GABAergicCannabinoid receptor 2 Homo sapiens (human)
response to lipopolysaccharideCannabinoid receptor 2 Homo sapiens (human)
negative regulation of mast cell activationCannabinoid receptor 2 Homo sapiens (human)
cannabinoid signaling pathwayCannabinoid receptor 2 Homo sapiens (human)
negative regulation of action potentialCannabinoid receptor 2 Homo sapiens (human)
regulation of metabolic processCannabinoid receptor 2 Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayCannabinoid receptor 2 Homo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
xenobiotic metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of glucose metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of steroid metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor ROR-gammaHomo sapiens (human)
circadian regulation of gene expressionNuclear receptor ROR-gammaHomo sapiens (human)
cellular response to sterolNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of circadian rhythmNuclear receptor ROR-gammaHomo sapiens (human)
regulation of fat cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor ROR-gammaHomo sapiens (human)
adipose tissue developmentNuclear receptor ROR-gammaHomo sapiens (human)
T-helper 17 cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
startle responsePotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
regulation of muscle contractionPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
neuroblast proliferationPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
protein localizationPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
cell communication by electrical couplingPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
magnesium ion homeostasisPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
neuronal action potentialPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
optic nerve developmentPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
hippocampus developmentPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
cerebral cortex developmentPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
corpus callosum developmentPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
neuronal signal transductionPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
regulation of membrane potentialPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
neuromuscular processPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
detection of mechanical stimulus involved in sensory perception of painPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
detection of mechanical stimulus involved in sensory perception of touchPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
protein homooligomerizationPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
regulation of postsynaptic membrane potentialPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
axon developmentPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
cellular response to magnesium ionPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
regulation of presynaptic membrane potentialPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
action potentialPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
cell surface receptor signaling pathwayCorticotropin-releasing factor receptor 2Homo sapiens (human)
cellular response to corticotropin-releasing hormone stimulusCorticotropin-releasing factor receptor 2Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayCorticotropin-releasing factor receptor 2Homo sapiens (human)
long-term synaptic potentiationCorticotropin-releasing factor receptor 2Homo sapiens (human)
thermoceptionTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IITransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
fever generationTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
microglial cell activationTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
diet induced thermogenesisTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
peptide secretionTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
negative regulation of systemic arterial blood pressureTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
lipid metabolic processTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
cell surface receptor signaling pathwayTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
chemosensory behaviorTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
negative regulation of heart rateTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
negative regulation of mitochondrial membrane potentialTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
glutamate secretionTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
calcium-mediated signalingTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
cellular response to heatTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
positive regulation of apoptotic processTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
response to peptide hormoneTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
positive regulation of nitric oxide biosynthetic processTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
behavioral response to painTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
sensory perception of mechanical stimulusTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
detection of temperature stimulus involved in thermoceptionTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
detection of temperature stimulus involved in sensory perception of painTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of painTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
protein homotetramerizationTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
excitatory postsynaptic potentialTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
smooth muscle contraction involved in micturitionTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
calcium ion transmembrane transportTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
cellular response to alkaloidTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
cellular response to ATPTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
cellular response to tumor necrosis factorTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
cellular response to acidic pHTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
cellular response to temperature stimulusTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
negative regulation of establishment of blood-brain barrierTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
calcium ion import across plasma membraneTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
response to capsazepineTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
cellular response to nerve growth factor stimulusTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (87)

Processvia Protein(s)Taxonomy
telomeric DNA bindingLysine-specific histone demethylase 1AHomo sapiens (human)
p53 bindingLysine-specific histone demethylase 1AHomo sapiens (human)
chromatin bindingLysine-specific histone demethylase 1AHomo sapiens (human)
transcription coactivator activityLysine-specific histone demethylase 1AHomo sapiens (human)
protein bindingLysine-specific histone demethylase 1AHomo sapiens (human)
oxidoreductase activityLysine-specific histone demethylase 1AHomo sapiens (human)
enzyme bindingLysine-specific histone demethylase 1AHomo sapiens (human)
nuclear receptor coactivator activityLysine-specific histone demethylase 1AHomo sapiens (human)
demethylase activityLysine-specific histone demethylase 1AHomo sapiens (human)
histone demethylase activityLysine-specific histone demethylase 1AHomo sapiens (human)
histone H3K4 demethylase activityLysine-specific histone demethylase 1AHomo sapiens (human)
histone H3K9 demethylase activityLysine-specific histone demethylase 1AHomo sapiens (human)
identical protein bindingLysine-specific histone demethylase 1AHomo sapiens (human)
MRF bindingLysine-specific histone demethylase 1AHomo sapiens (human)
flavin adenine dinucleotide bindingLysine-specific histone demethylase 1AHomo sapiens (human)
nuclear androgen receptor bindingLysine-specific histone demethylase 1AHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingLysine-specific histone demethylase 1AHomo sapiens (human)
telomeric repeat-containing RNA bindingLysine-specific histone demethylase 1AHomo sapiens (human)
DNA-binding transcription factor bindingLysine-specific histone demethylase 1AHomo sapiens (human)
FAD-dependent H3K4me/H3K4me3 demethylase activityLysine-specific histone demethylase 1AHomo sapiens (human)
promoter-specific chromatin bindingLysine-specific histone demethylase 1AHomo sapiens (human)
transcription factor bindingLysine-specific histone demethylase 1AHomo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
NADH dehydrogenase (ubiquinone) activityNADH-ubiquinone oxidoreductase chain 1Bos taurus (cattle)
monooxygenase activityCytochrome P450 1A2Homo sapiens (human)
iron ion bindingCytochrome P450 1A2Homo sapiens (human)
protein bindingCytochrome P450 1A2Homo sapiens (human)
electron transfer activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 1A2Homo sapiens (human)
enzyme bindingCytochrome P450 1A2Homo sapiens (human)
heme bindingCytochrome P450 1A2Homo sapiens (human)
demethylase activityCytochrome P450 1A2Homo sapiens (human)
caffeine oxidase activityCytochrome P450 1A2Homo sapiens (human)
aromatase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1A2Homo sapiens (human)
arachidonate 5-lipoxygenase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
arachidonate 12(S)-lipoxygenase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
iron ion bindingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
protein bindingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
hydrolase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
cannabinoid receptor activityCannabinoid receptor 1Homo sapiens (human)
protein bindingCannabinoid receptor 1Homo sapiens (human)
identical protein bindingCannabinoid receptor 1Homo sapiens (human)
G protein-coupled receptor activityCannabinoid receptor 1Homo sapiens (human)
amyloid-beta bindingAcetylcholinesteraseHomo sapiens (human)
acetylcholinesterase activityAcetylcholinesteraseHomo sapiens (human)
cholinesterase activityAcetylcholinesteraseHomo sapiens (human)
protein bindingAcetylcholinesteraseHomo sapiens (human)
collagen bindingAcetylcholinesteraseHomo sapiens (human)
hydrolase activityAcetylcholinesteraseHomo sapiens (human)
serine hydrolase activityAcetylcholinesteraseHomo sapiens (human)
acetylcholine bindingAcetylcholinesteraseHomo sapiens (human)
protein homodimerization activityAcetylcholinesteraseHomo sapiens (human)
laminin bindingAcetylcholinesteraseHomo sapiens (human)
peroxidase activityProstaglandin G/H synthase 1Homo sapiens (human)
prostaglandin-endoperoxide synthase activityProstaglandin G/H synthase 1Homo sapiens (human)
protein bindingProstaglandin G/H synthase 1Homo sapiens (human)
heme bindingProstaglandin G/H synthase 1Homo sapiens (human)
metal ion bindingProstaglandin G/H synthase 1Homo sapiens (human)
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygenProstaglandin G/H synthase 1Homo sapiens (human)
protein bindingCannabinoid receptor 2 Homo sapiens (human)
cannabinoid receptor activityCannabinoid receptor 2 Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein bindingNuclear receptor ROR-gammaHomo sapiens (human)
oxysterol bindingNuclear receptor ROR-gammaHomo sapiens (human)
zinc ion bindingNuclear receptor ROR-gammaHomo sapiens (human)
ligand-activated transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
nuclear receptor activityNuclear receptor ROR-gammaHomo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
disordered domain specific bindingPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
voltage-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
voltage-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
protein bindingCorticotropin-releasing factor receptor 2Homo sapiens (human)
peptide hormone bindingCorticotropin-releasing factor receptor 2Homo sapiens (human)
corticotrophin-releasing factor receptor activityCorticotropin-releasing factor receptor 2Homo sapiens (human)
G protein-coupled peptide receptor activityCorticotropin-releasing factor receptor 2Homo sapiens (human)
corticotropin-releasing hormone receptor activityCorticotropin-releasing factor receptor 2Homo sapiens (human)
transmembrane signaling receptor activityTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
extracellular ligand-gated monoatomic ion channel activityTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activityTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
voltage-gated calcium channel activityTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
calcium channel activityTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
protein bindingTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
calmodulin bindingTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
ATP bindingTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
intracellularly gated calcium channel activityTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
chloride channel regulator activityTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
phosphatidylinositol bindingTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
identical protein bindingTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
metal ion bindingTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
phosphoprotein bindingTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
temperature-gated ion channel activityTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (68)

Processvia Protein(s)Taxonomy
chromatinLysine-specific histone demethylase 1AHomo sapiens (human)
nucleusLysine-specific histone demethylase 1AHomo sapiens (human)
chromosome, telomeric regionLysine-specific histone demethylase 1AHomo sapiens (human)
nucleusLysine-specific histone demethylase 1AHomo sapiens (human)
nucleoplasmLysine-specific histone demethylase 1AHomo sapiens (human)
transcription regulator complexLysine-specific histone demethylase 1AHomo sapiens (human)
protein-containing complexLysine-specific histone demethylase 1AHomo sapiens (human)
DNA repair complexLysine-specific histone demethylase 1AHomo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
mitochondrial inner membraneNADH-ubiquinone oxidoreductase chain 1Bos taurus (cattle)
respiratory chain complex INADH-ubiquinone oxidoreductase chain 1Bos taurus (cattle)
endoplasmic reticulum membraneCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
extracellular regionPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
extracellular spacePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear envelopePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear envelope lumenPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nucleoplasmPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
cytosolPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear matrixPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear membranePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
secretory granule lumenPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
perinuclear region of cytoplasmPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
ficolin-1-rich granule lumenPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear envelopePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
mitochondrial outer membraneCannabinoid receptor 1Homo sapiens (human)
plasma membraneCannabinoid receptor 1Homo sapiens (human)
actin cytoskeletonCannabinoid receptor 1Homo sapiens (human)
growth coneCannabinoid receptor 1Homo sapiens (human)
presynaptic membraneCannabinoid receptor 1Homo sapiens (human)
membrane raftCannabinoid receptor 1Homo sapiens (human)
glutamatergic synapseCannabinoid receptor 1Homo sapiens (human)
GABA-ergic synapseCannabinoid receptor 1Homo sapiens (human)
plasma membraneCannabinoid receptor 1Homo sapiens (human)
cytoplasmCannabinoid receptor 1Homo sapiens (human)
extracellular regionAcetylcholinesteraseHomo sapiens (human)
basement membraneAcetylcholinesteraseHomo sapiens (human)
extracellular spaceAcetylcholinesteraseHomo sapiens (human)
nucleusAcetylcholinesteraseHomo sapiens (human)
Golgi apparatusAcetylcholinesteraseHomo sapiens (human)
plasma membraneAcetylcholinesteraseHomo sapiens (human)
cell surfaceAcetylcholinesteraseHomo sapiens (human)
membraneAcetylcholinesteraseHomo sapiens (human)
neuromuscular junctionAcetylcholinesteraseHomo sapiens (human)
synaptic cleftAcetylcholinesteraseHomo sapiens (human)
synapseAcetylcholinesteraseHomo sapiens (human)
perinuclear region of cytoplasmAcetylcholinesteraseHomo sapiens (human)
side of membraneAcetylcholinesteraseHomo sapiens (human)
photoreceptor outer segmentProstaglandin G/H synthase 1Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 1Homo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 1Homo sapiens (human)
Golgi apparatusProstaglandin G/H synthase 1Homo sapiens (human)
intracellular membrane-bounded organelleProstaglandin G/H synthase 1Homo sapiens (human)
extracellular exosomeProstaglandin G/H synthase 1Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 1Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 1Homo sapiens (human)
plasma membraneCannabinoid receptor 2 Homo sapiens (human)
dendriteCannabinoid receptor 2 Homo sapiens (human)
extrinsic component of cytoplasmic side of plasma membraneCannabinoid receptor 2 Homo sapiens (human)
perikaryonCannabinoid receptor 2 Homo sapiens (human)
endoplasmic reticulumCannabinoid receptor 2 Homo sapiens (human)
plasma membraneCannabinoid receptor 2 Homo sapiens (human)
cytoplasmCannabinoid receptor 2 Homo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
nucleoplasmNuclear receptor ROR-gammaHomo sapiens (human)
nuclear bodyNuclear receptor ROR-gammaHomo sapiens (human)
chromatinNuclear receptor ROR-gammaHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
endoplasmic reticulumPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
cytosolPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
apical plasma membranePotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
cell junctionPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
dendritePotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
cytoplasmic vesiclePotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
paranode region of axonPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
presynaptic membranePotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
neuronal cell bodyPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
axon initial segmentPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
perikaryonPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
axon terminusPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
juxtaparanode region of axonPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
calyx of HeldPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
synapsePotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
postsynaptic membranePotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
anchoring junctionPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
glutamatergic synapsePotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
dendritePotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
paranode region of axonPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
membranePotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
synapsePotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
juxtaparanode region of axonPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
neuronal cell bodyPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
plasma membraneCorticotropin-releasing factor receptor 2Homo sapiens (human)
axon terminusCorticotropin-releasing factor receptor 2Homo sapiens (human)
plasma membraneCorticotropin-releasing factor receptor 2Homo sapiens (human)
dendriteCorticotropin-releasing factor receptor 2Homo sapiens (human)
plasma membraneTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
external side of plasma membraneTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
membraneTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
dendritic spine membraneTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
neuronal cell bodyTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
postsynaptic membraneTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
plasma membraneTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (278)

Assay IDTitleYearJournalArticle
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1590145Cytotoxicity against human A2058 cells assessed as decrease in cell viability incubated for 24 hrs by MTT assay
AID1727013Agonist activity at human recombinant TRPV1 expressed in HEK293 cells assessed as effect on intracellular calcium level by FLOU-4 dye based fluorescence spectrometry2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Amide Bond Bioisosteres: Strategies, Synthesis, and Successes.
AID130359In vivo analgesic dose in mouse tail flick latency model1993Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16
Analogues of capsaicin with agonist activity as novel analgesic agents; structure-activity studies. 2. The amide bond "B-region".
AID1169294Inhibition of TTR V30M mutant (unknown origin) expressed in Escherichia coli assessed as inhibition of amyloid fibril formation at 20 uM by fluorescence assay2014Journal of medicinal chemistry, Nov-13, Volume: 57, Issue:21
Inhibitory activities of propolis and its promising component, caffeic acid phenethyl ester, against amyloidogenesis of human transthyretin.
AID1833779Induction of apoptosis in human NCI-H460 cells assessed as early apoptotic cells measured after 72 hrs by Annexin V-FITC and propidium iodide staining based flow cytometry analysis (Rvb= 6.61%)2021ACS medicinal chemistry letters, Nov-11, Volume: 12, Issue:11
Apoptosis Inducing 1,3,4-Oxadiazole Conjugates of Capsaicin: Their
AID1191868Agonist activity at rat recombinant TRPA1 expressed in HEK293 cells assessed as Ca2+ influx by Fluo-4 dye based assay2015Bioorganic & medicinal chemistry letters, Mar-01, Volume: 25, Issue:5
Discovery of non-electrophilic capsaicinoid-type TRPA1 ligands.
AID1392623Drug metabolism in human keratinocytes assessed as residual substrate levels at 50 uM up to 120 mins by HPLC-UV analysis2018Journal of medicinal chemistry, 05-24, Volume: 61, Issue:10
Targeting Transient Receptor Potential Vanilloid 1 (TRPV1) Channel Softly: The Discovery of Passerini Adducts as a Topical Treatment for Inflammatory Skin Disorders.
AID1191865Agonist activity at human recombinant TRPV1 expressed in HEK293 cells assessed as Ca2+ influx by Fluo-4 dye based assay2015Bioorganic & medicinal chemistry letters, Mar-01, Volume: 25, Issue:5
Discovery of non-electrophilic capsaicinoid-type TRPA1 ligands.
AID1854424Inhibition of LSD1 (unknown origin) by KDM1A assay kit2022European journal of medicinal chemistry, Oct-05, Volume: 240A comprehensive comparative study on LSD1 in different cancers and tumor specific LSD1 inhibitors.
AID1317244Agonist activity at rat TRPV1 channel expressed in HEK293 cells assessed as reversal potential at 0.1 uM and -60 mV holding potential by whole-cell patch-clamp method2016Journal of natural products, 05-27, Volume: 79, Issue:5
Partial Activation and Inhibition of TRPV1 Channels by Evodiamine and Rutaecarpine, Two Major Components of the Fruits of Evodia rutaecarpa.
AID1845955Inhibition of recombinant LSD1 (unknown origin) using 10-acetyl-3,7-dihydroxyphenoxazine fluorometric substrate measured after 30 mins by multiplate reader2021European journal of medicinal chemistry, Mar-15, Volume: 214Annual review of LSD1/KDM1A inhibitors in 2020.
AID229032Percent absolute effect obtained with ionomycin, measured by the entry of [Ca2+] into human embryonic kidney HEK293 cells overexpressing hVR12002Journal of medicinal chemistry, Aug-15, Volume: 45, Issue:17
N-Acylvanillamides: development of an expeditious synthesis and discovery of new acyl templates for powerful activation of the vanilloid receptor.
AID1390827Agonist activity at recombinant TRPV1 (unknown origin) expressed in HEK293 cells assessed as induction of calcium flux administered for 1 min followed by compound washout via perfusion for 1 min by FURA-2AM-dye based fluorescence assay2018Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7
Analyses of Synthetic N-Acyl Dopamine Derivatives Revealing Different Structural Requirements for Their Anti-inflammatory and Transient-Receptor-Potential-Channel-of-the-Vanilloid-Receptor-Subfamily-Subtype-1 (TRPV1)-Activating Properties.
AID1495469Agonist activity at human TRPV1 expressed in HEK293 cells assessed as increase in calcium influx by measuring ratio of 340/380 nm excitatory wavelength at 10 uM treated for 2 mins by Fura-2AM dye-based fluorescence assay (Rvb = 0.999 No_unit)2018Bioorganic & medicinal chemistry, 05-15, Volume: 26, Issue:9
Design, synthesis and biological evaluation of novel hydrogen sulfide releasing capsaicin derivatives.
AID1603728Inhibition of human PMNL 5-LOX using arachidonic acid as substrate after 5 mins by HPLC method2019Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17
5-Lipoxygenase as a drug target: A review on trends in inhibitors structural design, SAR and mechanism based approach.
AID1392621Drug metabolism in human plasma assessed as residual substrate levels at 100 uM up to 20 mins by HPLC-UV analysis2018Journal of medicinal chemistry, 05-24, Volume: 61, Issue:10
Targeting Transient Receptor Potential Vanilloid 1 (TRPV1) Channel Softly: The Discovery of Passerini Adducts as a Topical Treatment for Inflammatory Skin Disorders.
AID1676797Induction of membrane perturbation in DC18:1PC LUV bilayer assessed as fluorescence quench rate by measuring gramicidin mixture monomer to dimer equilibrium at 100 uM by fluorescence quenching assay2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Assessing the Perturbing Effects of Drugs on Lipid Bilayers Using Gramicidin Channel-Based
AID1392619Agonist activity at TRPV1 (unknown origin) expressed in human SH-SY5Y cells assessed as increase in calcium influx after 25 mins by Fluo-4 NW dye-based fluorescence assay2018Journal of medicinal chemistry, 05-24, Volume: 61, Issue:10
Targeting Transient Receptor Potential Vanilloid 1 (TRPV1) Channel Softly: The Discovery of Passerini Adducts as a Topical Treatment for Inflammatory Skin Disorders.
AID1581154Displacement of [3H]-RTX from rat TRPV1 expressed in CHO cells incubated for 60 mins by radioligand competition assay based scintillation counting method2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Discovery of Nonpungent Transient Receptor Potential Vanilloid 1 (TRPV1) Agonist as Strong Topical Analgesic.
AID175848In vitro effective concentration for [Ca2+] uptake into dorsal root ganglia neurones in culture1993Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16
Analogues of capsaicin with agonist activity as novel analgesic agents; structure-activity studies. 3. The hydrophobic side-chain "C-region".
AID1603446Drug degradation in PBS assessed as hydrolysis of western conjugate region at 0.2 mM at 37 degC incubated up to 6 hrs by LC-MS analysis2019Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12
Natural product-drug conjugates for modulation of TRPV1-expressing tumors.
AID1676776Induction of membrane perturbation in DC22:1PC LUV bilayer assessed as change in deltaG for gramicidin mixture monomer to to dimer by fluorescence quenching assay (Rvb = 0 kcal/mol)2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Assessing the Perturbing Effects of Drugs on Lipid Bilayers Using Gramicidin Channel-Based
AID131535Effective analgesic dose in mouse tail-flick latency assay1993Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16
Analogues of capsaicin with agonist activity as novel analgesic agents; structure-activity studies. 3. The hydrophobic side-chain "C-region".
AID1875054Agonist activity at human TRPV1 expressed in HEK293 cells assessed as increase in intracellular calcium accumulation measured at 180 sec by fluorescence based microplate reader analysis
AID1390828Agonist activity at TRPV1 in human HUVEC cells assessed as inhibition of TNFalpha-induced VCAM1 expression at 100 uM by Western blot analysis relative to TNFalpha2018Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7
Analyses of Synthetic N-Acyl Dopamine Derivatives Revealing Different Structural Requirements for Their Anti-inflammatory and Transient-Receptor-Potential-Channel-of-the-Vanilloid-Receptor-Subfamily-Subtype-1 (TRPV1)-Activating Properties.
AID1707534Inhibition of recombinant human AChE using acetylthiocholineiodide as substrate preincubated for 20 mins followed by substrate addition by Ellman's method
AID1495478Ulcerogenic activity in Kunming mouse assessed as lesion in stomach at 30 mg/kg, po qd for 6 days measured on day 7 by microscopic analysis2018Bioorganic & medicinal chemistry, 05-15, Volume: 26, Issue:9
Design, synthesis and biological evaluation of novel hydrogen sulfide releasing capsaicin derivatives.
AID1609879Neuroprotective activity against H2O2-induced cell damage in human SH-SY5Y cells assessed as increase in cell viability preincubated for 24 hrs followed by H2O2 addition and measured after 4 hrs by MTT assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Design, synthesis and biological evaluation of cinnamic acid derivatives with synergetic neuroprotection and angiogenesis effect.
AID1317294Agonist activity at rat TRPV1 channel expressed in HEK293 cells assessed as induction of maximum channel current at 0.1 uM at -60 mV holding potential by whole-cell patch-clamp method2016Journal of natural products, 05-27, Volume: 79, Issue:5
Partial Activation and Inhibition of TRPV1 Channels by Evodiamine and Rutaecarpine, Two Major Components of the Fruits of Evodia rutaecarpa.
AID1727055Antiproliferative activity against human MDA-MB-231 cells incubated for 24 hrs by MTT assay2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Amide Bond Bioisosteres: Strategies, Synthesis, and Successes.
AID1875070Metabolic stability in mouse liver microsomes assessed as intrinsic clearance at 10 mM measured upto 45 mins in the presence of NADPH by LC/MS analysis
AID1676795Induction of membrane perturbation in DC22:1PC LUV bilayer assessed as fluorescence quench rate by measuring gramicidin mixture monomer to dimer equilibrium at 100 uM by fluorescence quenching assay2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Assessing the Perturbing Effects of Drugs on Lipid Bilayers Using Gramicidin Channel-Based
AID1581176Drug uptake in porcine skin assessed as dermal accumulation applied topically as carbopol-gel with 1% formulation measured for 8 hrs by Franz diffusion cell based in vitro transdermal delivery test2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Discovery of Nonpungent Transient Receptor Potential Vanilloid 1 (TRPV1) Agonist as Strong Topical Analgesic.
AID171637Change in blood pressure was tested by inducing ia injection at a dose 0.01 mg/kg in rat1994Journal of medicinal chemistry, Apr-01, Volume: 37, Issue:7
Guaiacoxypropanolamine derivatives of capsaicin: a new family of beta-adrenoceptor blockers with intrinsic cardiotonic properties.
AID345835Activity at rat TRPV1 receptor expressed in CHO cells assessed as changes in intracellular calcium levels at 30 nM by calcium imaging2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Non-vanillyl resiniferatoxin analogues as potent and metabolically stable transient receptor potential vanilloid 1 agonists.
AID218314In vitro [Ca2+] influx relative to capsaicin by Rat Vanilloid receptor (VR1) expressing CHO cells2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
N-(3-acyloxy-2-benzylpropyl)-N'-[4-(methylsulfonylamino)benzyl]thiourea analogues: novel potent and high affinity antagonists and partial antagonists of the vanilloid receptor.
AID175476Compound tested in vitro for [Ca2+] influx into neonatal rat dorsal root ganglia (DRG)1996Journal of medicinal chemistry, Dec-06, Volume: 39, Issue:25
Analogues of capsaicin with agonist activity as novel analgesic agents: structure-activity studies. 4. Potent, orally active analgesics.
AID1467697Activation of TRPA1 in Sprague-Dawley rat DRG neuron assessed as induction of current response at -60 mV holding potential at 1 uM incubated for 30 secs by whole-cell patch-clamp assay2017Bioorganic & medicinal chemistry letters, 07-15, Volume: 27, Issue:14
Synthesis of resveratrol derivatives as new analgesic drugs through desensitization of the TRPA1 receptor.
AID1317250Desensitization of rat TRPV1 expressed in HEK293 cells at 0.1 uM for 30 sec at -60 mV holding potential in presence of extracellular calcium by whole-cell patch clamp method2016Journal of natural products, 05-27, Volume: 79, Issue:5
Partial Activation and Inhibition of TRPV1 Channels by Evodiamine and Rutaecarpine, Two Major Components of the Fruits of Evodia rutaecarpa.
AID1685518Inhibition of human TRPV6 expressed in HEK293 cells assessed as reduction in Cd2+ influx up to 100 uM by calcium-5 fluorescence dye-based FLIPR assay2020RSC medicinal chemistry, Sep-01, Volume: 11, Issue:9
Natural product inspired optimization of a selective TRPV6 calcium channel inhibitor.
AID1590148Cytotoxicity against human U87 cells assessed as decrease in cell viability incubated for 24 hrs by MTT assay
AID390724Inhibition of HSL in Wistar rat isolated fat cells at 10 uM by spectrophotometric assay2008Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20
Combining ligand-based pharmacophore modeling, quantitative structure-activity relationship analysis and in silico screening for the discovery of new potent hormone sensitive lipase inhibitors.
AID292699Agonist activity at human recombinant TRPV1 expressed in human HEK293 cells2007Bioorganic & medicinal chemistry letters, Jan-01, Volume: 17, Issue:1
Structure-activity relationships of the ultrapotent vanilloid resiniferatoxin (RTX): the homovanillyl moiety.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID478381Agonist activity at human TRPV1 expressed in tetracycline-stimulated HEK293 cells assessed as increase in intracellular calcium levels by fluorimetric assay relative to control2010Bioorganic & medicinal chemistry, May-01, Volume: 18, Issue:9
In vitro TRPV1 activity of piperine derived amides.
AID1872409Inhibition of KDM1A (unknown origin)2022European journal of medicinal chemistry, Mar-05, Volume: 231Drug discovery of histone lysine demethylases (KDMs) inhibitors (progress from 2018 to present).
AID1875111Acute toxicity in ip dosed C57BL/6 mouse assessed as lethal dose
AID1390843Agonist activity at TRPV1 in human HUVEC cells assessed as inhibition of TNFalpha-induced VCAM1 expression at 12.5 to 100 uM by Western blot analysis2018Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7
Analyses of Synthetic N-Acyl Dopamine Derivatives Revealing Different Structural Requirements for Their Anti-inflammatory and Transient-Receptor-Potential-Channel-of-the-Vanilloid-Receptor-Subfamily-Subtype-1 (TRPV1)-Activating Properties.
AID1700044Agonist activity at human TRPV1 stably transfected in HEK293 cells assessed as increase in calcium influx in presence of ionomycin by Fluo-4-AM dye based spectrofluorimetric method2020Journal of natural products, 11-25, Volume: 83, Issue:11
Discovery of a Remarkable Methyl Shift Effect in the Vanilloid Activity of Triterpene Amides.
AID1845961Antiproliferative activity against human BGC-823 cells assessed as reduction in cell viability incubated for 5 days by MTS assay2021European journal of medicinal chemistry, Mar-15, Volume: 214Annual review of LSD1/KDM1A inhibitors in 2020.
AID218324In vitro binding affinity towards Rat Vanilloid receptor 1 (VR1) by [3H]RTX displacement.2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
N-(3-acyloxy-2-benzylpropyl)-N'-[4-(methylsulfonylamino)benzyl]thiourea analogues: novel potent and high affinity antagonists and partial antagonists of the vanilloid receptor.
AID1105529Inhibition of Bos taurus (bovine) heart submitochondrial particle NDH1 assessed as NADH-DB reductase activity1996Biochimica et biophysica acta, Jan-11, Volume: 1273, Issue:1
Comparison of the inhibitory action of synthetic capsaicin analogues with various NADH-ubiquinone oxidoreductases.
AID1868463Inhibition of TRPV1 (unknown origin) at a holding potential +100 mV at 10 uM by whole cell patch clamp electrophysiology relative to control2022European journal of medicinal chemistry, Jul-05, Volume: 237Optimization of 4-arylthiophene-3-carboxylic acid derivatives as inhibitors of ANO1: Lead optimization studies toward their analgesic efficacy for inflammatory pain.
AID1727011Displacement of [3H]-CP55940 from human recombinant cannabinoid CB1 receptor expressed in HEK cells by Cheng-Prusoff analysis2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Amide Bond Bioisosteres: Strategies, Synthesis, and Successes.
AID538418Binding affinity to human recombinant TRPV12010Bioorganic & medicinal chemistry letters, Dec-01, Volume: 20, Issue:23
Discovery and synthesis of 6,7,8,9-tetrahydro-5H-pyrimido-[4,5-d]azepines as novel TRPV1 antagonists.
AID1676774Induction of membrane perturbation in DC22:1PC LUV bilayer assessed as effect on potential of mean force by measuring reduction in deltaG for gramicidin mixture monomer to dimer and pure gramicidin-bilayer by fluorescence quenching assay2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Assessing the Perturbing Effects of Drugs on Lipid Bilayers Using Gramicidin Channel-Based
AID1066644Antagonist at TRPM8 isolated from mouse dorsal root ganglion cells expressed in HEK T-REx cells assessed as inhibition of icilin-induced intracellular Ca2+ influx by fluorescence-based assay2014Journal of natural products, Feb-28, Volume: 77, Issue:2
Activation and inhibition of thermosensitive TRP channels by voacangine, an alkaloid present in Voacanga africana, an African tree.
AID1390826Agonist activity at TRPV1 in human HUVEC cells assessed as induction of HO-1 at protein level at 100 uM by Western blot analysis relative to control2018Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7
Analyses of Synthetic N-Acyl Dopamine Derivatives Revealing Different Structural Requirements for Their Anti-inflammatory and Transient-Receptor-Potential-Channel-of-the-Vanilloid-Receptor-Subfamily-Subtype-1 (TRPV1)-Activating Properties.
AID1434436Agonist activity at recombinant mouse TRPV1 expressed in HEK293 cells assessed as increase in calcium influx at 0.01 to 1 uM measured for 380 sec by Fluo-4 dye based FLIPR assay2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Chemical synthesis and biological evaluation of ω-hydroxy polyunsaturated fatty acids.
AID1700045Antagonist activity at human TRPV1 stably transfected in HEK293 cells assessed as decrease in calcium influx preincubated for 5 mins followed by capsaicin addition by Fluo-4-AM dye based spectrofluorimetric method2020Journal of natural products, 11-25, Volume: 83, Issue:11
Discovery of a Remarkable Methyl Shift Effect in the Vanilloid Activity of Triterpene Amides.
AID1609880Neuroprotective activity against H2O2-induced cell damage in human HBMEC2 cells assessed as increase in cell viability preincubated for 24 hrs followed by H2O2 addition and measured after 4 hrs by MTT assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Design, synthesis and biological evaluation of cinnamic acid derivatives with synergetic neuroprotection and angiogenesis effect.
AID130863In vivo tail-flick latency after subcutaneous administration in mouse as an evaluation of antinociceptive potency1996Journal of medicinal chemistry, Dec-06, Volume: 39, Issue:25
Analogues of capsaicin with agonist activity as novel analgesic agents: structure-activity studies. 4. Potent, orally active analgesics.
AID1590171Effect on Ca2+ transport in human HEK293T cells incubated for 5 mins by calcium-5 fluorescence dye-based FLIPR assay
AID1066645Antagonist at TRPM8 isolated from mouse dorsal root ganglion cells expressed in HEK T-REx cells assessed as inhibition of menthol-induced intracellular Ca2+ influx by fluorescence-based assay2014Journal of natural products, Feb-28, Volume: 77, Issue:2
Activation and inhibition of thermosensitive TRP channels by voacangine, an alkaloid present in Voacanga africana, an African tree.
AID218326In vitro binding to Rat Vanilloid receptor 1 (VR1) expressing CHO cells compared to capsaicin2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
N-(3-acyloxy-2-benzylpropyl)-N'-[4-(methylsulfonylamino)benzyl]thiourea analogues: novel potent and high affinity antagonists and partial antagonists of the vanilloid receptor.
AID452447Agonist activity at human TRPV1 expressed in HEK293 cells assessed as increase in intracellular calcium level2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
Structure-activity relationships of the ultrapotent vanilloid resiniferatoxin (RTX): The side chain benzylic methylene.
AID1392620Drug metabolism in human HaCaT cells assessed as residual substrate levels at 25 uM up to 240 mins by HPLC-UV analysis2018Journal of medicinal chemistry, 05-24, Volume: 61, Issue:10
Targeting Transient Receptor Potential Vanilloid 1 (TRPV1) Channel Softly: The Discovery of Passerini Adducts as a Topical Treatment for Inflammatory Skin Disorders.
AID1390842Agonist activity at recombinant TRPV1 R491A mutant (unknown origin) expressed in HEK293 cells assessed increase in calcium flux response at 0.3 to 10 uM dosed for 1 min followed by compound washout via perfusion for 1 min by FURA-2AM-dye based fluorescenc2018Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7
Analyses of Synthetic N-Acyl Dopamine Derivatives Revealing Different Structural Requirements for Their Anti-inflammatory and Transient-Receptor-Potential-Channel-of-the-Vanilloid-Receptor-Subfamily-Subtype-1 (TRPV1)-Activating Properties.
AID1738319Antibacterial activity against Staphylococcus aureus Newman strain assessed as reduction in bacterial growth incubated for 16 to 18 hrs by two fold serial dilution method2020European journal of medicinal chemistry, Jul-15, Volume: 198Capsaicin derivatives with nitrothiophene substituents: Design, synthesis and antibacterial activity against multidrug-resistant S. aureus.
AID246881Effective dose to produce maximal thermal desensitization in human at 5 ug2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Identification and biological evaluation of 4-(3-trifluoromethylpyridin-2-yl)piperazine-1-carboxylic acid (5-trifluoromethylpyridin-2-yl)amide, a high affinity TRPV1 (VR1) vanilloid receptor antagonist.
AID538419Binding affinity to rat TRPV12010Bioorganic & medicinal chemistry letters, Dec-01, Volume: 20, Issue:23
Discovery and synthesis of 6,7,8,9-tetrahydro-5H-pyrimido-[4,5-d]azepines as novel TRPV1 antagonists.
AID1390831Agonist activity at recombinant TRPV1 (unknown origin) expressed in HEK293 cells assessed increase in calcium flux response at 10 uM dosed for 1 min followed by compound washout via perfusion for 1 min by FURA-2AM-dye based fluorescence assay relative to 2018Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7
Analyses of Synthetic N-Acyl Dopamine Derivatives Revealing Different Structural Requirements for Their Anti-inflammatory and Transient-Receptor-Potential-Channel-of-the-Vanilloid-Receptor-Subfamily-Subtype-1 (TRPV1)-Activating Properties.
AID1581177Systemic drug absorption in porcine skin assessed as drug accumulation in acceptor Franz cell applied topically as carbopol-gel with 1% formulation measured for 8 hrs by Franz diffusion cell based in vitro transdermal delivery test2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Discovery of Nonpungent Transient Receptor Potential Vanilloid 1 (TRPV1) Agonist as Strong Topical Analgesic.
AID1511041Antitumor activity against human Aspc-1 cells xenografted in athymic nude mouse assessed as reduction in tumor volume at 5 mg/kg after 35 days relative to control2019European journal of medicinal chemistry, Oct-15, Volume: 180Recent advances of analogues of curcumin for treatment of cancer.
AID1875114Agonist activity at human TRPV1 R557A mutant expressed in HEK293 cells assessed as activation of TRPV1 current at 1 uM at 0 mV holding potential by whole-cell voltage clamp assay
AID589100Mechanism based inhibition of human cytochrome P450 2E12005Current drug metabolism, Oct, Volume: 6, Issue:5
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID345832Agonist activity at rat TRPV1 receptor expressed in CHO cells assessed as calcium uptake2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Non-vanillyl resiniferatoxin analogues as potent and metabolically stable transient receptor potential vanilloid 1 agonists.
AID1581187Agonist activity at human TRPV1 expressed in HEK293 cells assessed as increase in calcium influx at 1 uM incubated for 1 min by Fluo-4-AM dye based FLIPR assay2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Discovery of Nonpungent Transient Receptor Potential Vanilloid 1 (TRPV1) Agonist as Strong Topical Analgesic.
AID1495470Antiproliferative activity against human K562 cells after 48 hrs by MTT assay2018Bioorganic & medicinal chemistry, 05-15, Volume: 26, Issue:9
Design, synthesis and biological evaluation of novel hydrogen sulfide releasing capsaicin derivatives.
AID1191864Agonist activity at human recombinant TRPV1 expressed in HEK293 cells assessed as Ca2+ influx by Fluo-4 dye based assay relative to 4 uM ionomycin2015Bioorganic & medicinal chemistry letters, Mar-01, Volume: 25, Issue:5
Discovery of non-electrophilic capsaicinoid-type TRPA1 ligands.
AID1105525Inhibition of Escherichia coli GR19N NDH2 assessed as deaminoNADH-DB reductase activity at 100 uM relative to control1996Biochimica et biophysica acta, Jan-11, Volume: 1273, Issue:1
Comparison of the inhibitory action of synthetic capsaicin analogues with various NADH-ubiquinone oxidoreductases.
AID218307Binding affinity against Vanilloid receptor in dorsal Root Ganglion (DRG) membranes using [3H]RTX binding assay.1996Journal of medicinal chemistry, Jul-19, Volume: 39, Issue:15
Similarities and differences in the structure-activity relationships of capsaicin and resiniferatoxin analogues.
AID1590176In-vivo activation of TRPV1 receptor in Swiss mouse assessed as induction of nociception by measuring paw flinching/licking response at 5.2 nmol/paw administrated via intraplantar route and measured for first 5 mins post treatment
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1471309Inhibition of Staphylococcus aureus 1199B NorA assessed as potentiation of ciprofloxacin-induced antibacterial activity by measuring fold reduction in ciprofloxacin MIC at 12.5 to 25 uM2017Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20
Pharmaceutical Approaches to Target Antibiotic Resistance Mechanisms.
AID473863Antagonist activity at AR in human MDA-kb2 cells co-transfected with MMTV-luc assessed as decrease in DHT-induced luciferase activity at 1 mM by reporter gene assay2010Bioorganic & medicinal chemistry letters, Apr-01, Volume: 20, Issue:7
Effect of essential oils, such as raspberry ketone and its derivatives, on antiandrogenic activity based on in vitro reporter gene assay.
AID1581188Agonist activity at rat TRPV1 expressed in HEK293 cells assessed as increase in calcium influx at 1 uM incubated for 1 min by Fluo-4-AM dye based FLIPR assay2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Discovery of Nonpungent Transient Receptor Potential Vanilloid 1 (TRPV1) Agonist as Strong Topical Analgesic.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1495479Acute toxicity in po dosed CD rat measured for 7 days2018Bioorganic & medicinal chemistry, 05-15, Volume: 26, Issue:9
Design, synthesis and biological evaluation of novel hydrogen sulfide releasing capsaicin derivatives.
AID1676775Induction of membrane perturbation in DC22:1PC LUV bilayer assessed as change in deltaG for pure gramicidin monomer to to dimer by fluorescence quenching assay (Rvb = 0 kcal/mol)2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Assessing the Perturbing Effects of Drugs on Lipid Bilayers Using Gramicidin Channel-Based
AID218163In vitro agonist activity, increased [Ca2+] influx, at vanilloid receptor of rat dorsal root ganglia2004Bioorganic & medicinal chemistry letters, Feb-09, Volume: 14, Issue:3
N-4-Substituted-benzyl-N'-tert-butylbenzyl thioureas as vanilloid receptor ligands: investigation on the role of methanesulfonamido group in antagonistic activity.
AID1581181Toxicity in po dosed ICR mouse administered as single dose2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Discovery of Nonpungent Transient Receptor Potential Vanilloid 1 (TRPV1) Agonist as Strong Topical Analgesic.
AID1875062Agonist activity at human TRPV1 expressed in HEK293 cells assessed as induction of calcium influx by measuring increase in intracellular fluorescence intensity at 1 uM measured for 180 sec by Fluo-8 based calcium imaging analysis relative to ionomycin
AID1590150Cytotoxicity against human T75 cells assessed as decrease in cell viability incubated for 24 hrs by MTT assay
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID130862In vivo tail-flick latency after peroral administration in mouse as an evaluation of antinociceptive potency1996Journal of medicinal chemistry, Dec-06, Volume: 39, Issue:25
Analogues of capsaicin with agonist activity as novel analgesic agents: structure-activity studies. 4. Potent, orally active analgesics.
AID1495471Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay2018Bioorganic & medicinal chemistry, 05-15, Volume: 26, Issue:9
Design, synthesis and biological evaluation of novel hydrogen sulfide releasing capsaicin derivatives.
AID500214Agonist activity at TRPV12005Nature chemical biology, Jul, Volume: 1, Issue:2
Sensing with TRP channels.
AID644961Agonist activity at human TRPV1 ion channel expressed in HEK293 cells assessed as calcium influx by fluo-4-Am-based fluorimetry relative to ionomycin2012Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4
Synthesis and biological evaluation of [6]-gingerol analogues as transient receptor potential channel TRPV1 and TRPA1 modulators.
AID1590170Agonist activity at human TRPV1 expressed in HEK293T cells assessed as increase in Ca2+ transport incubated for 5 mins by calcium-5 fluorescence dye-based FLIPR assay
AID1392622Drug metabolism in human liver S9 fraction assessed as residual substrate levels at 50 uM up to 60 mins by HPLC-UV analysis2018Journal of medicinal chemistry, 05-24, Volume: 61, Issue:10
Targeting Transient Receptor Potential Vanilloid 1 (TRPV1) Channel Softly: The Discovery of Passerini Adducts as a Topical Treatment for Inflammatory Skin Disorders.
AID353804Agonist activity at human recombinant TRPV1 expressed in HEK293 cells assessed as increase in intracellular calcium level2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID1390847Agonist activity at recombinant TRPV1 (unknown origin) expressed in HEK293 cells assessed as induction of calcium flux by measuring efficacy for receptor activation administered for 1 min followed by compound washout via perfusion for 1 min by FURA-2AM-dy2018Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7
Analyses of Synthetic N-Acyl Dopamine Derivatives Revealing Different Structural Requirements for Their Anti-inflammatory and Transient-Receptor-Potential-Channel-of-the-Vanilloid-Receptor-Subfamily-Subtype-1 (TRPV1)-Activating Properties.
AID1581155Agonist activity at rat TRPV1 expressed in CHO cells assessed as increase in 45Ca2+ uptake incubated for 5 mins by liquid scintillation counting method2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Discovery of Nonpungent Transient Receptor Potential Vanilloid 1 (TRPV1) Agonist as Strong Topical Analgesic.
AID1833780Induction of apoptosis in human NCI-H460 cells assessed as late apoptotic cells measured after 72 hrs by Annexin V-FITC and propidium iodide staining based flow cytometry analysis (Rvb= 6.93%)2021ACS medicinal chemistry letters, Nov-11, Volume: 12, Issue:11
Apoptosis Inducing 1,3,4-Oxadiazole Conjugates of Capsaicin: Their
AID1392624Drug metabolism in human fibroblast cells assessed as residual substrate levels at 50 uM up to 120 mins by HPLC-UV analysis2018Journal of medicinal chemistry, 05-24, Volume: 61, Issue:10
Targeting Transient Receptor Potential Vanilloid 1 (TRPV1) Channel Softly: The Discovery of Passerini Adducts as a Topical Treatment for Inflammatory Skin Disorders.
AID1707537Inhibition of recombinant human BACE-1 at 1 uM using methoxycoumarin-Ser-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Lys-dinitrophenyl as substrate preincubated for 1 hr followed by substrate addition and measured after 15 mins by fluorescence based assay relative to
AID1317296Desensitization of rat TRPV1 expressed in HEK293 cells at 0.1 uM for 20 sec at -60 mV holding potential in absence of extracellular calcium by whole-cell patch clamp method2016Journal of natural products, 05-27, Volume: 79, Issue:5
Partial Activation and Inhibition of TRPV1 Channels by Evodiamine and Rutaecarpine, Two Major Components of the Fruits of Evodia rutaecarpa.
AID1707539Permeability of the compound in PBS/EtOH buffer (70:30) by PAMPA-BBB assay
AID1700043Agonist activity at human TRPV1 stably transfected in HEK293 cells assessed as increase in calcium influx by Fluo-4-AM dye based spectrofluorimetric method relative to ionomycin2020Journal of natural products, 11-25, Volume: 83, Issue:11
Discovery of a Remarkable Methyl Shift Effect in the Vanilloid Activity of Triterpene Amides.
AID130358In vivo analgesic activity, mouse tail flick latency in antinociceptive assay1993Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16
Analogues of capsaicin with agonist activity as novel analgesic agents; structure-activity studies. 1. The aromatic "A-region".
AID1390844Agonist activity at TRPV1 in human HUVEC cells assessed as induction of HO-1 at protein level at 12.5 to 100 uM by Western blot analysis2018Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7
Analyses of Synthetic N-Acyl Dopamine Derivatives Revealing Different Structural Requirements for Their Anti-inflammatory and Transient-Receptor-Potential-Channel-of-the-Vanilloid-Receptor-Subfamily-Subtype-1 (TRPV1)-Activating Properties.
AID1495472Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay2018Bioorganic & medicinal chemistry, 05-15, Volume: 26, Issue:9
Design, synthesis and biological evaluation of novel hydrogen sulfide releasing capsaicin derivatives.
AID433909Toxicity in KM mouse assessed as moderate pain producing potency for 30 mins by wiping test2009European journal of medicinal chemistry, Aug, Volume: 44, Issue:8
Synthesis and antinociceptive activity of capsinoid derivatives.
AID1451859Displacement of [3H]RTX from human TRPV1 expressed in CHO cell membranes after 45 mins by scintillation counting method2017Journal of medicinal chemistry, 10-12, Volume: 60, Issue:19
Novel Radiolabeled Vanilloid with Enhanced Specificity for Human Transient Receptor Potential Vanilloid 1 (TRPV1).
AID403341Inhibition of COX12005Journal of natural products, Jul, Volume: 68, Issue:7
Expanding the ChemGPS chemical space with natural products.
AID1875110Toxicity in C57BL/6 mouse assessed as irritant effect by measuring eye wiping behavior at 10 microg/ml, OU measured for 60 sec by eye wiping test
AID1451870Displacement of [3H]MPOU from human TRPV1 expressed in CHO cell membranes after 45 mins by scintillation counting method2017Journal of medicinal chemistry, 10-12, Volume: 60, Issue:19
Novel Radiolabeled Vanilloid with Enhanced Specificity for Human Transient Receptor Potential Vanilloid 1 (TRPV1).
AID473865Agonist activity at AR in human MDA-kb2 cells co-transfected with MMTV-luc assessed as increase in DHT-induced luciferase activity at 1 mM by reporter gene assay2010Bioorganic & medicinal chemistry letters, Apr-01, Volume: 20, Issue:7
Effect of essential oils, such as raspberry ketone and its derivatives, on antiandrogenic activity based on in vitro reporter gene assay.
AID1066627Antagonist at TRPM8 isolated from mouse dorsal root ganglion cells expressed in HEK T-REx cells assessed as inhibition of icilin-induced intracellular Ca2+ influx at >100 uM by fluorescence-based assay2014Journal of natural products, Feb-28, Volume: 77, Issue:2
Activation and inhibition of thermosensitive TRP channels by voacangine, an alkaloid present in Voacanga africana, an African tree.
AID1390846Agonist activity at recombinant TRPV1 (unknown origin) expressed in HEK293 cells assessed increase in calcium flux response at 10 uM followed by TRPV1 antagonist CPZ addition 30 secs before second compound dose for 1 min followed by compound washout via p2018Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7
Analyses of Synthetic N-Acyl Dopamine Derivatives Revealing Different Structural Requirements for Their Anti-inflammatory and Transient-Receptor-Potential-Channel-of-the-Vanilloid-Receptor-Subfamily-Subtype-1 (TRPV1)-Activating Properties.
AID1105527Inhibition of Solanum tuberosum (potato) inner mitochondrial membrane NDH2 assessed as deaminoNADH-DB reductase activity at 100 uM relative to control1996Biochimica et biophysica acta, Jan-11, Volume: 1273, Issue:1
Comparison of the inhibitory action of synthetic capsaicin analogues with various NADH-ubiquinone oxidoreductases.
AID229033Concentration necessary to induce a relative half-maximal response measured by the entry of [Ca2+] into human embryonic kidney HEK293 cells overexpressing the human VR12002Journal of medicinal chemistry, Aug-15, Volume: 45, Issue:17
N-Acylvanillamides: development of an expeditious synthesis and discovery of new acyl templates for powerful activation of the vanilloid receptor.
AID1191866Antagonist activity against human recombinant TRPV1 expressed in HEK293 cells assessed as inhibition of capsaicin-induced Ca2+ influx pre-treated 5 mins before capsaicin addition by Fluo-4 dye based assay2015Bioorganic & medicinal chemistry letters, Mar-01, Volume: 25, Issue:5
Discovery of non-electrophilic capsaicinoid-type TRPA1 ligands.
AID1833763Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition measured after 72 hrs by crystal violet staining based assay2021ACS medicinal chemistry letters, Nov-11, Volume: 12, Issue:11
Apoptosis Inducing 1,3,4-Oxadiazole Conjugates of Capsaicin: Their
AID478379Agonist activity at human TRPV1 expressed in tetracycline-stimulated HEK293 cells assessed as increase in intracellular calcium levels by fluorimetric assay2010Bioorganic & medicinal chemistry, May-01, Volume: 18, Issue:9
In vitro TRPV1 activity of piperine derived amides.
AID1676772Induction of membrane perturbation in DC18:1PC LUV bilayer assessed as effect on potential of mean force by measuring reduction in deltaG for gramicidin mixture monomer to dimer and pure gramicidin-bilayer by fluorescence quenching assay2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Assessing the Perturbing Effects of Drugs on Lipid Bilayers Using Gramicidin Channel-Based
AID644964Agonist activity at rat TRPA1 ion channel expressed in HEK293 cells assessed as calcium influx by fluo-4-Am-based fluorimetry relative to allyl isothiocyanate2012Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4
Synthesis and biological evaluation of [6]-gingerol analogues as transient receptor potential channel TRPV1 and TRPA1 modulators.
AID1833765Antiproliferative activity against human SK-OV-3 cells assessed as cell growth inhibition measured after 72 hrs by crystal violet staining based assay2021ACS medicinal chemistry letters, Nov-11, Volume: 12, Issue:11
Apoptosis Inducing 1,3,4-Oxadiazole Conjugates of Capsaicin: Their
AID1590144Cytotoxicity against human SK-MEL-25 cells assessed as decrease in cell viability incubated for 24 hrs by MTT assay
AID1581178Toxicity in ICR mouse assessed as skin irritation by measuring ear scratching administered topically and measured for 30 mins2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Discovery of Nonpungent Transient Receptor Potential Vanilloid 1 (TRPV1) Agonist as Strong Topical Analgesic.
AID1390840Agonist activity at recombinant TRPV1 (unknown origin) S512A mutant expressed in HEK293 cells assessed increase in calcium flux response at 10 to 100 uM dosed for 1 min followed by compound washout via perfusion for 1 min by FURA-2AM-dye based fluorescenc2018Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7
Analyses of Synthetic N-Acyl Dopamine Derivatives Revealing Different Structural Requirements for Their Anti-inflammatory and Transient-Receptor-Potential-Channel-of-the-Vanilloid-Receptor-Subfamily-Subtype-1 (TRPV1)-Activating Properties.
AID218309Displacement of [3H]RTX from Vanilloid receptor in Rat spinal cord membranes1996Journal of medicinal chemistry, Aug-02, Volume: 39, Issue:16
Synthesis and evaluation of phorboid 20-homovanillates: discovery of a class of ligands binding to the vanilloid (capsaicin) receptor with different degrees of cooperativity.
AID1581167Induction of hypothermia in ICR mouse assessed as decrease in body temperature at 3 mg/kg, ip measured after 30 mins2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Discovery of Nonpungent Transient Receptor Potential Vanilloid 1 (TRPV1) Agonist as Strong Topical Analgesic.
AID1833764Antiproliferative activity against human NCI-H460 cells assessed as cell growth inhibition measured after 72 hrs by crystal violet staining based assay2021ACS medicinal chemistry letters, Nov-11, Volume: 12, Issue:11
Apoptosis Inducing 1,3,4-Oxadiazole Conjugates of Capsaicin: Their
AID1371465Induction of DOPC/n-decane bilayer property changes assessed as concentration required to double gramicidin-induced quencher influx rate by single-channel electrophysiology method2017Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
Polyphenolic Phytochemicals in Cancer Prevention and Therapy: Bioavailability versus Bioefficacy.
AID73731In vitro effective dose for contraction of guinea pig ileum1993Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16
Analogues of capsaicin with agonist activity as novel analgesic agents; structure-activity studies. 2. The amide bond "B-region".
AID348212Displacement of [3H]RTX form rat TRPV1 receptor expressed in CHO/VR1 cell system2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Non-vanillyl resiniferatoxin analogues as potent and metabolically stable transient receptor potential vanilloid 1 agonists.
AID1707538Antioxidant activity assessed as DPPH radical scavenging activity incubated for 30 mins under dark condition by UV-Vis spectrophotometric analysis
AID1590175Agonist activity at human TRPV6 expressed in human HEK293 cells assessed as increase in Ca2+ transport at 100 nM incubated for 5 mins by calcium-5 fluorescence dye-based FLIPR assay
AID218302In vitro antagonist activity at vanilloid receptor in rat dorsal root ganglia at 0.5 uM2004Bioorganic & medicinal chemistry letters, Feb-09, Volume: 14, Issue:3
N-4-Substituted-benzyl-N'-tert-butylbenzyl thioureas as vanilloid receptor ligands: investigation on the role of methanesulfonamido group in antagonistic activity.
AID353803Displacement of [3H]CP-55940 from human recombinant CB2 receptor expressed in HEK293 cell membrane2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes.
AID1581179Toxicity in ICR mouse assessed as ear edema administered topically and measured after 30 mins2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Discovery of Nonpungent Transient Receptor Potential Vanilloid 1 (TRPV1) Agonist as Strong Topical Analgesic.
AID129479Compound tested for in vivo writhing antinociceptive assay in mouse after subcutaneous administration1996Journal of medicinal chemistry, Dec-06, Volume: 39, Issue:25
Analogues of capsaicin with agonist activity as novel analgesic agents: structure-activity studies. 4. Potent, orally active analgesics.
AID226640Effect on cooperativity of Resiniferatoxin (RTX) binding (Hill coefficient)1996Journal of medicinal chemistry, Aug-02, Volume: 39, Issue:16
Synthesis and evaluation of phorboid 20-homovanillates: discovery of a class of ligands binding to the vanilloid (capsaicin) receptor with different degrees of cooperativity.
AID1581180Toxicity in ip dosed ICR mouse administered as single dose2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Discovery of Nonpungent Transient Receptor Potential Vanilloid 1 (TRPV1) Agonist as Strong Topical Analgesic.
AID175668Effective concentration for [Ca2+] uptake into dorsal root ganglia neurones in rat cultured spinal sensory neurones1993Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16
Analogues of capsaicin with agonist activity as novel analgesic agents; structure-activity studies. 2. The amide bond "B-region".
AID1390836Agonist activity at recombinant TRPV1 E570A mutant (unknown origin) expressed in HEK293 cells assessed increase in calcium flux response at 0.3 to 10 uM dosed for 1 min followed by compound washout via perfusion for 1 min by FURA-2AM-dye based fluorescenc2018Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7
Analyses of Synthetic N-Acyl Dopamine Derivatives Revealing Different Structural Requirements for Their Anti-inflammatory and Transient-Receptor-Potential-Channel-of-the-Vanilloid-Receptor-Subfamily-Subtype-1 (TRPV1)-Activating Properties.
AID1744407Agonist activity at human TRPV1 expressed in CHO cells assessed as stimulation of calcium uptake by 45Ca2+ uptake assay2021Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1
Discovery of Benzopyridone-Based Transient Receptor Potential Vanilloid 1 Agonists and Antagonists and the Structural Elucidation of Their Activity Shift.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID192646Minimum dose of iv injection that shows vagus reflex and a heart rate decrease of 50 beats/min in non-vagotomized rats1994Journal of medicinal chemistry, Apr-01, Volume: 37, Issue:7
Guaiacoxypropanolamine derivatives of capsaicin: a new family of beta-adrenoceptor blockers with intrinsic cardiotonic properties.
AID1590149Cytotoxicity against mouse B16F10 cells assessed as decrease in cell viability incubated for 24 hrs by MTT assay
AID1066640Antagonist at TRPM8 isolated from mouse dorsal root ganglion cells expressed in HEK T-REx cells assessed as inhibition of icilin-induced intracellular Ca2+ influx at 10 to 100 uM by fluorescence-based assay2014Journal of natural products, Feb-28, Volume: 77, Issue:2
Activation and inhibition of thermosensitive TRP channels by voacangine, an alkaloid present in Voacanga africana, an African tree.
AID218328Inhibition of capsaicin-induced [Ca2+] uptake by Rat Vanilloid receptor 1 (VR1) expressing CHO cells (ineffective)2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
N-(3-acyloxy-2-benzylpropyl)-N'-[4-(methylsulfonylamino)benzyl]thiourea analogues: novel potent and high affinity antagonists and partial antagonists of the vanilloid receptor.
AID625295Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in Pfizer data2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1105075Antifeedant activity against Schistocerca americana in compound treated healthy romaine lettuce plants assessed as area consumed from leaf disk at 31.3 ml/l by choice tests (1.79 +/- 0.2 cm'2)2011Pest management science, Jul, Volume: 67, Issue:7
Antifeedant effect of commercial chemicals and plant extracts against Schistocerca americana (Orthoptera: Acrididae) and Diaprepes abbreviatus (Coleoptera: Curculionidae).
AID1650479Agonist activity at LPA1 receptors in Wistar rat DRG neurons assessed as increase in calcium influx at 500 nM measured after 10 secs in presence of capsaicin by Fluo-4 NW dye based inverted microscopic method2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
A Novel Agonist of the Type 1 Lysophosphatidic Acid Receptor (LPA
AID73895In vitro contraction in guinea pig ileum equivalent to 50% capsaicin response1993Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16
Analogues of capsaicin with agonist activity as novel analgesic agents; structure-activity studies. 1. The aromatic "A-region".
AID1441978Inhibition of Kv1.1 (unknown origin)2017Journal of medicinal chemistry, 03-23, Volume: 60, Issue:6
A Rational Design of a Selective Inhibitor for Kv1.1 Channels Prevalent in Demyelinated Nerves That Improves Their Impaired Axonal Conduction.
AID1105074Antifeedant activity against Diaprepes abbreviatus in compound treated healthy romaine lettuce plants assessed as area consumed from leaf disk at 31.3 ml/l by choice tests (1.39 +/- 0.1 cm'2)2011Pest management science, Jul, Volume: 67, Issue:7
Antifeedant effect of commercial chemicals and plant extracts against Schistocerca americana (Orthoptera: Acrididae) and Diaprepes abbreviatus (Coleoptera: Curculionidae).
AID73732Effective concentration for guinea pig ileum contraction in an in vitro assay1993Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16
Analogues of capsaicin with agonist activity as novel analgesic agents; structure-activity studies. 3. The hydrophobic side-chain "C-region".
AID1707582Inhibition of human serum BChE at 100 uM using butyrylthiocholineiodide as substrate preincubated for 20 mins followed by substrate addition by Ellman's method relative to control
AID1581152Displacement of [3H]-RTX from human TRPV1 expressed in CHO cells incubated for 60 mins by radioligand competition assay based scintillation counting method2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Discovery of Nonpungent Transient Receptor Potential Vanilloid 1 (TRPV1) Agonist as Strong Topical Analgesic.
AID1590173Agonist activity at human TRPV1 expressed in human HEK293T cells assessed as increase in Ca2+ transport at 100 nM incubated for 5 mins in presence of TRPV1 antagonist capsazepine by calcium-5 fluorescence dye-based FLIPR assay
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1069031Agonist activity at TRPV1 in rat dorsal root ganglia neurons by 45Ca2+ uptake assay2014Bioorganic & medicinal chemistry letters, Feb-01, Volume: 24, Issue:3
Constrained TRPV1 agonists synthesized via silver-mediated intramolecular azo-methine ylide cycloaddition of α-iminoamides.
AID1707545Displacement of propidium iodide from PAS-region of electric eel AChE assessed as decrease in fluorescence intensity at 4 to 92 uM by spectrofluorimetric analysis relative to control
AID353802Displacement of [3H]CP-55940 from human recombinant CB1 receptor expressed in HEK293 cell membrane2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID1676796Induction of membrane perturbation in DC20:1PC LUV bilayer assessed as fluorescence quench rate by measuring gramicidin mixture monomer to dimer equilibrium at 100 uM by fluorescence quenching assay2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Assessing the Perturbing Effects of Drugs on Lipid Bilayers Using Gramicidin Channel-Based
AID1537419Agonist activity at rat TRPV1 expressed in human SH-SY5Y cells assessed as intracellular calcium accumulation by Fluo-4 NW dye based fluorescence assay2019ACS medicinal chemistry letters, Feb-14, Volume: 10, Issue:2
TRPV1 Modulators for the Treatment of Pain and Inflammation.
AID175840In vitro agonist activity against [Ca2+] uptake in neonatal rat cultured spinal sensory neurons1994Journal of medicinal chemistry, Jun-24, Volume: 37, Issue:13
The discovery of capsazepine, the first competitive antagonist of the sensory neuron excitants capsaicin and resiniferatoxin.
AID1390835Agonist activity at recombinant TRPV1 Y511A mutant (unknown origin) expressed in HEK293 cells assessed increase in calcium flux response at 0.3 to 10 uM dosed for 1 min followed by compound washout via perfusion for 1 min by FURA-2AM-dye based fluorescenc2018Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7
Analyses of Synthetic N-Acyl Dopamine Derivatives Revealing Different Structural Requirements for Their Anti-inflammatory and Transient-Receptor-Potential-Channel-of-the-Vanilloid-Receptor-Subfamily-Subtype-1 (TRPV1)-Activating Properties.
AID175843In vitro effective concentration for [Ca2+] uptake and accumulation of [Ca2+] in neonatal rat cultured spinal sensory neurons1993Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16
Analogues of capsaicin with agonist activity as novel analgesic agents; structure-activity studies. 1. The aromatic "A-region".
AID1603442Agonist activity at TRPV1 (unknown origin) expressed in HEK-293 cells assessed as induction of calcium influx at 5 uM incubated for 48 hrs by Fura2-AM dye based calcium imaging assay2019Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12
Natural product-drug conjugates for modulation of TRPV1-expressing tumors.
AID1105528Inhibition of Solanum tuberosum (potato) submitochondrial particle NDH1 assessed as deaminoNADH-DB reductase activity1996Biochimica et biophysica acta, Jan-11, Volume: 1273, Issue:1
Comparison of the inhibitory action of synthetic capsaicin analogues with various NADH-ubiquinone oxidoreductases.
AID65831Increased [Ca2+] influx into Dorsal Root Ganglion(DRG) neurons1996Journal of medicinal chemistry, Jul-19, Volume: 39, Issue:15
Similarities and differences in the structure-activity relationships of capsaicin and resiniferatoxin analogues.
AID1875053Agonist activity at human TRPV1 expressed in HEK293 cells assessed as increase in intracellular calcium accumulation by measuring efficacy at 100 nM measured at 180 sec by fluorescence based microplate reader analysis relative to capsaicin
AID1390845Redox activity of the compound assessed as quenching activity by luminol-based chemiluminescence assay2018Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7
Analyses of Synthetic N-Acyl Dopamine Derivatives Revealing Different Structural Requirements for Their Anti-inflammatory and Transient-Receptor-Potential-Channel-of-the-Vanilloid-Receptor-Subfamily-Subtype-1 (TRPV1)-Activating Properties.
AID1581153Agonist activity at human TRPV1 expressed in CHO cells assessed as increase in 45Ca2+ uptake incubated for 5 mins by liquid scintillation counting method2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Discovery of Nonpungent Transient Receptor Potential Vanilloid 1 (TRPV1) Agonist as Strong Topical Analgesic.
AID75776Threshold dose required to cause increase in airway opening pressure in carotid artery of guinea pig after intravenous administration1996Journal of medicinal chemistry, Dec-06, Volume: 39, Issue:25
Analogues of capsaicin with agonist activity as novel analgesic agents: structure-activity studies. 4. Potent, orally active analgesics.
AID644962Agonist activity at human TRPV1 ion channel expressed in HEK293 cells assessed as calcium influx by fluo-4-Am-based fluorimetry2012Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4
Synthesis and biological evaluation of [6]-gingerol analogues as transient receptor potential channel TRPV1 and TRPA1 modulators.
AID1727056Antitumor activity against human MDA-MB-231 cells xenografted in nude mouse assessed as reduction in tumor volume at 90 mg/kg, ip administered for 15 days (Rvb = 550 +/- 98.6 mm3)2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Amide Bond Bioisosteres: Strategies, Synthesis, and Successes.
AID1105526Inhibition of Escherichia coli GR19N NDH1 assessed as deaminoNADH-DB reductase activity1996Biochimica et biophysica acta, Jan-11, Volume: 1273, Issue:1
Comparison of the inhibitory action of synthetic capsaicin analogues with various NADH-ubiquinone oxidoreductases.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1346704Rat Kv1.2 (Voltage-gated potassium channels)1994Molecular pharmacology, Jun, Volume: 45, Issue:6
Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines.
AID1346681Mouse Kv3.1 (Voltage-gated potassium channels)1994Molecular pharmacology, Jun, Volume: 45, Issue:6
Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines.
AID1346617Human TRPV1 (Transient Receptor Potential channels)2004Nature, Aug-12, Volume: 430, Issue:7001
The principle of temperature-dependent gating in cold- and heat-sensitive TRP channels.
AID1346643Rat TRPV1 (Transient Receptor Potential channels)1997Nature, Oct-23, Volume: 389, Issue:6653
The capsaicin receptor: a heat-activated ion channel in the pain pathway.
AID1346587Mouse TRPV1 (Transient Receptor Potential channels)2004Neuroscience letters, Nov-03, Volume: 370, Issue:1
Cloning and pharmacological characterization of mouse TRPV1.
AID1346659Mouse Kv1.7 (Voltage-gated potassium channels)1998The Journal of biological chemistry, Mar-06, Volume: 273, Issue:10
Genomic organization, chromosomal localization, tissue distribution, and biophysical characterization of a novel mammalian Shaker-related voltage-gated potassium channel, Kv1.7.
AID1346690Mouse Kv1.1 (Voltage-gated potassium channels)1994Molecular pharmacology, Jun, Volume: 45, Issue:6
Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines.
AID1797975Radioligand Binding Assay and Agonist Ca2+ Influx Functional Assay from Article 10.1124/jpet.107.124305: \\[3H]A-778317 [1-((R)-5-tert-butyl-indan-1-yl)-3-isoquinolin-5-yl-urea]: a novel, stereoselective, high-affinity antagonist is a useful radioligand fo2007The Journal of pharmacology and experimental therapeutics, Oct, Volume: 323, Issue:1
[3H]A-778317 [1-((R)-5-tert-butyl-indan-1-yl)-3-isoquinolin-5-yl-urea]: a novel, stereoselective, high-affinity antagonist is a useful radioligand for the human transient receptor potential vanilloid-1 (TRPV1) receptor.
AID1798961CB Receptor Radioligand Binding Assay (Ki) from Article 10.1021/jm900130m: \\Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes.\\2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes.
AID1798962TRPV1 Channel Activity Assay from Article 10.1021/jm900130m: \\Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes.\\2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID45136Compound was evaluated for inhibitory activity against Candida albicans; 2-3.21998Bioorganic & medicinal chemistry letters, Sep-22, Volume: 8, Issue:18
New antifungals selected by molecular topology.
AID200326Compound was evaluated for inhibitory activity against Saccharomyces cerevisiae; 2-3.21998Bioorganic & medicinal chemistry letters, Sep-22, Volume: 8, Issue:18
New antifungals selected by molecular topology.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347129qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347112qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID493017Wombat Data for BeliefDocking2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
N-(3-acyloxy-2-benzylpropyl)-N'-[4-(methylsulfonylamino)benzyl]thiourea analogues: novel potent and high affinity antagonists and partial antagonists of the vanilloid receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10,909)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901139 (10.44)18.7374
1990's2736 (25.08)18.2507
2000's3279 (30.06)29.6817
2010's2908 (26.66)24.3611
2020's847 (7.76)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 93.24

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index93.24 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index5.35 (4.65)
Search Engine Demand Index182.15 (26.88)
Search Engine Supply Index2.28 (0.95)

This Compound (93.24)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials661 (5.88%)5.53%
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Reviews751 (6.68%)6.00%
Reviews0 (0.00%)6.00%
Reviews0 (0.00%)6.00%
Case Studies108 (0.96%)4.05%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational15 (0.13%)0.25%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other9,703 (86.34%)84.16%
Other5 (100.00%)84.16%
Other10 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (178)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Multicentre, Single-Arm, Open-Label Study Of The Repeated Administration Of QUTENZA For The Treatment Of Peripheral Neuropathic Pain [NCT01252160]Phase 4306 participants (Actual)Interventional2010-10-28Completed
Safety and Feasibility of High-Dose Topical Capsaicin for the Treatment of Neuropathic Pain in Pediatric Sickle Cell Disease [NCT03899246]Phase 110 participants (Actual)Interventional2019-07-03Completed
Neuro-immunological Analysis of Idiopathic Rhinitis Patients and Controls Treated With Capsaicin. [NCT01223820]Phase 436 participants (Anticipated)Interventional2011-01-31Completed
Capsaicin 179 mg Patch Versus Oral Duloxetine in Patients With Chemotherapy-induced Peripheral Neuropathy : a Phase 3 Randomized Multicentric Open-label Study. [NCT05840562]Phase 3274 participants (Anticipated)Interventional2023-09-30Not yet recruiting
Aalborg University, Aalborg, Denmark [NCT05158309]24 participants (Actual)Interventional2021-05-31Completed
Quantitative Response of Healthy Muscle Following the Induction of Capsaicin [NCT03944889]Early Phase 120 participants (Actual)Interventional2019-07-01Completed
A Two-Period Crossover Study to Compare the Systemic Exposure to Trans-Capsaicin and Cis-Capsaicin From an Intra-Articular Injection of CNTX-4975-05 (Trans-capsaicin for Injection) and Topical 8% Capsaicin Patch (Qutenza®) in Subjects With Painful Knee Os [NCT03576508]Phase 116 participants (Actual)Interventional2018-06-25Completed
Spinal and Supra-Spinal Pain Mechanisms in Patients With Fibromyalgia [NCT03464292]55 participants (Actual)Observational2018-07-05Completed
Capsaicin-induced Muscle Pain in Humans: From Investigating Central Pain Processing to Developing Clinical Applications [NCT02377180]72 participants (Actual)Interventional2014-09-30Completed
A Randomized, Multi-Dose, Placebo-Controlled Pain Relief Study of 0.25% 920-CGS-200 in Subjects With Preexisting Knee Pain (for at Least 6 Months) Caused by Osteoarthritis (OA) [NCT03124407]Phase 4120 participants (Actual)Interventional2016-07-31Completed
Establishing Normal Swallowing and Breathing Profiles in Healthy Adults Across the Age Span [NCT03122145]Phase 1/Phase 249 participants (Actual)Interventional2017-05-23Completed
Adenosine Triphosphate and Capsaicin Cough Provocation Test for Identifing Patients With Chronic Cough Who Have Differential Responses to Purinergic Receptor Antagonists: a Randomized, Cross-over, Single-blind Trial [NCT03638063]200 participants (Anticipated)Observational2018-10-29Recruiting
Sensory Neuromodulation Protocol for the Treatment of Post-stroke Oropharyngeal Dysphagia. Short-term Neurophysiological Effects. [NCT04052178]36 participants (Actual)Interventional2016-02-10Completed
Analgesic Effectiveness of Capsaicin 8% Cutaneous Patch for the Treatment of Chronic Postsurgical or Post-traumatic Neuropathic Pain: a Randomized Placebo Controlled Study in Children Aged 12 to 17-y [NCT05997979]Phase 246 participants (Anticipated)Interventional2023-12-01Not yet recruiting
The Pain Biomarker Study: Changes in Circulating Pain Signalling Molecules With Activation of Pain Receptors [NCT03511846]Phase 1371 participants (Anticipated)Interventional2018-03-21Active, not recruiting
CAPSAICIN Trial: A Prospective Study of Capsaicin in Subjects With Clinically Localized Prostate Cancer Undergoing Active Surveillance or Radical Prostatectomy [NCT02037464]Phase 2100 participants (Anticipated)Interventional2014-01-31Not yet recruiting
Effect of Intradermal Morphine Application on Histaminergic and Non-histaminergic Itch and Related TRPV1 and Antihistamine Treatments (2nd Sub-project) [NCT04700007]26 participants (Actual)Interventional2021-01-18Completed
A Functional Magnetic Resonance Imaging Study to Investigate ATP-sensitive Cough Neural Pathways in Patients With Chronic Cough Hypersensitivity [NCT03722849]58 participants (Actual)Interventional2019-03-01Completed
A Double Blind, Randomized, Placebo-Controlled, Third-Party Open, Modified Cross-Over Study To Examine The Acute Effect Of PF-04427429 On Capsaicin Flare Response In Healthy Volunteers Using EMLA Cream As Positive Control [NCT01147432]Phase 112 participants (Actual)Interventional2010-08-31Completed
An Open Label, Single Dose, Bioavailability Study of Topical Transdermal Glucosamine Cream on the Synovial Fluid Tapped From Osteoarthritic Adult, Male and Female Human Subjects Already Undergoing Arthrocentesis [NCT03743896]Phase 4240 participants (Actual)Interventional2016-05-18Completed
A Non-interventional Post-registration Clinical Study of Efficacy and Safety of Qutenza in Patients With Post-operative Peripheral Neuropathic Pain [NCT02171182]319 participants (Actual)Observational2014-01-31Completed
Topical Capsaicin Cream for Treatment of Suspected Cyclical Vomiting Syndromes [NCT03223350]Phase 230 participants (Actual)Interventional2017-12-20Completed
Treatment of Chronic Post-stroke Oropharyngeal Dysphagia With Paired Stimulation Through Peripheral TRVP1 Agonists and Non-invasive Brain Stimulation [NCT05720871]200 participants (Anticipated)Interventional2022-11-28Recruiting
A Phase 1b Study to Characterize the Effect of Injection Site Cooling on Pain Experienced After CNTX-4975-05 (Trans-capsaicin) Intra-articular and Capsaicin Intradermal Injections in Healthy Volunteers and Subjects With Bilateral Painful Knee Osteoarthrit [NCT03472677]Phase 120 participants (Actual)Interventional2018-03-21Completed
Mechanisms of Airway Protection Dysfunction in Parkinson's Disease [NCT03321019]260 participants (Anticipated)Observational2017-12-12Recruiting
The Efficacy of Capsaicin Sensitivity Testing in Patients With Irritable Larynx Syndrome [NCT02065128]0 participants (Actual)Observational2017-08-01Withdrawn(stopped due to Logistical challenges with research pharmacy prevented the dilution of the capsaicin. No participants were ever recruited, enrolled, or approached.)
Capsaicin for Post-stroke Dysphagia [NCT04470752]Phase 282 participants (Anticipated)Interventional2021-08-24Recruiting
An Interventional, Phase III, Double-blind, Randomized, Controlled, Parallel-group, Multi-site, Clinical Trial Evaluating the Efficacy and Safety of Qutenza® in Subjects With Post-surgical Neuropathic Pain [NCT04967664]Phase 3408 participants (Anticipated)Interventional2021-07-13Recruiting
Efficacy and Safety of 0.625% and 1.25% Capsaicin Patch in the Management of Peripheral Neuropathic Pain ; Early Phase II, Multi-center, Randomized, and Semi-double Blind Controlled Clinical Trial [NCT02228928]Phase 1/Phase 260 participants (Actual)Interventional2009-02-28Completed
The Physiological Effects of Capsaicinoid Ingestion on Human Metabolism and Exercise Performance [NCT02139852]0 participants (Actual)Observational2014-06-30Withdrawn(stopped due to Project abandoned)
Phase 3 Confirmatory, Randomised 1:1 Double-blind, Placebo-controlled Study Evaluating the Analgesic Efficacy of Capsaicin 8% Patches in Chronic Coccygodynia. [NCT06023706]Phase 3188 participants (Anticipated)Interventional2023-11-15Recruiting
Temporal Profile of the Nociceptive Desensitization Induced by 8% Topical Capsaicin and the Functional Independence of Transient Receptor Potential Ankyrin 1 (TPRA1)- and Vanilloid 1 (TRPV1)-Expressing Nociceptive Afferents [NCT03132142]22 participants (Anticipated)Interventional2017-04-30Recruiting
Neuromodulation of Placebo and Nocebo Effects [NCT03102710]103 participants (Actual)Interventional2016-05-31Completed
A Phase 2 Double-Blind Clinical Trial to Examine the Comparative Effects on Osteoarthritic Knee Pain of CGS-200-1 (1% Capsaicin Topical Liquid), CGS-200-5 (5% Capsaicin Topical Liquid), and CGS-200-0 (Vehicle, No Capsaicin) [NCT03528369]Phase 2122 participants (Actual)Interventional2018-05-14Completed
A Randomized, Single Blind Study to Investigate the Tolerability and Effects on Epidermal Nerve Fiber Density of Multiple Low-Concentrations of Capsaicin Topical Liquid NGX-1998 in Healthy Volunteers [NCT00912262]Phase 136 participants (Anticipated)Interventional2008-06-30Completed
Efficacy of Topical Capsaicin on Chronic Neck Pain ; Double-blinded Randomized Trial [NCT01200745]60 participants (Anticipated)Interventional2010-09-30Not yet recruiting
Study of Topical Preparation of Capsaicin Nanoparticle in Patient With Painful Diabetic Neuropathy [NCT01125215]Phase 2/Phase 360 participants (Anticipated)Interventional2009-09-30Active, not recruiting
A SINGLE CENTER, MULTIPLE DOSE, OPEN-LABEL, RANDOMIZED, THREE-PERIOD CROSSOVER STUDY TO DETERMINE THE RELATIVE BIOAVAILABILITY OF DICLOFENAC IN THE TOPICAL GEL COMBINATION PRODUCT (DICLOFENAC 2% + CAPSAICIN 0.075%) COMPARED TO DICLOFENAC MONO GEL 2% AND V [NCT03074162]Phase 148 participants (Actual)Interventional2017-04-20Completed
Capsaicin Consumption on Resting Energy Expenditure and Glucose Metabolism [NCT03859583]30 participants (Anticipated)Interventional2018-05-29Recruiting
An Open-Label Study Of The Use Of Topical Lidocaine (2.5%)/Prilocaine (2.5%) Cream As Pre-Treatment For NGX-4010 In Subjects With Postherpetic Neuralgia (PHN) [NCT00916942]Phase 220 participants (Anticipated)Interventional2009-06-30Completed
The Effect of Ablation of Epidermal Nerve Fibers Using 0.1% Capsaicin Cream on Spontaneous Cutaneous Burning Pain, Tactile Hyperalgesia, and Thermal Hyperalgesia: A Controlled, Masked Trial With an N of 1 [NCT01883102]Phase 11 participants (Actual)Interventional2013-06-30Completed
Cervical Capsaicin for Labor Induction and Pain Relief [NCT00771511]Phase 40 participants (Actual)Interventional2010-10-31Withdrawn(stopped due to Study never started)
Influence on Cough and Airway Symptoms by Oral Capsaicin - a Phase 2, Randomised, Placebo-controlled Clinical Study in Patients With Chronic Idiopathic Cough [NCT04125563]Phase 260 participants (Anticipated)Interventional2019-06-01Active, not recruiting
Effect of Administration of Capsaicin on Inflammatory Cytokines Profile(TNFα , IL - 1β , IL - 6, IL -8 , MIP - 1β) in Individuals With Dyslipidemia. [NCT02823912]Phase 2/Phase 317 participants (Anticipated)Interventional2016-10-31Not yet recruiting
The Efficacy and Safety Profile of Capsaicin 8% Patch Versus 5% Lidocaine Patch in Patients With Diabetic Peripheral Neuropathic Pain: a Randomized, Placebo-controlled Study of South Asian Male Patients [NCT04238208]Phase 4290 participants (Actual)Interventional2019-01-10Completed
Capsaicin 8% Patch for Spinal Cord Injury Neuropathic Pain [NCT02441660]11 participants (Actual)Interventional2016-04-30Completed
Prospective Analgesic Compound Efficacy (PACE) Study [NCT02403687]300 participants (Actual)Observational [Patient Registry]2015-06-30Completed
Safety, Efficacy and Patient Acceptability of Topical Treatment Versus Systemic Treatment: a Randomized, Multicentre, Comparative Pragmatic Trial in Adult Patients Suffering From Diverse Localized Neuropathic Pain (LNP) Syndromes [NCT03348735]Phase 433 participants (Actual)Interventional2018-12-03Terminated(stopped due to Low inclusion rate)
Burning Mouth Syndrome - Optimized Diagnostic Criteria and Treatment [NCT05059418]40 participants (Anticipated)Interventional2021-11-01Not yet recruiting
Single-blinded, Randomized Study of Capsaicin to Prevent Delayed Chemotherapy-induced Nausea and Vomiting [NCT04918069]Phase 2160 participants (Actual)Interventional2019-10-18Completed
Phase II Randomized Controlled Study Aiming to Evaluate the Interest of Qutenza in Patients With Head and Neck Cancer in Remission and With Sequelae Neuropathic Pain. [NCT04704453]Phase 2130 participants (Anticipated)Interventional2021-04-28Recruiting
A Double-Blind, Randomized, Controlled, Parallel-Group, Multicenter Study Evaluating the Safety and Efficacy of Civamide Cream 0.075% as a Treatment in Subjects With Osteoarthritis of the Knee [NCT00995306]Phase 3695 participants (Actual)Interventional2003-06-30Completed
A Phase 1 Open-Label, Single-Dose, Dose Escalation Study in Healthy Subjects to Evaluate the Safety and Pharmacokinetics of Orally Administered Civamide (Zucapsaicin) [NCT00802217]Phase 112 participants (Anticipated)Interventional2008-11-30Terminated(stopped due to PK results demonstrated no systemic absorption)
The Effect of Capsaicin-Phenylephrine-Caffeine Formulation on Aborting Tilt Induced Syncope in Patients With a History of Vasovagal Syncope or Near Syncope [NCT04972123]Phase 2140 participants (Actual)Interventional2021-07-20Completed
The Impact of Respiratory Strength Training in Individuals With Amyotrophic Lateral Sclerosis (ALS) [NCT02710110]Early Phase 150 participants (Actual)Interventional2016-04-30Completed
Effect of Differing Doses of A Sweet Pepper Extract - Capsiate (A Capsaicin Analogue) - On Energy Expenditure and Blood Parameters in Humans During Exercise [NCT00692601]Phase 112 participants (Actual)Interventional2008-04-30Completed
Randomized, Double Blind, Positive- Controlled, Three-way Cross-over Human Experimental Biomarker Study of V116517 in Healthy Male Subjects [NCT02695745]Phase 137 participants (Actual)Interventional2011-09-30Completed
Perifollicular Nerves in Alopecia Areata: Response to Topical Capsaicin [NCT00176969]Phase 424 participants Interventional1997-08-31Completed
Neurogenic Mechanisms in Burning Mouth Syndrome With Focus on Localization and Desensibilization of Vanilloid Receptor TRPV1 [NCT00875537]22 participants (Actual)Interventional2009-01-31Completed
Effects of Capsaicin on the Structure, Distribution, and Function of Cutaneous Small Nerve Fibers in Psoriatic Skin [NCT00697034]Phase 412 participants (Actual)Interventional2006-06-30Terminated(stopped due to Lack of qualified and willing volunteers.)
Biomechanical, Neurophysiological and Clinical Effects of 6-month Stimulation Using TRPV1 and TRPA1 Agonists in Older Patients With Oropharyngeal Dysphagia [NCT05958173]150 participants (Anticipated)Interventional2023-09-01Not yet recruiting
Activation of Endogenous Inhibitory Modulation During Gastric and Somatic Stimulation in Functional Dyspepsia Patients and Healthy Controls [NCT00693407]80 participants (Actual)Interventional2008-09-30Completed
Double-blinded, Cross-over Randomized Controlled Trial to Evaluate the Efficacy of Topical Capsaicin to Reduce Pain and Improve Health-related Quality of Life in Adults With Chronic Myofascial Neck Pain [NCT00795106]Phase 20 participants (Actual)Interventional2009-11-30Withdrawn(stopped due to Difficulty finding a monitor)
Heat-, Cold-, and Mechanical Pain Thresholds Under Exposition of High Dose Topical Capsaicin [NCT02570841]Phase 420 participants (Actual)Interventional2015-02-28Completed
"Effect of capsaïcin Infusion on Esophageal Mucosal Integrity - a Role for TRPV1-mediated Neuropeptides?" [NCT02603783]13 participants (Actual)Interventional2015-11-30Completed
Randomized, Double-Blind, Placebo-Controlled Evaluation of the Tolerability of Two Civamide (Zucapsaicin) Patch Strengths Compared to Placebo Patch in Healthy Volunteers [NCT00758433]Phase 139 participants (Actual)Interventional2008-09-30Completed
Brain and Brainstem Activation Following Duodenal Nociceptive Stimulation With Capsaicin, an Exploratory High-resolution fMRI Study in Healthy Volunteers [NCT02551029]19 participants (Actual)Interventional2016-02-29Completed
Delineating Physiologic Mechanisms of Swallowing Impairment and Decline in ALS [NCT02962050]109 participants (Actual)Observational2017-05-31Completed
Effect of Muscular Exercise on Cough Reflex [NCT02882555]60 participants (Actual)Interventional2012-06-30Completed
Determination of Accurate Screening Tools for Dysphagia in Amyotrophic Lateral Sclerosis (ALS) [NCT02710162]Early Phase 121 participants (Actual)Interventional2016-04-30Completed
A Pilot Study of Cough Reflex Desensitization for the Treatment of Cough Hypersensitivity Syndrome [NCT04256733]Early Phase 120 participants (Actual)Interventional2019-05-01Completed
The Physiological Effects of Capsaicinoid Ingestion on Human Metabolism and Exercise Performance [NCT02138630]0 participants (Actual)Interventional2014-06-30Withdrawn(stopped due to Project abandoned)
An Open-label, 8-Week Study to Compare the Comfort and Ease of Use of Five Different Treatment Regimens for CNTX-4975-05 Intra-articular Injection in Subjects With Chronic, Moderate-to-Severe Osteoarthritis Knee Pain [NCT03661996]Phase 3854 participants (Actual)Interventional2018-09-18Completed
An Open-Label Extension Study of NGX-4010 for the Treatment of Neuropathic Pain [NCT00089557]Phase 20 participants InterventionalTerminated
Effect of 4-week Dihydrocapsiate Ingestion on Resting Metabolic Rate: A Double-blind Randomized Parallel Arm Study [NCT00999297]79 participants (Actual)Interventional2008-07-31Completed
A Randomized, Crossover, Double Blinded, Placebo Controlled Trial of Topical Capsaicin in Treatment of Painful Diabetic Neuropathy [NCT00993070]Phase 2/Phase 333 participants (Actual)Interventional2009-10-31Completed
An Open Label, Ascending Dose Study to Evaluate the Safety and Tolerability of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton's Neuroma) [NCT02550756]Phase 111 participants (Actual)Interventional2014-02-28Completed
The Role of Qutenza (Topical Capsaicin 8%) in Treating Neuropathic Pain From Arteriovenous Fistulae in Patients With End Stage Renal Failure [NCT01748422]20 participants (Anticipated)Observational2015-11-30Recruiting
Evaluation of Vanilloid Receptor Inactivation for Preemptive Analgesia [NCT00008476]Phase 2162 participants Interventional2001-01-31Completed
Vurdering af Perifere GABAA-receptorer Med Henblik på Lokal Smertelindring [NCT02928328]90 participants (Anticipated)Interventional2016-10-31Recruiting
Elaboration of Patient-friendly Treatment Strategy With Capsaicin Nasal Spray in Patients With Idiopathic Rhinitis [NCT02288156]Phase 480 participants (Actual)Interventional2015-07-31Completed
SINOL + MucoAd™ (SMAN) Evaluation Trial: A Double-Blind, Cross-Over Comparison of SINOL and SMAN in Subjects With Congestion Due to Allergic Rhinitis [NCT00825656]Phase 420 participants (Anticipated)Interventional2008-09-30Active, not recruiting
A Multicenter Randomized, Double-Blind, Controlled Study of NGX-4010 for the Treatment of Painful HIV-Associated Neuropathy [NCT00321672]Phase 3494 participants (Actual)Interventional2006-06-30Completed
The Functional Consequences of the CTNS-deletion for the TRPV1-receptor in Cystinosis Patients [NCT02533076]Early Phase 150 participants (Actual)Interventional2014-11-30Completed
[NCT01884116]100 participants (Actual)Interventional2011-03-31Completed
An Open-Label Pilot Study of High-Concentration Capsaicin Patches in the Treatment of Painful HIV-Associated Neuropathy [NCT00061152]Phase 20 participants InterventionalActive, not recruiting
Evaluation of Vanilloid Receptor Inactivation for Preemptive Analgesia [NCT00088686]Phase 275 participants Interventional2004-07-31Completed
Salivary Interactions With Chemosensations [NCT03883880]32 participants (Actual)Interventional2019-01-05Terminated(stopped due to COVID (completed first intervention type only))
Evaluation of the Effect of Different Treatments on Pain Scores and Self-reported Oral Health-related Quality of Life in Individuals With Burning Mouth Syndrome: a Randomized Controlled Clinical Trial [NCT06040190]Phase 4150 participants (Anticipated)Interventional2023-11-01Not yet recruiting
Effects of Capsaicin on Salty Gustatory Cortices in Human [NCT01974037]Phase 480 participants (Actual)Interventional2013-05-31Completed
Interventional Study for the Comparison of the Oral Bioavailability of Two Melatonin Supplements [NCT05835258]12 participants (Actual)Interventional2023-05-30Completed
Multicentric, Open, Randomized Study Comparing Topical Treatment by Patch of Capsaicin to 8% (Qutenza) to Pregabalin Oral in the Early Treatment of Neuropathic Pain After Primary Surgery for Breast Cancer [NCT03794388]Phase 3140 participants (Actual)Interventional2019-03-19Completed
An International, Multicenter, Randomized, Double-Blind, 12-Week Controlled Study of NGX-4010 for Treatment of Painful HIV-Associated Neuropathy [NCT00085761]Phase 30 participants InterventionalTerminated(stopped due to Terminated in view of the C107 findings demonstrating efficacy at doses of 90 and 30 minutes)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Two-Stage Exploratory Study to Evaluate Safety, Tolerability, Efficacy, and Pharmacokinetics of Intraoperative Subacromial Injection With 4975 in Patients Undergoing Arthroscopic Rotator Cuff Re [NCT00672568]Phase 224 participants (Actual)Interventional2008-07-31Terminated(stopped due to Study has been halted after completing Stage 1, for corporate reasons. No future patients will be enrolled or treated.)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of a Single Intraoperative Localized Instillation of 4975 in Patients Undergoing Primary Unilateral Total Hi [NCT00683267]Phase 2118 participants (Actual)Interventional2007-09-30Terminated(stopped due to Enrollment of patients has halted prematurely and will not resume. No future patients will be enrolled or treated.)
The Role of Pre-established Skin Inflammation on the Susceptibility to Histamine and Cowhage-induced Itch in Healthy Humans [NCT02769910]Phase 1/Phase 216 participants (Actual)Interventional2016-05-31Completed
Improving Clinical and Instrumental Diagnostic Standards in Dysphagia. [NCT04773184]264 participants (Anticipated)Observational2021-04-27Recruiting
Capsaicin for the Treatment of Cannabinoid Hyperemesis Syndrome [NCT04283292]Phase 450 participants (Anticipated)Interventional2020-12-01Recruiting
Cough Desensitization Therapy for Cough Hypersensitivity Syndrome: Pilot 2 [NCT05226299]Phase 122 participants (Actual)Interventional2021-05-01Completed
Cannabinoid Modulation of Pain [NCT01595620]Early Phase 16 participants (Actual)Interventional2011-11-09Completed
Tolerability of QUTENZATM When Applied After Pre-treatment With Lidocaine or Tramadol in Subjects With Peripheral Neuropathic Pain - A Randomized, Multi-center, Assessor-blinded Study [NCT01416116]Phase 4122 participants (Actual)Interventional2011-07-06Completed
Cutaneous Sensory Function After Wound Instillation of Capsaicin During Groin Hernia Repair [NCT00583180]42 participants (Anticipated)Observational2008-01-31Completed
Efficacy Study on Symptomatic Control of Patient With Knee Osteoarthritis Between 0.0125% of Capsaicin to Placebo [NCT00471055]Phase 3100 participants (Actual)Interventional2007-06-30Completed
Unraveling the Mechanisms of Capsaicin Treatment in Idiopathic Rhinitis Patients and Controls by Measuring Mucosal Potentials in the Nose. [NCT01862523]Phase 439 participants (Actual)Interventional2012-02-29Completed
A Randomized, Controlled, Single-Blind Study to Investigate the Effect of Three Capsaicin Dermal Liquid Formulations on Epidermal Nerve Fiber Immunostaining and Sensory Function In Healthy Volunteers [NCT00528216]Phase 120 participants (Anticipated)InterventionalCompleted
A Randomized, Controlled, Open-Label Study to Investigate the Effect of NGX-4010 on Epidermal Nerve Fiber Density and Sensory Function in Healthy Volunteers [NCT00254449]Phase 136 participants Interventional2005-11-30Completed
Subacute Effect of Pharmacological Sensory Stimulation of the Oropharynx by Agonists of TRP Receptors in Swallowing Neurophysiology in the Elderly With Oropharyngeal Dysphagia. [NCT04741620]150 participants (Actual)Interventional2019-01-17Completed
Effect of Capsaicin on the Augmentation of Cerebral Perfusion. A Phase II Study. [NCT05543837]Phase 220 participants (Actual)Interventional2022-09-20Completed
A Randomized, Controlled, Long-term Safety Study Evaluating the Effect of Repeated Applications of QUTENZATM Plus Standard of Care Versus Standard of Care Alone in Subjects With Painful Diabetic Peripheral Neuropathy [NCT01478607]Phase 3468 participants (Actual)Interventional2011-11-30Completed
A Multicenter, Open-Label, Phase 2 Study of NGX-4010 for the Treatment of Neuropathic Pain in Patients With Painful HIV-Associated Neuropathy (HIV-AN) or Postherpetic Neuralgia (PHN) [NCT00233155]Phase 2100 participants Interventional2005-08-31Completed
A Randomized, Double-Blind, Controlled Study of NGX-4010 for the Treatment of Postherpetic Neuralgia [NCT00068081]Phase 3150 participants InterventionalCompleted
A Randomized, Open-Label Study of the Tolerability of Three Local Anesthetic Formulations in Conjunction With NGX-4010 for the Treatment of Neuropathic Pain [NCT00082316]Phase 20 participants InterventionalCompleted
Cough and Swallow Rehabilitation Following Stroke [NCT01907321]Phase 1/Phase 214 participants (Actual)Interventional2011-01-31Completed
A Randomized, Double-Blind, Controlled Study of NGX-4010 for the Treatment of Postherpetic Neuralgia [NCT00115310]Phase 3400 participants Interventional2005-06-30Completed
Etude de la Reserve Vasomotrice Microcirculatoire cutanée [NCT00152724]85 participants (Actual)Observational1996-01-31Completed
The Use of Capsaicin Challenge for Diagnosis, Monitoring and Follow-up of Chronic Cough. [NCT01807832]25 participants (Anticipated)Interventional2013-03-31Not yet recruiting
[NCT01540877]28 participants (Actual)Interventional2011-04-30Completed
Remote Ischemic Preconditioning Effects on Central and Peripheral Sensitization in Healthy Volunteers-A Pilot Study [NCT01541436]Early Phase 120 participants (Actual)Interventional2012-03-31Completed
The Role of Topical Capsaicin in Treatment of Rhinogenic Headache [NCT03330639]0 participants (Actual)Interventional2017-07-31Withdrawn(stopped due to Grant funding for study was not obtained.)
A Double-Blind Controlled Pilot Study of High-Dose Capsaicin Patches in the Treatment of Pain Associated With Postherpetic Neuralgia [NCT00034710]Phase 242 participants Interventional2002-03-31Completed
A Randomized, Double-Blind, Controlled Dose Finding Study of NGX-4010 for the Treatment of Postherpetic Neuralgia [NCT00061776]Phase 2/Phase 3300 participants InterventionalCompleted
A Randomized, Double-Blind, Controlled Dose Finding Study of NGX-4010 for the Treatment of Painful HIV-Associated Distal Symmetrical Polyneuropathy [NCT00064623]Phase 3300 participants Interventional2003-08-31Completed
Evaluation of Motor Unit Abnormalities After Experimentally Induced Sensitization Using Capsaicin: A Randomized, Double-Blinded, Placebo-Controlled Study [NCT04361149]Phase 423 participants (Actual)Interventional2019-10-01Completed
Treatment of Acute Post-stroke Oropharyngeal Dysphagia With Paired Stimulation Through Peripheral TRVP1 Agonists and Non-invasive Brain Stimulation [NCT05735626]60 participants (Anticipated)Interventional2021-07-01Recruiting
A Double-blind, Randomized, Crossover Clinical Study to Assess the Efficacy of Qutenza® for the Reduction of Site Pain Caused by Continuous Subcutaneous Infusion of Remodulin®, in Pulmonary Arterial Hypertension Patients [NCT01393795]Phase 211 participants (Actual)Interventional2011-08-31Completed
Clinical Trial Assessing the Efficacy of Capsaicin Patch (Qutenza®) in Cancer Patients With Neuropathic Pain [NCT03317613]Phase 284 participants (Actual)Interventional2017-11-09Completed
Ethnic Differences in Response to Topical Capsaicin: A Psychophysical Study on Healthy Subjects [NCT00655811]Phase 440 participants (Actual)Interventional2008-02-29Completed
Randomized, Double Blind, Placebo Controlled Crossover Trial With Open Label Extension Of Topical 20% Beta Caryophyllene Alone And In Combination With 0.025% Capsaicin In The Treatment Of Pain Caused By Osteoarthritis Of The Knee [NCT03152578]Phase 256 participants (Actual)Interventional2017-07-01Completed
The Role of Transient Receptor Potential Channels in Chemotherapy-Induced Peripheral Neuropathic Pain. [NCT04415892]240 participants (Anticipated)Interventional2019-10-01Recruiting
Dose-Escalation and Safety of Capsaicin for Cerebral Perfusion Augmentation. A Pilot Study [NCT04545892]Phase 130 participants (Actual)Interventional2019-12-01Completed
A Multicenter Randomized, Double-Blind, Controlled Study of NGX-4010 for the Treatment of Postherpetic Neuralgia [NCT00300222]Phase 3400 participants Interventional2006-03-31Completed
Chest Pain Perception and Capsaicin Sensitivity [NCT02346903]99 participants (Actual)Interventional2013-04-30Completed
Effects of Acute Pain on Cognitive Performance in Young Adults [NCT05625776]23 participants (Actual)Interventional2023-03-22Completed
The Effect of Capsaicin and Cinnamaldehyde on Intestinal Permeability, Gallbladder Motility and Satiety [NCT01667523]13 participants (Actual)Interventional2011-02-28Completed
[NCT01699854]Phase 350 participants (Anticipated)Interventional2012-08-31Terminated(stopped due to Expiration of the placebo patch)
The Role of Qutenza (Topical Capsaicin 8%) in Treating Neuropathic Pain From Critical Ischaemia in Patients With End-stage Renal Failure [NCT01704339]Phase 420 participants (Anticipated)Interventional2012-12-31Not yet recruiting
Qutenza Versus Pregabalin in Subjects With Peripheral Neuropathic Pain: an Open-label, Randomized, Multicenter, Non-inferiority Efficacy and Tolerability Study [NCT01713426]Phase 4568 participants (Actual)Interventional2012-07-11Completed
The Use of QUTENZA™ in Standard Clinical Practice: a Phase IV, Multicentre, European Non-interventional Study [NCT01737294]429 participants (Actual)Observational2012-02-29Completed
The Role of Pre-emptive Analgesia With Qutenza (Topical Capsaicin 8%) in Preventing Neuropathic Pain Following Lower Limb Amputation: a Pilot Randomised Controlled Study [NCT01748435]30 participants (Anticipated)Observational2013-02-28Not yet recruiting
Brain Imaging of Pain Phenotype and Genotype With Novel Scanning Techniques [NCT01777087]15 participants (Actual)Interventional2013-01-31Completed
A Double Blind, Randomized, Placebo-Controlled, Third-Party Open, Cross-Over Study To Examine The Effect Of PF-06305591 On Capsaicin And Capsaicin/Heat-Induced Neurogenic Flare In Healthy Volunteers [NCT01797796]Phase 116 participants (Actual)Interventional2013-04-30Completed
Assessment of Dystussia in Traumatic Brain Injury [NCT02240329]Early Phase 14 participants (Actual)Interventional2013-03-31Completed
En undersøgelse af Mekanismerne Bag Nociceptiv Desensibilisering forårsaget af Topikal Capsaicin [NCT03587220]44 participants (Actual)Interventional2018-08-01Completed
Capsaïcin patch8% in Adult Complex Regional Pain Syndromes: a Retrospective Analysis [NCT05523934]50 participants (Anticipated)Observational2022-09-16Recruiting
[NCT02854670]Phase 2/Phase 310 participants (Actual)Interventional2016-01-20Terminated(stopped due to Recruitment difficulties)
A Randomized, Placebo-Controlled, Cross-Over Study to Assess the Safety and Efficacy of TOPical CAPsaicin With Stable Angina (TOPCAP) [NCT01231750]Phase 37 participants (Actual)Interventional2010-10-31Terminated(stopped due to Unable to identify study population to achieve number expected)
A Phase III, Double-blind, Randomized, Placebo-controlled, Multicenter Study Evaluating the Efficacy and Safety of QUTENZA® in Subjects With Painful Diabetic Peripheral Neuropathy [NCT01533428]Phase 3369 participants (Actual)Interventional2012-02-29Completed
Phase III Comparison of Oral Capsaicin Lozenge Versus Placebo Lozenge for Radiation-Induced Mucositis [NCT00003610]Phase 318 participants (Actual)Interventional1998-10-31Completed
ToAST: Investigating the Effect of Bronchial Thermoplasty on Cough in Patients With Severe Asthma [NCT03281941]24 participants (Anticipated)Interventional2016-08-06Recruiting
Trial of Capsaicin Cream as an Adjunctive Therapy for Nausea and Vomiting of Pregnancy: A Pilot Investigation [NCT05098067]Phase 230 participants (Anticipated)Interventional2022-05-24Recruiting
The Effects of High Definition Transcranial Direct Current Stimulation Over Primary Motor Cortex Versus Insular Cortical Targets on Experimental Capsaicin Induced Hyperalgesia and Pain in Healthy Volunteers [NCT03216707]60 participants (Actual)Interventional2017-09-01Completed
Effect of Cannabidiol on Microglial Activation and Central Pain-Sensitization [NCT04398719]Early Phase 115 participants (Anticipated)Interventional2021-05-07Recruiting
The Qutenza® Patch for Disabling Treprostinil Infusion Site Pain [NCT01260454]Phase 26 participants (Actual)Interventional2010-11-30Completed
[NCT00004316]Phase 1/Phase 2139 participants Interventional1995-06-30Completed
A Multinational, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Multiple Doses of Finalgon® Cream (1.08% Nicoboxil/ 0.17% Nonivamide) in the Treatment of Acute Low Back Pain [NCT02300311]Phase 3138 participants (Actual)Interventional2015-01-31Completed
Somatosensory Studies of Pain and Pain Control Measured With Oxygen-15 Water Positron Emission Tomography and Functional MRI in Normals and Patients With Neuropathic or Chronic Pain Conditions [NCT00001307]273 participants Observational1992-08-31Completed
Autofluorescent Flavoprotein Imaging of Intraepidermal Nerve Fibers: a Pilot Study [NCT02537951]10 participants (Actual)Interventional2015-09-30Completed
Double-Blinded Randomized Prospective Trial of Intranasal Capsaicin Treatment for Non-Allergic Irritant Rhinitis [NCT02493257]Phase 222 participants (Actual)Interventional2014-10-31Completed
A Double-Blind, Randomized, Pilot Study to Investigate the Thermosensitivity of a Topical Palmitated Formulation of Capsaicin [NCT05649228]Early Phase 142 participants (Anticipated)Interventional2022-12-31Recruiting
LY2951742 Biomarker Study in Patients With Migraine [NCT02766517]Early Phase 137 participants (Actual)Interventional2016-09-28Completed
0.075% Capsaicin Lotion for the Treatment of Painful Diabetic Neuropathy: A Randomized, Double- Blind, Crossover, Placebo-Controlled Trial [NCT03113448]Phase 342 participants (Actual)Interventional2017-01-19Completed
Neuroinflammatory Interactions of ATP and P2X3 Receptor in the Airways of Chronic Cough Patients: an Exploratory Study [NCT05713019]20 participants (Anticipated)Interventional2023-02-28Not yet recruiting
The Effect of Capsaicin-induced Pain on Homeostatic Plasticity in Healthy Human Participants [NCT04485689]24 participants (Anticipated)Interventional2020-07-01Recruiting
A Randomized, Controlled Multi-centre Parallel Group Study to Assess the Efficacy and Safety of Multiple Doses of a Topically Applied Combination Containing Diclofenac 2% + Capsaicin 0.075% (2 g Formulation Per Application; 2-times Daily for 5 Days) Compa [NCT02700815]Phase 3746 participants (Actual)Interventional2016-05-09Completed
Comparison of Cold Dry Air Exposure, Hyperosmolar Sponge and Capsaicin Nasal Spray for Objective Evaluation of Nasal Hyperreactivity [NCT02334605]36 participants (Anticipated)Interventional2015-01-31Recruiting
Airway Protection Deficits According to Stimulus Type in Parkinson's Disease [NCT02390089]Phase 1158 participants (Actual)Interventional2015-04-30Completed
Identifying Treatment Responders to a Topical Non-steroidal Anti-inflammatory Drug (NSAID) or Topical Capsaicin in Painful Knee Osteoarthritis: A Pilot Series of N-of-1 Trials [NCT03146689]22 participants (Actual)Interventional2017-08-04Completed
The Prevalence of Local IgE Elevation and Its Effect on Intranasal Capsaicin Therapy in the Non-allergic Rhinitis Population [NCT05093478]Phase 333 participants (Anticipated)Interventional2019-09-10Recruiting
Respiratory Kinematics During Voluntary and Reflex Cough in Healthy Adults [NCT01854268]Phase 1/Phase 225 participants (Actual)Interventional2013-05-31Completed
Effect of Intrathecal Ketorolac on Mechanical Hypersensitivity Following Acute Opioid Exposure [NCT00693160]Phase 230 participants (Actual)Interventional2007-12-31Terminated(stopped due to the manufacturing of preservative free ketorolac (Acular-PF) was discontinued)
Efficacy And Safety Of High Concentration Capsaicin Patches In Knee Osteoarthritis In Obese Patients: A Randomized Prospective Double Blind Placebo Controlled Study [NCT03153813]Phase 322 participants (Actual)Interventional2015-07-31Terminated
A Multi-centre, Double-blind, Randomised, Parallel Group Study to Assess the Efficacy and Safety of Multiple Doses of Topically Applied Hyperemisation-inducing Ointment (2cm Ointment Line Per Application; up to 3 Times Daily for up to 4 Days) Containing 2 [NCT01708915]Phase 3805 participants (Actual)Interventional2012-10-31Completed
Study of Efficacy and Non-inferiority, With Two Capsaicin Topic Treatments, for the Moderate to Severe Pain in Diabetic Neuropathy. [NCT05029297]Phase 3161 participants (Actual)Interventional2010-11-04Completed
Chest Pain Perception and Capsaicin Sensitivity in Patients With Acute Cardiac Ischemia [NCT02346916]22 participants (Actual)Interventional2013-10-31Completed
Neuropathic Determining Factors and Analgesic Efficacy of Capsaicin 8% (QUTENZA®) Patches in Refractory Coccygodygnia [NCT05983263]106 participants (Anticipated)Observational2023-08-15Not yet recruiting
The Influence of Topical Capsaicin on Thermoregulatory and Perceptual Outcomes During Exercise Within the Heat [NCT05298202]Phase 412 participants (Actual)Interventional2022-04-01Completed
Respiratory Kinematics of Reflex and Voluntary Cough in Healthy Older Adults and Parkinson's Disease [NCT02183519]Phase 1/Phase 244 participants (Actual)Interventional2014-10-31Completed
Algology in Oncology Osteopathic Support [NCT05726929]120 participants (Anticipated)Interventional2023-01-11Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00321672 (3) [back to overview]"The Primary Measure of Efficacy Was the Percent Change in the Average Pain for the Past 24 Hours Numeric Pain Rating Scale (NPRS) Score From Baseline During Weeks 2 to 12."
NCT00321672 (3) [back to overview]"Proportion of Subjects Reaching 30% Decrease in Their Mean Average Pain for the Past 24 Hours Numeric Pain Rating Scale (NPRS) Score From Baseline During Weeks 2 to 12"
NCT00321672 (3) [back to overview]"Absolute Change in the Mean Average Pain for the Past 24 Hours Numeric Pain Rating Scale (NPRS) Score From Baseline During Weeks 2 to 12."
NCT00655811 (3) [back to overview]Ethnic Differences on the Effects of Topical Capsaicin on Thermal Sensory Thermal Thresholds
NCT00655811 (3) [back to overview]Ethnic Differences in Burning Pain Induced by Topical Capsaicin
NCT00655811 (3) [back to overview]The Difference in Burning/Pain Sensation Ratings Between the Capsaicin or Placebo Application.
NCT00693160 (2) [back to overview]Hyperalgesia
NCT00693160 (2) [back to overview]Cerebrospinal Fluid (CSF) Prostaglandin E2 (PGE2) Concentration
NCT01260454 (3) [back to overview]Number of Participants Who Experienced Greater Than 6 Pain Level Using the 10 Point Visual Analog Score
NCT01260454 (3) [back to overview]Pain Score on a Visual Analogue Scale
NCT01260454 (3) [back to overview]Number of Participants Who Used of Narcotics Following a Treprostinil Infusion Site Change
NCT01533428 (18) [back to overview]Change in Hospital Anxiety and Depression Scale (HADS) Depression Scale From Baseline to Weeks 2, 8 and 12.
NCT01533428 (18) [back to overview]Percentage of Participants With 50% Reduction in Average Daily Pain Score.
NCT01533428 (18) [back to overview]Percent Change in the Average Daily Pain Score From Baseline to Between Weeks 2 and 12
NCT01533428 (18) [back to overview]Percent Change in the Average Daily Pain Score From Baseline to Between Weeks 2 and 8
NCT01533428 (18) [back to overview]Weekly Percent Change From Baseline in Average Daily Pain Score
NCT01533428 (18) [back to overview]Weekly Average of Average Daily Pain at Baseline and Every Week After Baseline
NCT01533428 (18) [back to overview]Treatment Satisfaction Assessment Based on Self-Assessment of Treatment (SAT II) Questionnaire at Baseline, Weeks 8 and 12
NCT01533428 (18) [back to overview]Tolerability of Patch Application Assessed by Dermal Assessment on Day 1, 15 Minutes and 60 Minutes After Patch Removal.
NCT01533428 (18) [back to overview]Safety Assessed Through Adverse Events (AE) and Serious Adverse Events (SAE), Vital Signs, and Laboratory Analyses From Baseline to Week 12
NCT01533428 (18) [back to overview]Change in Hospital Anxiety and Depression Scale (HADS) Anxiety Scale From Baseline to Weeks 2, 8 and 12
NCT01533428 (18) [back to overview]Percentage of Participants With 30% Reduction in Average Daily Pain Score.
NCT01533428 (18) [back to overview]Percent Change in Average Sleep Interference Score From Baseline to Between Weeks 2-8 and Weeks 2-12
NCT01533428 (18) [back to overview]Overall Participant Status Assessed Using Patient Global Impression of Change (PGIC) Self-assessment Questionnaire in Week 8
NCT01533428 (18) [back to overview]Change From Baseline in the European Quality Of Life (QOL) Questionnaire in 5 Dimensions (EQ-5D) With Visual Analog Scale (VAS) to Weeks 2, 8 and 12
NCT01533428 (18) [back to overview]"Change From Pre-application inPain Now Score"
NCT01533428 (18) [back to overview]Overall Participant Status Assessed Using Patient Global Impression of Change (PGIC) Self-assessment Questionnaire in Week 2
NCT01533428 (18) [back to overview]Overall Participant Status Assessed Using Patient Global Impression of Change (PGIC) Self-assessment Questionnaire in Week 12
NCT01533428 (18) [back to overview]Number of Participants Who Used Rescue Pain Medication Days 1 Through 5
NCT01708915 (4) [back to overview]Difference Between Baseline Pain Intensity and Average Pain Intensity on the Last Individual Treatment Day
NCT01708915 (4) [back to overview]Pain Intensity Difference (PID) Between Pre-dose Baseline and 4 Hours After First Application
NCT01708915 (4) [back to overview]Pain Intensity Difference (PID) Between Pre-dose Baseline and 8hours After First Application
NCT01708915 (4) [back to overview]Patient Assessment of Efficacy on the Last Individual Treatment Day
NCT01854268 (3) [back to overview]Lung Volume Initiation
NCT01854268 (3) [back to overview]Urge-to-cough
NCT01854268 (3) [back to overview]Peak Expiratory Airflow Rate
NCT01907321 (2) [back to overview]Cough Expiratory Airflow
NCT01907321 (2) [back to overview]Maximum Expiratory Pressure
NCT02183519 (1) [back to overview]Peak Expiratory Flow Rate
NCT02240329 (2) [back to overview]Number of Coughs in Response to Stimulation With 200 Micro Moles Capsaicin in Solution
NCT02240329 (2) [back to overview]Average Urge to Cough (UTC) Following Administration of 200 Micro Mole Capsaicin Solution Concentration
NCT02288156 (6) [back to overview]Change of Nasal Hyperreactivity in All Treatment Modalities.
NCT02288156 (6) [back to overview]Change in Visual Analogue Scale for Major Nasal Symptoms
NCT02288156 (6) [back to overview]Change in Visual Analogue Scale for Individual Nasal Symptoms
NCT02288156 (6) [back to overview]Number of Adverse Events in All Treatment Groups
NCT02288156 (6) [back to overview]Number of Patients Without Improvement of Symptoms at the End of the Trial in All Treatment Modalities
NCT02288156 (6) [back to overview]Therapeutic Response in All Treatment Regimes
NCT02300311 (4) [back to overview]Difference of Average Pain Intensity (APID) From Pre-dose Baseline on the Last Individual Treatment Day
NCT02300311 (4) [back to overview]Pain Intensity Difference (PID) From Pre-dose Baseline to 4 Hours After the First Trial Medication Application (PID4h)
NCT02300311 (4) [back to overview]Pain Intensity Difference (PID) From Pre-dose Baseline to 8h After the First Trial Medication Application (PID8h)
NCT02300311 (4) [back to overview]Patient's Assessment of the Efficacy on the Last Individual Treatment Day
NCT02346903 (2) [back to overview]Capsaicin Sensitivity
NCT02346903 (2) [back to overview]Chest Pain Score During PCI
NCT02346916 (2) [back to overview]Capsaicin Sensitivity
NCT02346916 (2) [back to overview]Chest Pain
NCT02441660 (3) [back to overview]Change in Pain Relief With Visual Analog (VAS) Pain Scale
NCT02441660 (3) [back to overview]Change in Quality of Life as Measured by the World Health Organization Quality of Life (WHOQOL-BREF)
NCT02441660 (3) [back to overview]Change in Spinal Cord Independence Measure (SCIM)
NCT02493257 (4) [back to overview]Change in Nasal Blood Flow as Indicated by Change in Maximal Optical Density Assessed by Optical Rhinometry
NCT02493257 (4) [back to overview]Change in Nasal Blood Flow as Indicated by Change in Maximal Optical Density Assessed by Optical Rhinometry
NCT02493257 (4) [back to overview]Change in Total Symptom Score
NCT02493257 (4) [back to overview]Change in Total Symptom Score
NCT02537951 (1) [back to overview]AFI-intensity After Nociceptive Stimulation
NCT02700815 (8) [back to overview]Number of Patients With Decrease in POMwp of at Least 30% From Baseline
NCT02700815 (8) [back to overview]Change From Baseline in POMwp (cm) at Day 6 Morning
NCT02700815 (8) [back to overview]Change From Baseline in Pressure Algometry (PA) at Day 2 Evening, Before Drug Application
NCT02700815 (8) [back to overview]Change From Baseline in Pressure Algometry (PA) at Day 6 Morning
NCT02700815 (8) [back to overview]Change in POM Between Baseline and Day 2 Evening, 1 Hour After Drug Application
NCT02700815 (8) [back to overview]Number of Patients With Decrease in POMwp of at Least 50% From Baseline
NCT02700815 (8) [back to overview]POMwp Area Under the Curve (AUC) Calculated From 0 to 72 Hours (h) (POMwp AUC(0-72 h))
NCT02700815 (8) [back to overview]POMwp Area Under the Curve (AUC) Calculated From 0 to 120 Hours (h) (POMwp AUC(0-120 h))
NCT02766517 (2) [back to overview]The Capsaicin-Induced Dermal Blood Flow (DBF)
NCT02766517 (2) [back to overview]Plasma Calcitonin Gene-Related Peptide (CGRP) Levels
NCT03074162 (5) [back to overview]Percentage Peak-trough Fluctuation (%PTF), Calculated as [100*(Cmax,ss - Cpre,ss)/Cav,ss]
NCT03074162 (5) [back to overview]Maximum Plasma Concentration During a Dosage Interval (Cmax,ss) Obtained Directly From the Concentration-time Data for Diclofenac at Steady State (Day 7)
NCT03074162 (5) [back to overview]Average Plasma Concentration (Cav,ss) for Diclofenac at Steady State
NCT03074162 (5) [back to overview]Area Under the Plasma Concentration-time Curve (AUC) Over One Dosing Interval for Diclofenac at Steady State (AUC0-τ,ss) (τ = 12 Hours) (Day 7)
NCT03074162 (5) [back to overview]Time to Maximum Observed Plasma Concentration at Steady State for Diclofenac at Steady State (Tmax,ss) (Day 7)
NCT03102710 (3) [back to overview]Gracely Sensory Scale Pain Rating Changes in Response to Lidocaine and Capsaicin Creams and tDCS
NCT03102710 (3) [back to overview]fMRI Resting States Functional Connectivity Changes During Pain Stimulation
NCT03102710 (3) [back to overview]Comparison of Functional Connectivity Changes of the DLPFC Before and After tDCS Stimulation
NCT03122145 (4) [back to overview]Reflexive Cough Testing (With Urge-to-Cough)
NCT03122145 (4) [back to overview]Duration of Laryngeal Vestibule Closure (dLVC)
NCT03122145 (4) [back to overview]Voluntary Peak Cough Flow Testing (With Electronic Peak Cough Flow Meter Device)
NCT03122145 (4) [back to overview]Laryngeal Vestibule Closure Reaction Time (LVCrt)
NCT03124407 (3) [back to overview]Percentage of Subjects With 50% or Greater Pain Score Reduction From Baseline to Day 8 Post Study Drug Treatment.
NCT03124407 (3) [back to overview]Percentage of Subjects With 50% or Greater Pain Score Reduction From Baseline to 24 Hours After First Dose of Study Drug Treatment.
NCT03124407 (3) [back to overview]Percentage of Subjects With 50% or Greater Pain Score Reduction From Baseline to Day 28 Post Study Drug Treatment.
NCT03223350 (1) [back to overview]Nausea Visual Analog Scale
NCT03528369 (8) [back to overview]Number of Subjects With Skin Reactions of Erythema or Pruritus.
NCT03528369 (8) [back to overview]Primary Efficacy Endpoint: Change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Score From Baseline to Day 35
NCT03528369 (8) [back to overview]Western Ontario and McMaster Universities Osteoarthritis (WOMAC) Index Total Scores (Pain, Stiffness and Function).
NCT03528369 (8) [back to overview]Number of Subjects With Durability of Efficacy Response
NCT03528369 (8) [back to overview]Western Ontario and McMaster Universities Osteoarthritis (WOMAC) Index Stiffness Scores.
NCT03528369 (8) [back to overview]Western Ontario and McMaster Universities Osteoarthritis (WOMAC) Index Function Scores.
NCT03528369 (8) [back to overview]Patient Reported Burning-Stinging Pain (BSP) During Application of Study Drug.
NCT03528369 (8) [back to overview]Secondary Efficacy Endpoint #1: Extent of Change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Score From Baseline to Day 5, 19, 64 and 94.
NCT03661996 (8) [back to overview]"Mean Change From Baseline in KOOS Pain With Walking Single Question Score by Subject Type"
NCT03661996 (8) [back to overview]"Mean Change From Baseline in KOOS Pain Subscale Score by Subject Type"
NCT03661996 (8) [back to overview]Mean Change From Baseline in Average Daily Pain With Walking NPRS (0-10) Score by Subject Type
NCT03661996 (8) [back to overview]"Mean Change From Baseline in KOOS Function (Sport and Recreational Activities) Subscale Score by Subject Type"
NCT03661996 (8) [back to overview]"Mean Change From Baseline in KOOS Function (Daily Living) Subscale Score by Subject Type"
NCT03661996 (8) [back to overview]Determination of Optimal Procedure for Administering CNTX-4975-05 With Regards to Pain, Participant Satisfaction, and Investigator's Satisfaction
NCT03661996 (8) [back to overview]"Mean Change From Baseline in KOOS Symptoms Subscale Score by Subject Type"
NCT03661996 (8) [back to overview]"Mean Change From Baseline in KOOS Knee-Related Quality of Life Subscale Score by Subject Type"

"The Primary Measure of Efficacy Was the Percent Change in the Average Pain for the Past 24 Hours Numeric Pain Rating Scale (NPRS) Score From Baseline During Weeks 2 to 12."

"Efficacy was assessed by daily Numeric Pain Rating Scale (NPRS) capturing average pain for the past 24 hours for painful HIV-associated neuropathy area(s) at approximately 9 PM every evening throughout the 12-week study period. The NPRS is an 11-point scale (0 to 10) with 0 indicating no pain and 10 indicating the worst possible pain." (NCT00321672)
Timeframe: Weeks 2-12

InterventionPercent Change from baseline (Least Squares Mean)
NGX-4010, 60 Minutes-32.8
Control Group, 60 Minutes-30.0
NGX-4010, 30 Minutes-26.2
Control Group , 30 Minutes-19.1
NGX-4010 Total-29.5
Control, Total-24.5

[back to top]

"Proportion of Subjects Reaching 30% Decrease in Their Mean Average Pain for the Past 24 Hours Numeric Pain Rating Scale (NPRS) Score From Baseline During Weeks 2 to 12"

(NCT00321672)
Timeframe: Weeks 2-12

InterventionPercentage of Participants (Number)
NGX-4010, 60 Minutes48
Control Group, 60 Minutes45
NGX-4010, 30 Minutes39
Control Group , 30 Minutes26
NGX-4010 Total43
Control, Total36

[back to top]

"Absolute Change in the Mean Average Pain for the Past 24 Hours Numeric Pain Rating Scale (NPRS) Score From Baseline During Weeks 2 to 12."

(NCT00321672)
Timeframe: Weeks 2-12.

InterventionNumeric Pain Rating Scale (0 to 10) (Least Squares Mean)
NGX-4010, 60 Minutes-2.0
Control Group, 60 Minutes-1.8
NGX-4010, 30 Minutes-1.6
Control Group , 30 Minutes-1.1
NGX-4010 Total-1.8
Control, Total-1.4

[back to top]

Ethnic Differences on the Effects of Topical Capsaicin on Thermal Sensory Thermal Thresholds

A secondary endpoint is to see if topical capsaicin has an effect on warm and heat pain thresholds. Quantitative thermosensory testing was carried out using the Medoc TSA 2001 (Medoc Ltd). The probe baseline temperature was 32 °C and the contact area was 12 cm2. The probe warmed the skin surface at a linear rate of 0·4 °C per second, up to a cut-off of 50 °C. Thermal thresholds were measured in the following order: warmth sensation threshold was measured followed by heat pain detection threshold; each of them was determined four times by the ascending method of limits. (NCT00655811)
Timeframe: 1 day

,,,
InterventionChange in degrees Celsius (Mean)
Heat pain detection threshold changeWarmth sensation threshold change
African Americans-2.112.36
Caucasians-6.10-0.68
East Asians-5.010.56
Hispanics-7.24-3.15

[back to top]

Ethnic Differences in Burning Pain Induced by Topical Capsaicin

The primary endpoint is to test the burning pain effect of topical capsaicin by using an continuous visual analog scale (CoVAS) intensity scale as an outcome measure. Participants will rate burning pain intensity after topical capsaicin application. The burning or pain sensation intensity was recorded continuously on a 100-mm COVAS (0, no sensation to 100, maximum, strongest imaginable pain sensation). The subjects were also asked to indicate whether they experienced any nonpainful sensation. (NCT00655811)
Timeframe: 1 day

,,,
Interventionunits on a scale (Mean)
CapsaicinPlacebo
African Americans0.810
Caucasians4.070
East Asians17.050
Hispanics13.30

[back to top]

The Difference in Burning/Pain Sensation Ratings Between the Capsaicin or Placebo Application.

This secondary outcome is to see if subjects rated burning/pain differently between the topical capsaicin or placebo application. Participants will rate burning/pain intensity after topical capsaicin and placebo application. The burning/pain sensation intensity was recorded continuously on a 100-mm COVAS (0, no sensation to 100, maximum, strongest imaginable burning/pain sensation). The subjects were also asked to indicate whether they experienced any non-burning/-painful sensation. (NCT00655811)
Timeframe: 1 day

Interventionunits on a scale (Mean)
Capsaicin8.81
Placebo0

[back to top]

Hyperalgesia

Total Area of hypersensitivity (measured in centimeters) were assessed approximately 24 hours post intrathecal ketorolac injection by the method of using a von Frey filament (NCT00693160)
Timeframe: 24 hours

Interventioncentimeters^2 (Mean)
Intrathecal Ketorolac70.1
Placebo Intrathecal Injection48.4

[back to top]

Cerebrospinal Fluid (CSF) Prostaglandin E2 (PGE2) Concentration

Concentration of prostaglandin E2 (PGE2) in Cerebrospinal fluid (CSF) 2.5 hours post injection of intrathecal ketorolac (NCT00693160)
Timeframe: 2.5 hours

Interventionpicograms per milliliter (Mean)
Intrathecal Ketorolac87
Placebo Intrathecal Injection75

[back to top]

Number of Participants Who Experienced Greater Than 6 Pain Level Using the 10 Point Visual Analog Score

Qutenza has not previously been used in patients with normal, healthy skin. We will assess the reaction to capsaicin in these patients as compared to the patients with unhealthy skin (post-herpetic neuralgia) who were studied in the registration trials for Qutenza. Pain immediately following Qutenza application was measured on a 10 point visual analog score with the word 'none' above 0 and 'agonizing' above 10. (NCT01260454)
Timeframe: 60 minute period of patch application and subsequent 3 days

Interventionparticipants (Number)
Qutenza Patch3

[back to top]

Pain Score on a Visual Analogue Scale

"Patients will record the maximum intensity of pain (0-10) each day after placing an infusion site in a diary with which they are already comfortable. They will record the score each day for 14 days unless they have recorded 0 for two consecutive days.~The primary outcome measure will be the average of those 14 maximum intensity pain scores (the sum of the maximum for each day divided by the number of days, generally 14; range 0-10)." (NCT01260454)
Timeframe: 14 days after a new infusion site

InterventionVisual Analogue Scale (Mean)
Qutenza Patch2.89

[back to top]

Number of Participants Who Used of Narcotics Following a Treprostinil Infusion Site Change

We counted the number of participants who used any amount of narcotic during the 14 day diary period. (NCT01260454)
Timeframe: 14 days

Interventionparticipants (Number)
Qutenza Patch4

[back to top]

Change in Hospital Anxiety and Depression Scale (HADS) Depression Scale From Baseline to Weeks 2, 8 and 12.

The Hospital Anxiety and Depression Scale (HADS) is a self-report scale developed for the assessment of anxiety and depression, it contains 14 items rated on a 4-point Likert-type scale. There are 2 subscales,one assessing depression and the other anxiety. The 7-item depression and anxiety subscales yield scores of 0 to 21 that are interpreted with the following cut-off points: 0 to 7, normal; 8 to 10, mild mood disturbance; 11 to 14, moderate mood disturbance; and 15 to 21, severe mood disturbance. (NCT01533428)
Timeframe: Baseline to Weeks 2, 8 and 12

,
Interventionunits on a scale (Mean)
Week 2 [ N=184; N=181]Week 8 [N=180; N=171]Week 12 [N=169; N=171]
Capsaicin 8%-0.6-0.7-0.8
Placebo-0.6-0.4-0.6

[back to top]

Percentage of Participants With 50% Reduction in Average Daily Pain Score.

Percentage of participants achieving 50% decrease in the average daily pain score in Weeks 2 and 8 and Weeks 2 and 12 measured using Question 5 of the Brief Pain Inventory-Diabetic Neuropathy (BPI-DN). Participants assessed their pain on a numeric rating scale from 0 (no pain) to 10 (pain as bad as you can imagine). (NCT01533428)
Timeframe: Baseline, Weeks 2-8 and Weeks 2-12

,
Interventionpercentage of participants (Number)
50% Pain Reduction-Week 2 to 850% Pain Reduction-Week 2 to 12
Capsaicin 8%3941
Placebo3335

[back to top]

Percent Change in the Average Daily Pain Score From Baseline to Between Weeks 2 and 12

Percent Change in the Average Daily Pain Score from baseline to between Weeks 2 and 12 measured using Question 5 of the Brief Pain Inventory-Diabetic Neuropathy (BPI-DN). Participants assessed their pain due to diabetes in the last 24 hours on a numeric rating scale from 0 (no pain) to 10 (pain as bad as you can imagine). (NCT01533428)
Timeframe: Baseline to between Weeks 2 and 12

Interventionpercentage change (Mean)
Capsaicin 8%-27.96
Placebo-21.00

[back to top]

Percent Change in the Average Daily Pain Score From Baseline to Between Weeks 2 and 8

Percent change in the average daily pain score from baseline to between Weeks 2 and 8, measured using Question 5 of the Brief Pain Inventory-Diabetic Neuropathy (BPI-DN). Participants assessed their pain due to diabetes in the last 24 hours on a numeric rating scale from 0 (no pain) to 10 (pain as bad as you can imagine). (NCT01533428)
Timeframe: Baseline to between Weeks 2 to 8

Interventionpercentage change (Mean)
Capsaicin 8%-27.44
Placebo-20.85

[back to top]

Weekly Percent Change From Baseline in Average Daily Pain Score

Weekly Percent Change from baseline in average daily pain score from baseline to Week 12 measured using Question 5 of the Brief Pain Inventory-Diabetic Neuropathy (BPI-DN). Participants assessed their pain due to diabetes in the last 24 hours on a numeric rating scale from 0 (no pain) to 10 (pain as bad as you can imagine). (NCT01533428)
Timeframe: Baseline to Weeks 2, 3, 4, 5, 6, 7, 8, 9,10, 11 and 12

,
Interventionpercentage change (Mean)
Week 2Week 3Week 4Week 5Week 6Week 7Week 8Week 9Week 10Week 11Week 12
Capsaicin 8%-22.97-27.17-28.18-28.35-27.87-29.03-28.53-28.61-28.17-29.04-29.64
Placebo-19.00-20.51-21.11-21.17-21.66-21.02-21.46-21.78-20.73-21.75-20.76

[back to top]

Weekly Average of Average Daily Pain at Baseline and Every Week After Baseline

Weekly average of average daily pain score at Baseline and Weeks 2,4,8 and 12 measured using Question 5 of the Brief Pain Inventory-Diabetic Neuropathy (BPI-DN). Participants assessed their pain due to diabetes in the last 24 hours on a numeric rating scale from 0 (no pain) to 10 (pain as bad as you can imagine). (NCT01533428)
Timeframe: Baseline and Weeks 2, 4, 8 and 12

,
Interventionunits on a scale (Mean)
BaselineWeek 2Week 4Week 8Week 12
Capsaicin 8%6.645.144.834.784.73
Placebo6.385.145.025.015.08

[back to top]

Treatment Satisfaction Assessment Based on Self-Assessment of Treatment (SAT II) Questionnaire at Baseline, Weeks 8 and 12

"Treatment satisfaction assessment based on Self-Assessment Treatment (SAT II) questionnaire and the question Over the past 7 days, how much has the study treatment improved your pain level?" (NCT01533428)
Timeframe: Baseline, Weeks 8 and 12

,
Interventionparticipants (Number)
Week 8 [N=177; N=170] [Not at all]Week 8 [N=177; N=170] [Slightly Better]Week 8 [N=177; N=170] [Moderately Better]Week 8 [N=177; N=170] [Quite a Bit Better]Week 8 [N=177; N=170] [Very Much Better]Week 12 [N=166; N=171] [Not at all]Week 12 [N=166; N=171] [Slightly Better]Week 12 [N=166; N=171] [Moderately Better]Week 12 [N=166; N=171] [Quite a Bit Better]Week 12 [N=166; N=171][Very Much Better]
Capsaicin 8%59353730166930232915
Placebo82332121139138121416

[back to top]

Tolerability of Patch Application Assessed by Dermal Assessment on Day 1, 15 Minutes and 60 Minutes After Patch Removal.

Tolerability of patch application was assessed by dermal assessment (0 to 7 point severity score on Dermal Assessment Scale). Data reported is based on the number of participants in the combined category with a score ≥ 4 (Definite edema or higher), 15 and 60 minutes after patch removal. (NCT01533428)
Timeframe: Day 1, 15 minutes and 60 minutes after patch removal

,
Interventionparticipants (Number)
15 minutes after patch removal [N=185,N=180]60 minutes after patch removal [N=185,N=179]
Capsaicin 8%00
Placebo22

[back to top]

Safety Assessed Through Adverse Events (AE) and Serious Adverse Events (SAE), Vital Signs, and Laboratory Analyses From Baseline to Week 12

Number of patients assessed for Safety through Adverse Events (AE) and Serious Adverse Events (SAE), vital signs, and laboratory analyses from baseline to week 12 (NCT01533428)
Timeframe: Baseline to Week 12

,
Interventionparticipants (Number)
Treatment-emergent adverse events (TEAEs)Drug-related TEAEsDeathsSerious TEAEsDrug-related serious TEAEsTEAEs permanent discontinuation of study drugDrug-related TEAEs to permanent discontinuationApplication site reactions
Capsaicin 8%87650200063
Placebo62230700015

[back to top]

Change in Hospital Anxiety and Depression Scale (HADS) Anxiety Scale From Baseline to Weeks 2, 8 and 12

The Hospital Anxiety and Depression Scale (HADS) is a self-report scale developed for the assessment of anxiety and depression, that contain 14 items rated on a 4-point Likert-type scale. There are 2 subscales,one assessing depression and the other anxiety. The 7-item depression and anxiety subscales yield scores of 0 to 21 that are interpreted with the following cut-off points: 0 to 7, normal; 8 to 10, mild mood disturbance; 11 to 14, moderate mood disturbance; and 15 to 21, severe mood disturbance. (NCT01533428)
Timeframe: Baseline to Weeks 2, 8 and 12

,
Interventionunits on a scale (Mean)
Week 2 [N=183; N=180]Week 8 [N=178; N=171]Week 12 [N=169; N=169]
Capsaicin 8%-0.4-0.7-0.9
Placebo-0.5-0.6-0.9

[back to top]

Percentage of Participants With 30% Reduction in Average Daily Pain Score.

Percentage of participants achieving 30% decrease in the average daily pain score in Weeks 2 and 8 and Weeks 2 and 12 measured using Question 5 of the Brief Pain Inventory-Diabetic Neuropathy (BPI-DN). Participants assessed their pain on a numeric rating scale from 0 (no pain) to 10 (pain as bad as you can imagine). (NCT01533428)
Timeframe: Baseline, Weeks 2-8 and Weeks 2-12

,
Interventionpercentage of participants (Number)
30% Pain Reduction-Week 2 to 830% Pain Reduction-Week 2 to 12
Capsaicin 8%7476
Placebo6058

[back to top]

Percent Change in Average Sleep Interference Score From Baseline to Between Weeks 2-8 and Weeks 2-12

"Percent change in average sleep interference was measured by Question 9F of the Brief Pain Inventory-Diabetic Neuropathy (BPI DN) and was used to assess pain and sleep interference index. Daily sleep interference rating scale consists of an 11-point numerical scale with which the patient describes how pain related to diabetes has interfered with their sleep during the past 24 hours. On a scale 0 identifies pain does not interfere with sleep and 10 identifies pain completely interferes with sleep. Average sleep interference score is assessed from baseline to Weeks 2-8 and Weeks 2-12." (NCT01533428)
Timeframe: Baseline, Weeks 2-8 and Weeks 2-12

,
Interventionpercentage of change (Mean)
Week 2-8Week 2-12
Capsaicin 8%-33.12-33.99
Placebo-24.15-24.67

[back to top]

Overall Participant Status Assessed Using Patient Global Impression of Change (PGIC) Self-assessment Questionnaire in Week 8

Overall participant status assessed using Patient Global Impression of Change (PGIC) self-assessment questionnaire which was used by participants to report on 7 categories listed as follows; Very Much Improved, Much Improved, Minimally Improved, No Change, Minimally Worse, Much Worse and Very Much Worse in Week 8 (NCT01533428)
Timeframe: Baseline to Week 8

,
Interventionparticipants (Number)
Very Much ImprovedMuch ImprovedMinimally ImprovedNo ChangeMinimally WorseMuch WorseVery Much Worse
Capsaicin 8%20515847400
Placebo16364859841

[back to top]

Change From Baseline in the European Quality Of Life (QOL) Questionnaire in 5 Dimensions (EQ-5D) With Visual Analog Scale (VAS) to Weeks 2, 8 and 12

Change from Baseline in the European Quality Of Life (QOL) questionnaire in 5 dimensions (EQ-5D) with Visual Analog Scale (VAS) to Weeks 2, 8 and 12. EQ-5D self-reported questionnaire is used to measure health-related quality of life by measuring 5 dimensions of health: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The EQ-5D questionnaire includes a visual analog scale (VAS) which records participants self-rated health status on a graduated (0-100) scale with higher scores indicating higher Health-Related Quality of Life (HRQoL). (NCT01533428)
Timeframe: Baseline to Weeks 2, 8 and 12

,
Interventionunits on a scale (Mean)
Week 8 [ N=180;N=170]Week 12 [N=170; N=172]Week 2 [N=184; N=181]
Capsaicin 8%4.03.81.3
Placebo3.53.73.9

[back to top]

"Change From Pre-application inPain Now Score"

"Change from pre-application inPain Now score was measured on a scale from 0-10 where 0 equates to No Pain and 10 to Pain as bad as you can imagine. Participants were asked to provide pain ratings relative only to the area of pain undergoing treatment." (NCT01533428)
Timeframe: Pre-application and 15 minutes and 60 minutes after patch removal

,
Interventionunits on a scale (Mean)
15 minutes after patch removal [N=185; N=183]60 minutes after patch removal [N=185; N=182]
Capsaicin 8%-1.6-1.8
Placebo-2.0-2.2

[back to top]

Overall Participant Status Assessed Using Patient Global Impression of Change (PGIC) Self-assessment Questionnaire in Week 2

Overall participant status assessed using Patient Global Impression of Change (PGIC) self-assessment questionnaire which was used by participants to report on 7 categories listed as follows; Very Much Improved, Much Improved, Minimally Improved, No Change, Minimally Worse, Much Worse and Very Much Worse in Week 2 (NCT01533428)
Timeframe: Baseline to Week 2

,
Interventionparticipants (Number)
Very Much ImprovedMuch ImprovedMinimally ImprovedNo ChangeMinimally WorseMuch WorseVery Much Worse
Capsaicin 8%10497245331
Placebo9385868601

[back to top]

Overall Participant Status Assessed Using Patient Global Impression of Change (PGIC) Self-assessment Questionnaire in Week 12

Overall participant status assessed using Patient Global Impression of Change (PGIC) self-assessment questionnaire which was used by participants to report on 7 categories listed as follows; Very Much Improved, Much Improved, Minimally Improved, No Change, Minimally Worse, Much Worse and Very Much Worse in Week 12 (NCT01533428)
Timeframe: Baseline to Week 12

,
Interventionparticipants (Number)
Very Much ImprovedMuch ImprovedMinimally ImprovedNo ChangeMinimally WorseMuch WorseVery Much Worse
Capsaicin 8%23453950920
Placebo22294072810

[back to top]

Number of Participants Who Used Rescue Pain Medication Days 1 Through 5

Summarized number of participants who used Rescue Pain Medications for Pain (NCT01533428)
Timeframe: Days 1 - 5

,
Interventionparticipants (Number)
OverallAnalgesicsAnilidesNatural opium alkaloidsOther opioidsSalicylic acid and derivativesAntiinflammatory and antirheumatic productsPropionic acid derivativesOther gynecologicalsAntiinflammatory products vaginal administrationTopical products for joint and muscular painAntiinflammatory preparations, nonsteroids for topPreparations with salicylic acid derivatives
Capsaicin 8%35222014211515151516151
Placebo10994001111110

[back to top]

Difference Between Baseline Pain Intensity and Average Pain Intensity on the Last Individual Treatment Day

Average pain intensity was assessed in the evening of days 1, 2, 3 and 4 on a 11-point numerical rating scale ranging from 0 (no pain) to 10 (worst pain possible). The last individual treatment day is the last day with diary-recorded ointment application. Means were adjusted for centre effect and baseline value. (NCT01708915)
Timeframe: Baseline and 1 to 4 days

Interventionunits on a scale (Least Squares Mean)
Placebo-1.884
Nicoboxil-2.371
Nonivamide-3.074
Nicoboxil/Nonivamide-3.540

[back to top]

Pain Intensity Difference (PID) Between Pre-dose Baseline and 4 Hours After First Application

Pain intensity was assessed on a 11-point numerical rating scale ranging from 0 (no pain) to 10 (worst pain possible) at pre-dose baseline and 0.5, 1, 2, 3 and 4 hours after first ointment application. Means were adjusted for centre effect and baseline value. (NCT01708915)
Timeframe: Baseline and 4 hours after first ointment application

Interventionunits on a scale (Least Squares Mean)
Placebo-0.650
Nicoboxil-0.968
Nonivamide-1.641
Nicoboxil/Nonivamide-1.699

[back to top]

Pain Intensity Difference (PID) Between Pre-dose Baseline and 8hours After First Application

Pain intensity (PI) was assessed on a 11-point numerical rating scale ranging from 0 (no pain) to 10 (worst pain possible) at pre-dose baseline and 0.5, 1, 2, 3, 4, 6 and 8 hours after first ointment application. Means were adjusted for centre effect and baseline value. (NCT01708915)
Timeframe: Baseline and 8 hours after first ointment application

Interventionunits on a scale (Least Squares Mean)
Placebo-1.049
Nicoboxil-1.428
Nonivamide-2.252
Nicoboxil/Nonivamide-2.410

[back to top]

Patient Assessment of Efficacy on the Last Individual Treatment Day

Patient assessment of efficacy was assessed on a 4-point verbal rating scale (VRS, 0 = 'poor', 1 = 'fair', 2 = 'good', 3 = 'very good' relief of the patients' low back pain) in the evening of days 1, 2, 3 and 4. The last individual treatment day is the last day with diary-recorded ointment application (NCT01708915)
Timeframe: 1 to 4 days

,,,
Interventionparticipants (Number)
Very goodGoodFairPoorMissing
Nicoboxil196720941
Nicoboxil/Nonivamide508820422
Nonivamide348527520
Placebo947221251

[back to top]

Lung Volume Initiation

Respiratory kinematic measure: lung volume initiation (LVI) Lung volume initiation is a measure of the volume of air in the lungs prior to a respiratory task. (NCT01854268)
Timeframe: 1 hour

Intervention% Vital Capacity, relative to EEL (Mean)
Healthy Adults Who Receive Capsaicin23.3

[back to top]

Urge-to-cough

Urge-to-cough: A measure of respiratory sensation that rates the perceived magnitude of the need to cough on a Borg scale (0=no urge-to-cough; 10=maximal urge-to-cough). (NCT01854268)
Timeframe: 1 hour

Interventionunits on a scale (Median)
Healthy Adults Who Receive Capsaicin6

[back to top]

Peak Expiratory Airflow Rate

Airflow measures: Peak expiratory airflow rate Peak expiratory flow rate is a measure of the velocity of air expelled from the respiratory apparatus during cough. Measured in liters/second. (NCT01854268)
Timeframe: 1 hour

InterventionLiters/second (Mean)
PEFR - Voluntary CoughPEFR - Reflex Cough
Healthy Adults Who Receive Capsaicin6.0585.437

[back to top]

Cough Expiratory Airflow

Cough airflow measure of peak expiratory flow rate (NCT01907321)
Timeframe: Change in baseline to 7 weeks

InterventionLiters of air/second (Mean)
Expiratory Muscle Strength Training (EMST)2.43

[back to top]

Maximum Expiratory Pressure

This measure will indicate if there are strength gains in the respiratory muscle by measuring expiratory pressure generating ability. (NCT01907321)
Timeframe: Change in baseline to week 7

Interventioncm H2O (pressure measurement) (Mean)
Expiratory Muscle Strength Training (EMST)104.31

[back to top]

Peak Expiratory Flow Rate

Peak expiratory flow rate is the maximum volume of air that is expelled per unit time for each cough in a cough epoch. Measured in liters/second. (NCT02183519)
Timeframe: 1-2 hours

InterventionLiters of air/second (Mean)
Healthy Older Adults4.34
Parkinson's Disease3.92

[back to top]

Number of Coughs in Response to Stimulation With 200 Micro Moles Capsaicin in Solution

The total cough count (CTot) was determined by counting all cough events that occurred following each presentation of capsaicin solution. CTot was made, in real time, by two investigators and confirmed via review of the recorded cough airflow signal. Capsaicin concentration necessary to elicit a two cough threshold response (C2) within 30 seconds of presentation, on at least two (out of three) trials of that concentration, was identified from the cough count record. An average across all measurements was performed for the analysis. (NCT02240329)
Timeframe: Day 1

Interventioncough events following stimulation (Mean)
Individuals With TBI2.83

[back to top]

Average Urge to Cough (UTC) Following Administration of 200 Micro Mole Capsaicin Solution Concentration

"Following 30 seconds of tidal breathing (to allow for acclimation to the facemask), participants were instructed to take a sharp breath in whereupon the nebulized capsaicin solution was automatically administered by the dosimeter. Following each aerosol presentation, the participant was instructed to rate their UTC using a modified Borg Rating Scale where 1 = no UTC and 10 = maximum UTC. Between presentations, participants were given a minimum of a one-minute rest period where they were offered water. An average across all measurements was performed for the analysis." (NCT02240329)
Timeframe: Day 1

InterventionUnits on a Borg scale (Mean)
Individuals With TBI4.5

[back to top]

Change of Nasal Hyperreactivity in All Treatment Modalities.

change in the number of participants with nasal hyperreactivity in all treatment modalities (NCT02288156)
Timeframe: baseline, week 4

,,,
Interventionparticipants (Number)
Baselineweek 4
0.001mM84
0.01mM95
0.1mM75
Placebo98

[back to top]

Change in Visual Analogue Scale for Major Nasal Symptoms

patients score their main nasal complaints from 0 to 10 on a scale of 10, with 0 meaning no complaints and 10 meaning the worst complaints. This is done at baseline and after 4 weeks of treatment (NCT02288156)
Timeframe: Baseline and week 4

,,,
Interventionscore on a scale (Mean)
Week 4Baseline
0,01mM4.298.03
0,1mM3.668.36
0.001mM4.497.74
Placebo5.68.24

[back to top]

Change in Visual Analogue Scale for Individual Nasal Symptoms

patients score all kinds of nasal symptoms from 0 to 10 on a scale of 10, with 0 meaning no complaints and 10 meaning the worst complaints. This is done at baseline and after 4 weeks of treatment (NCT02288156)
Timeframe: Baseline, week 4

,,,
Interventionscore on a scale (Mean)
Rhinorrhea BaselineRhinorrhea Week 4
0.001mM4.2122.383
0.01mM5.9942.313
0.1mM7.5942.738
Placebo5.8063.018

[back to top]

Number of Adverse Events in All Treatment Groups

All reported AEs were entered into the AE section so please see AE table for specifics. (NCT02288156)
Timeframe: week 4

InterventionTotal number of events (Number)
0.1mM27
0.01mM24
0.001mM32
Placebo29

[back to top]

Number of Patients Without Improvement of Symptoms at the End of the Trial in All Treatment Modalities

(NCT02288156)
Timeframe: week 4, 12 and 26

InterventionParticipants (Count of Participants)
0.1mM10
0.01mM6
0.001mM10
Placebo12

[back to top]

Therapeutic Response in All Treatment Regimes

Evaluation of the therapeutic response (TRE) on a scale from 1 (= no relief of symptoms) to 5 (= total relief of symptoms). (NCT02288156)
Timeframe: week 4

Interventionpercentage of patients with improvement (Number)
0.1mM70
0.01mM82
0.001mM35
Placebo23

[back to top]

Difference of Average Pain Intensity (APID) From Pre-dose Baseline on the Last Individual Treatment Day

"Difference of average pain intensity from pre-dose baseline on the last individual treatment day (The last individual treatment day was the last day on which the patient had recorded the study drug applications within the patient diary). Pain intensity was assessed by the patient using 0-10 numerical rating scale (NRS).~Patients were given two 0-10 numerical rating scales (NRS) - to self-report of pain intensity at given time points for the period 0-8 hours post first dose and to self-report of average pain intensity they had at each treatment day. The left side of each scale (0) is marked 'no pain' and the right side of the scale (10) is marked 'worst pain possible'. APIDtime point = APItime point - PI baseline (time point is the last individual treatment day (either Day 1, 2, 3 or 4 after drug administration)).~Means reported are the adjusted means." (NCT02300311)
Timeframe: Baseline and 1 to 4 days

Interventionpoints on a scale (Mean)
Placebo-2.17
Finalgon® Cream (Nicoboxil/ Nonivamide)-5.13

[back to top]

Pain Intensity Difference (PID) From Pre-dose Baseline to 4 Hours After the First Trial Medication Application (PID4h)

Pain intensity was assessed on a 11-point numerical rating scale ranging from 0 (no pain) to 10 (worst pain possible) at pre-dose baseline and 0.5, 1, 2, 3 and 4 hours after trial medication application. The left side of each scale (0) is marked 'no pain' and the right side of the scale (10) is marked 'worst pain possible'. PID4h= PI(4h) - PI(baseline). Means reported are the adjusted means. (NCT02300311)
Timeframe: Baseline and 4 hours after trial medication application

Interventionpoints on a scale (Mean)
Placebo-0.77
Finalgon® Cream (Nicoboxil/ Nonivamide)-2.11

[back to top]

Pain Intensity Difference (PID) From Pre-dose Baseline to 8h After the First Trial Medication Application (PID8h)

"Pain intensity (PI) was assessed on a 11-point numerical rating scale ranging from 0 (no pain) to 10 (worst pain possible) at pre-dose baseline and 0.5, 1, 2, 3, 4, 6 and 8 hours after trial medication application.~The left side of each scale (0) is marked 'no pain' and the right side of the scale (10) is marked 'worst pain possible'.~PID8h= Pain intensity (PI)8h - PI(baseline).~Means reported are the adjusted means." (NCT02300311)
Timeframe: Baseline and 8 hours after trial medication application

Interventionpoints on a scale (Mean)
Placebo-0.98
Finalgon® Cream (Nicoboxil/ Nonivamide)-2.82

[back to top]

Patient's Assessment of the Efficacy on the Last Individual Treatment Day

Patients were asked to rate the effect of the study medication for relieving their low back pain using a 4-point verbal rating scale (1=Poor, 2= Fair, 3=Good, 4=Very Good). (NCT02300311)
Timeframe: 1 to 4 days

,
Interventionpercentage of participants (Number)
Very goodGoodFairPoorMissing
Finalgon® Cream (Nicoboxil/ Nonivamide)29.058.013.00.00.0
Placebo13.017.420.347.81.4

[back to top]

Capsaicin Sensitivity

"Each patient will be asked to rate their discomfort at the application site based on a 10 point numerical rating scale for cutaneous discomfort, ranging from 0 (no discomfort) to 10 (the worst discomfort imaginable)" (NCT02346903)
Timeframe: 30 minutes

Interventionscore on a scale (Mean)
Cardiac Catheterization Patients2.47

[back to top]

Chest Pain Score During PCI

"patients are asked to rate their chest pain on a scale of 0-10 (0 no pain, 10 worst pain imaginable) during balloon inflation during PCI" (NCT02346903)
Timeframe: approximately 1 hour

Interventionscore on a scale (Mean)
Cardiac Catheterization Patients2.90

[back to top]

Capsaicin Sensitivity

"Each patient will be asked to rate their discomfort at the application site based on a 10 point numerical rating scale for cutaneous discomfort, ranging from 0 (no discomfort) to 10 (the worst discomfort imaginable)" (NCT02346916)
Timeframe: 30 minutes

Interventionscore on a scale (Mean)
Cardiac Catheterization Patients2.05

[back to top]

Chest Pain

"Patients are asked to rate their chest pain on a scale of 0 No pain to 10 Worst pain imaginable during balloon inflation during PCI." (NCT02346916)
Timeframe: 2 hours

Interventionscore on a scale (Mean)
Cardiac Catheterization Patients2.50

[back to top]

Change in Pain Relief With Visual Analog (VAS) Pain Scale

The Visual Analog Scale (VAS) was used as the primary outcome measure to quantify pain on a scale of 0-10, with 0 being no pain and 10 being the worst pain. VAS was measured at weeks 2,4,6,8,10 and12 during each 12- week block. (NCT02441660)
Timeframe: Change in pain at 2,4,6,8, 10 and 12 weeks

,
Interventionscore on a scale (Mean)
2 weeks4 weeks6 weeks8 weeks10 weeks12 weeks
Control Group5.4945.6775.7684.8344.7534.311
Experimental Group3.5864.0414.9844.1844.2844.049

[back to top]

Change in Quality of Life as Measured by the World Health Organization Quality of Life (WHOQOL-BREF)

The World Health Organization Quality of Life (WHOQOL-BREF) questionnaire is a scale used to assess an individual's perception of their quality of life. Its domains include physical health, psychological health, social relationships, and patient environment. It is scored from 0-100, where lower scores indicate poorer perception of quality of life and higher scores indicate better perception. This scale was used to investigate if there was any pattern of change in QOL due to improved pain control. WHO-QOL-BREF was also measured every 4 weeks of each period. (NCT02441660)
Timeframe: Every 4 weeks for 12 weeks

,
Interventionscore on a scale (Mean)
4 weeks8 weeks12 weeks
Control Group80.9185.4287.42
Experimental Group79.2680.9174.90

[back to top]

Change in Spinal Cord Independence Measure (SCIM)

"The Spinal Cord Independence Measure (SCIM) is a reliable scale that measures proficiency of activities of daily living (ADL's) of patients with spinal cord injuries. (28) It is broken up into four subscales including self-care, respiration and sphincter control, and mobility with a total score combining all 3 outcomes.~It is scored from 0-100, where lower numbers indicate more dependence on others and higher numbers indicate less dependence. This tool can be applied practically to the study to investigate everyday function before and after patch application. SCIM was administered every 4 weeks of each period." (NCT02441660)
Timeframe: Every 4 weeks for12 weeks

,
Interventionscore on a scale (Mean)
4 weeks8 weeks12 weeks
Control Group18.8618.6618.86
Experimental Group20.3220.7019.23

[back to top]

Change in Nasal Blood Flow as Indicated by Change in Maximal Optical Density Assessed by Optical Rhinometry

Optical rhinometry provides continuous measurement of blood flow in nasal vessels (via optical density measurements), which serves as an indirect assessment of nasal congestion. A greater decrease in optical density (OD) from baseline indicates less nasal blood flow and decreased congestion relative to baseline. (NCT02493257)
Timeframe: baseline and 12 weeks

Interventionlog ratio of light in to light out (OD) (Median)
Intranasal Capsaicin-0.08
Vehicle Solution-0.05

[back to top]

Change in Nasal Blood Flow as Indicated by Change in Maximal Optical Density Assessed by Optical Rhinometry

Optical rhinometry provides continuous measurement of blood flow in nasal vessels (via optical density measurements), which serves as an indirect assessment of nasal congestion. A greater decrease in optical density (OD) from baseline indicates less nasal blood flow and decreased congestion relative to baseline. (NCT02493257)
Timeframe: baseline and 4 weeks

Interventionlog ratio of light in to light out (OD) (Median)
Intranasal Capsaicin-0.05
Vehicle Solution-0.05

[back to top]

Change in Total Symptom Score

The Total Symptom Score (TSS) uses a visual analog scale (VAS) to assess typical nasal symptoms of non-allergic rhinitis (NAR), including sneezing, nasal irritation, nasal obstruction, and nasal congestion. The TSS is based on a commonly used rhinitis rating system recommended by the FDA for clinical trial studies on non-allergic rhinitis. 4 symptoms (sneezing, nasal irritation, nasal obstruction, and nasal congestion) are rated on a VAS ranging from 0 (none, no distress) to 10 (agonizing, unbearable distress). The TSS total score is the sum of the VAS score for each of the 4 symptoms, with the TSS total score ranging from 0 (none, no distress) to 40 (agonizing, unbearable distress). (NCT02493257)
Timeframe: baseline and 12 weeks

Interventionscore on a scale (Median)
Intranasal Capsaicin-4.5
Vehicle Solution1.5

[back to top]

Change in Total Symptom Score

The Total Symptom Score (TSS) uses a visual analog scale (VAS) to assess typical nasal symptoms of non-allergic rhinitis (NAR), including sneezing, nasal irritation, nasal obstruction, and nasal congestion. The TSS is based on a commonly used rhinitis rating system recommended by the FDA for clinical trial studies on non-allergic rhinitis. 4 symptoms (sneezing, nasal irritation, nasal obstruction, and nasal congestion) are rated on a VAS ranging from 0 (none, no distress) to 10 (agonizing, unbearable distress). The TSS total score is the sum of the VAS score for each of the 4 symptoms, with the TSS total score ranging from 0 (none, no distress) to 40 (agonizing, unbearable distress). (NCT02493257)
Timeframe: baseline and 4 weeks

Interventionscore on a scale (Median)
Intranasal Capsaicin-5
Vehicle Solution2

[back to top]

AFI-intensity After Nociceptive Stimulation

AFI-intensity (delta F/F) at the 3rd fingertip, directly after application of grading nociceptive stimuli (NCT02537951)
Timeframe: Day 1, T=0h (AFI measurements), Day 1, T=6h (AFI measurements after lidocaine/prilocaine), Day 7 (AFI measurements after capsaicin)

Interventionunitless (Mean)
AFI Intensity in Healthy Volunteers0.60
Negative Control 1: Lidocaine/Prilocaine0.25
Negative Control 2: 8% Capsaicin0.50

[back to top]

Number of Patients With Decrease in POMwp of at Least 30% From Baseline

This outcome measures the pattern of number of patients with a decrease in POMwp of at least 30% from baseline at 1 hour after dosing on Day 2 evening. (NCT02700815)
Timeframe: Baseline and day 2

InterventionParticipants (Number)
Placebo Gel34
Capsaicin (0.075%) Gel150
Diclofenac (2%) Gel107
Diclofenac (2%) +Capsaicin (0.075%) Gel134

[back to top]

Change From Baseline in POMwp (cm) at Day 6 Morning

Pain on movement (POM) was used to assess pain measurement for back and neck pain. The standardized movements have been established for which the measurement was taken. POMwp was the POM measure that gave the highest score at baseline; i.e. POM of worst procedure. Pain intensity was assessed at rest after standing in an upright position relatively motionless for 1 minute. The pain was evaluated by asking patient 'How would you rate your pain right now?' and by using a visual analogue scale (VAS) ranging from 0-10 cm wherein 0 cm = no pain to 10 cm = worst pain possible. The results presented here are adjusted mean change from baseline and standard error for POMwp in centimeters (cm). (NCT02700815)
Timeframe: Baseline and Day 6

InterventionUnits on a scale (Least Squares Mean)
Placebo Gel-3.83
Capsaicin (0.075%) Gel-5.08
Diclofenac (2%) Gel-3.77
Diclofenac (2%) +Capsaicin (0.075%) Gel-4.88

[back to top]

Change From Baseline in Pressure Algometry (PA) at Day 2 Evening, Before Drug Application

PA is a method described to determine pressure pain threshold (PPT) by applying controlled pressure to a given body point. The results presented here are adjusted mean change from baseline and standard error for PA. (NCT02700815)
Timeframe: Baseline and Day 2

InterventionNewton/centimeter square (N/cm^2) (Least Squares Mean)
Placebo Gel3.89
Capsaicin (0.075%) Gel3.46
Diclofenac (2%) Gel3.00
Diclofenac (2%) +Capsaicin (0.075%) Gel3.77

[back to top]

Change From Baseline in Pressure Algometry (PA) at Day 6 Morning

PA is a method described to determine pressure pain threshold (PPT) by applying controlled pressure to a given body point. The results presented here are adjusted mean change from baseline and standard error for PA. (NCT02700815)
Timeframe: Baseline and Day 6

InterventionNewton/centimeter square (N/cm^2) (Least Squares Mean)
Placebo Gel8.01
Capsaicin (0.075%) Gel9.38
Diclofenac (2%) Gel7.64
Diclofenac (2%) +Capsaicin (0.075%) Gel9.66

[back to top]

Change in POM Between Baseline and Day 2 Evening, 1 Hour After Drug Application

Pain on movement (POM) was used to assess pain measurement for back and neck pain. The standardized movements have been established for which the measurement was taken. POMwp was the POM measure that gave the highest score at baseline; i.e. POM of worst procedure. Pain intensity was assessed at rest after standing in an upright position relatively motionless for 1 minute. The pain was evaluated by asking patient 'How would you rate your pain right now?' and by using a visual analogue scale (VAS) ranging from 0-10 centimeters (cm) wherein 0 cm = no pain to 10 cm = worst pain possible. The results presented here are adjusted mean change from baseline and standard error for POMwp in cm. (NCT02700815)
Timeframe: Baseline and Day 2

InterventionUnits on a scale (Least Squares Mean)
Placebo Gel-2.45
Capsaicin (0.075%) Gel-3.26
Diclofenac (2%) Gel-2.33
Diclofenac (2%) +Capsaicin (0.075%) Gel-3.05

[back to top]

Number of Patients With Decrease in POMwp of at Least 50% From Baseline

This outcome measures the pattern of number of patients with a decrease in POMwp of at least 50% from baseline at 1 hour after dosing on Day 2 evening. (NCT02700815)
Timeframe: Baseline and day 2

InterventionParticipants (Number)
Placebo Gel20
Capsaicin (0.075%) Gel95
Diclofenac (2%) Gel50
Diclofenac (2%) +Capsaicin (0.075%) Gel85

[back to top]

POMwp Area Under the Curve (AUC) Calculated From 0 to 72 Hours (h) (POMwp AUC(0-72 h))

This is a key secondary endpoint. AUC for POMwp calculated from 0 to 72 h that is for first three treatment days using the trapezoidal rule divided by the observation time. The results presented here are adjusted mean and standard error for POMwp AUC (0-72 h) in centimeters (cm). The AUC represents POMwp as an average over the first 3 treatment days (Day 1 until Day 4 morning) - it is not meant here as a pharmacokinetics (PK) parameter (concentration over time). (NCT02700815)
Timeframe: 0 to 72 hours after start of treatment

Interventioncm (Least Squares Mean)
Placebo Gel4.62
Capsaicin (0.075%) Gel3.95
Diclofenac (2%) Gel4.81
Diclofenac (2%) +Capsaicin (0.075%) Gel4.25

[back to top]

POMwp Area Under the Curve (AUC) Calculated From 0 to 120 Hours (h) (POMwp AUC(0-120 h))

This is a key secondary endpoint. AUC for POMwp calculated from 0 to 120 h that is for first five treatment days using the trapezoidal rule divided by the observation time. The results presented here are adjusted mean and standard error for POMwp AUC (0-120 h) in centimeters (cm). The AUC represents POMwp as an average over the first 5 treatment days (Day 1 until Day 6 morning) - it is not meant here as a PK parameter (concentration over time). (NCT02700815)
Timeframe: 0 to 120 hours after start of treatment

Interventioncm (Least Squares Mean)
Placebo Gel3.92
Capsaicin (0.075%) Gel3.10
Diclofenac (2%) Gel4.10
Diclofenac (2%) +Capsaicin (0.075%) Gel3.41

[back to top]

The Capsaicin-Induced Dermal Blood Flow (DBF)

Change from pre-capsaicin DBF adjusting for vehicle at 30 minutes is reported. The capsaicin induced dermal blood flow (DBF) was measured by laser Doppler imaging (LDI). (NCT02766517)
Timeframe: Baseline (pre-capsaicin) and on assessment day over approximately one hour, after at least a 4 month wash out from treatment in study NCT02163993

InterventionFlux mean (Mean)
Placebo606.1
120 mg Galcanezumab599.5
300 mg Galcanezumab689.2

[back to top] [back to top]

Percentage Peak-trough Fluctuation (%PTF), Calculated as [100*(Cmax,ss - Cpre,ss)/Cav,ss]

Percentage peak-trough fluctuation (%PTF) which was calculated as [100*(Cmax,ss - Cpre,ss)/Cav,ss] for Diclofenac. Descriptive statistics by race are reported in addition. (NCT03074162)
Timeframe: Pharmacokinetic samples were collected on Day 7 at pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours after the drug administration

,,
InterventionPercentage of Cav,ss (%) (Geometric Mean)
OverallBy Race: BlackBy Race: Caucasian
Diclofenac 2% (A)33.9553348.5571226.75129
Diclofenac 2% + Capsaicin 0.075% (B)26.6962015.0712839.96865
Voltarol® 2.32% Gel (R)24.7555825.8525724.25970

[back to top]

Maximum Plasma Concentration During a Dosage Interval (Cmax,ss) Obtained Directly From the Concentration-time Data for Diclofenac at Steady State (Day 7)

Cmax,ss, Maximum plasma of diclofenac concentration during a dosage interval obtained directly from the concentration-time data at steady state for diclofenac on day 7. Stratification by race was analysed using a supportive Analysis of Variance (ANOVA) yielding point estimates for each underlying pairwise comparison analog to the main analysis. As the resulting two Least Square Means and gMeans per treatment and race are very similar, only gMeans per treatment and race are presented. (NCT03074162)
Timeframe: Pharmacokinetic samples were collected on Day 7 at pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours after the drug administration

,,
InterventionNanogram/millilitre (ng/mL) (Geometric Mean)
OverallBy Race: BlackBy Race: Caucasian
Diclofenac 2% (A)6.78259.39234.7551
Diclofenac 2% + Capsaicin 0.075% (B)5.69647.38634.3416
Voltarol® 2.32% Gel (R)10.833014.80408.1371

[back to top]

Average Plasma Concentration (Cav,ss) for Diclofenac at Steady State

Average plasma concentration (Cav,ss) calculated as AUC0-t,ss divided by τ=12 hours (τ is the duration of the dosing interval). Descriptive statistics by race are reported in addition. (NCT03074162)
Timeframe: Pharmacokinetic samples were collected on Day 7 at pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours after the drug administration

,,
Interventionnanogram/ millilitre (ng/mL) (Geometric Mean)
OverallBy Race: BlackBy Race: Caucasian
Diclofenac 2% (A)3.90465.07752.9317
Diclofenac 2% + Capsaicin 0.075% (B)3.34804.46912.4754
Voltarol® 2.32% Gel (R)6.97028.80555.6259

[back to top]

Area Under the Plasma Concentration-time Curve (AUC) Over One Dosing Interval for Diclofenac at Steady State (AUC0-τ,ss) (τ = 12 Hours) (Day 7)

AUC0-τ,ss, Area under the plasma concentration-time curve (AUC) over one dosing interval at steady state for diclofenac at day 7 (τ = 12 hours). Stratification by race was analysed using a supportive Analysis of Variance (ANOVA) yielding point estimates for each underlying pairwise comparison analog to the main analysis. As the resulting two Least Square Means and Geometric Means (gMeans) per treatment and race are very similar, only gMeans per treatment and race are presented. (NCT03074162)
Timeframe: Pharmacokinetic samples were collected on Day 7 at pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours after the drug administration

,,
InterventionHour*nanogram/millilitre (h*ng/mL) (Geometric Mean)
OverallBy race: BlackBy race: Caucasian
Diclofenac 2% (A)46.85560.93035.182
Diclofenac 2% + Capsaicin 0.075% (B)40.17553.62829.704
Voltarol® 2.32% Gel (R)83.644105.67067.513

[back to top]

Time to Maximum Observed Plasma Concentration at Steady State for Diclofenac at Steady State (Tmax,ss) (Day 7)

tmax,ss, Time to maximum observed plasma concentration at steady state for diclofenac at day 7 (tmax,ss). Descriptive statistics by race are reported in addition. (NCT03074162)
Timeframe: Pharmacokinetic samples were collected on Day 7 at pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours after the drug administration

,,
InterventionHour (h) (Median)
OverallBy Race: BlackBy Race: Caucasian
Diclofenac 2% (A)0.750.002.00
Diclofenac 2% + Capsaicin 0.075% (B)1.000.503.50
Voltarol® 2.32% Gel (R)0.000.004.00

[back to top]

Gracely Sensory Scale Pain Rating Changes in Response to Lidocaine and Capsaicin Creams and tDCS

The Gracely Sensory Scale allows participants to rate the intensity of heat pain stimuli on a scale from 0 to 20, with 0 indicating no pain sensation and 20 indicating extremely intense pain. The outcome measure data table shows mean pain ratings for the lidocaine, capsaicin, and neutral creams after enhancement, inhibition, or sham tDCS stimulation. (NCT03102710)
Timeframe: up to 2 weeks

,,
Interventionunits on a scale (Mean)
Pain rating on nocebo creamPain rating on placebo creamPain rating on neutral cream
Sham tDCS9.017.387.88
tDCS Enhancement8.547.298.10
tDCS Inhibition8.806.417.96

[back to top]

fMRI Resting States Functional Connectivity Changes During Pain Stimulation

"We measured changes in blood oxygen level-dependent (BOLD) activity in the brain during pain stimulation. In the outcome measure data table, placebo contrast indicates lidocaine - neutral and nocebo contrast indicates capsaicin - neutral." (NCT03102710)
Timeframe: up to 2 weeks

,,
InterventionArbitrary unit (Mean)
BOLD activity change in mPFC/ACC: placebo contrastBOLD activity change in mPFC/ACC: nocebo contrastBOLD activity in the left insula: placebo contrastBOLD activity in the left insula: nocebo contrast
Sham tDCS-0.170.250.180.30
tDCS Enhancement0.140.260.110.08
tDCS Inhibition0.500.270.210.16

[back to top]

Comparison of Functional Connectivity Changes of the DLPFC Before and After tDCS Stimulation

We investigated the effects of cathodal (inhibition) and anodal (enhancement) tDCS on rDLPFC functional connectivity (FC) with the supplementary motor area (SMA) and anterior insula. Higher Fisher Z-scores represent greater resting-state functional connectivity. (NCT03102710)
Timeframe: up to 2 weeks

,,
InterventionFisher Z value (Mean)
rDLPFC-SMA Functional Connectivity (post-pre)rDLPFC-Insula Functional Connectivity (post-pre)
Sham tDCS0.080.07
tDCS Enhancement-0.11-0.13
tDCS Inhibition-0.09-0.13

[back to top]

Reflexive Cough Testing (With Urge-to-Cough)

Reflexive cough testing will use a capsaicin challenge that will assess individual's cough motor and cough sensory thresholds. A modified Borg scale ranging from 0 (no cough) to 10 (maximal urge to cough) will be used to quantify these thresholds. A cough sensory threshold will be defined as a concentration of capsaicin eliciting a perceived urge to cough of 1 (very slight) >2/3 trials. A cough motor threshold will be the lowest concentration of capsaicin eliciting >2 cough responses in 2/3 trials. (NCT03122145)
Timeframe: Single assessment time period

Interventionunits on a scale (Median)
cough motor thresholdcough sensory threshold
Healthy Volunteers35

[back to top]

Duration of Laryngeal Vestibule Closure (dLVC)

LVC temporal measures will be used to calculate the duration of laryngeal vestibule closure (dLVC) (NCT03122145)
Timeframe: Single Visit

InterventionMilliseconds (Mean)
5 swallows with head in chin up position5 swallows with e-stim to anterior neck5 swallows with head in neutral position
Healthy Volunteers - Experiment 2435429461

[back to top]

Voluntary Peak Cough Flow Testing (With Electronic Peak Cough Flow Meter Device)

Voluntary peak cough flow testing will be used to capture the volume of air expelled in the 1st second of cough as measured in PEF and FEV1. (NCT03122145)
Timeframe: Baseline

Interventionliters per second (Mean)
Healthy Volunteers3.15

[back to top]

Laryngeal Vestibule Closure Reaction Time (LVCrt)

LVC temporal measures will be used to calculate the laryngeal vestibule closure reaction time (LVCrt) (NCT03122145)
Timeframe: Single Visit

InterventionMilliseconds (Mean)
5 swallows with head in chin up position5 swallows with e-stim to anterior neck5 swallows with head in neutral position
Healthy Volunteers - Experiment 2181174169

[back to top]

Percentage of Subjects With 50% or Greater Pain Score Reduction From Baseline to Day 8 Post Study Drug Treatment.

To evaluate the percentage of subjects who experience ≥50% reduction in osteoarthritis knee pain in the target knee compared with baseline after a 7 day period. Subjects in the once daily application group recorded their knee pain in a diary twice: at 12 hrs (± 1 hr) after their initial application and then again within ≤30 minutes before their daily topical application which was to be applied at 24 hrs (± 1 hr) after their previous day's application on all subsequent study days. Subjects in the twice daily application group recorded their knee pain in a diary within ≤30 minutes before each application on all study days. Subjects used a 100mm visual analogue scale when assessing their knee pain. (NCT03124407)
Timeframe: Study Days 1-7

Interventionpercentage of subjects (Number)
Once Daily-Active42.11
Once Daily-Vehicle25
Twice Daily-Active47.37
Twice Daily-Vehicle40

[back to top]

Percentage of Subjects With 50% or Greater Pain Score Reduction From Baseline to 24 Hours After First Dose of Study Drug Treatment.

To evaluate the percentage of subjects who experience ≥50% reduction in osteoarthritis knee pain in the target knee compared with baseline at 24 hours following the first study drug treatment. Subjects in the once daily application group recorded their knee pain in a diary twice: at 12 hrs (± 1 hr) after their initial application and then again within ≤30 minutes before their daily topical application which was to be applied at 24 hrs (± 1 hr) after their previous day's application on all subsequent study days. Subjects in the twice daily application group recorded their knee pain in a diary within ≤30 minutes before each application on all study days. Subjects used a 100mm visual analogue scale when assessing their knee pain. (NCT03124407)
Timeframe: Study Day 2

Interventionpercentage of subjects (Number)
Once Daily-Active27.03
Once Daily-Vehicle20.0
Twice Daily-Active23.08
Twice Daily-Vehicle20.0

[back to top]

Percentage of Subjects With 50% or Greater Pain Score Reduction From Baseline to Day 28 Post Study Drug Treatment.

To evaluate the percentage of subjects who experience ≥50% reduction in osteoarthritis knee pain in the target knee compared with baseline after 28 days. Subjects in the once daily application group recorded their knee pain in a diary twice: at 12 hrs (± 1 hr) after their initial application and then again within ≤30 minutes before their daily topical application which was to be applied at 24 hrs (± 1 hr) after their previous day's application on all subsequent study days. Subjects in the twice daily application group recorded their knee pain in a diary within ≤30 minutes before each application on all study days. Subjects used a 100mm visual analogue scale when assessing their knee pain. (NCT03124407)
Timeframe: Study Days 1-28

Interventionpercentage of subjects (Number)
Once Daily-Active53.85
Once Daily-Vehicle26.32
Twice Daily-Active57.89
Twice Daily-Vehicle47.37

[back to top]

Nausea Visual Analog Scale

Nausea visual analog scale, ranging from 0-100 mm, high measurement indicates worse nausea (NCT03223350)
Timeframe: 30 minutes

Interventionmm (Mean)
Capsaicin41
Placebo61

[back to top]

Number of Subjects With Skin Reactions of Erythema or Pruritus.

Investigator reports of erythema or pruritus at the site of study drug application. (NCT03528369)
Timeframe: Study Day 1 through Study Day 35 after the first application of study drug (Study Day 1)

,,
Interventionparticipants (Number)
ErythemaPruritus
CGS-200 Vehicle00
CGS-200-112
CGS-200-512

[back to top]

Primary Efficacy Endpoint: Change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Score From Baseline to Day 35

"The Primary Efficacy endpoint of this study will be to examine the extent of change in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score, relative to baseline, provided by once daily, one-hour application of Vehicle (CGS-200-0), CGS-200-1 and CGS-200-5 at Baseline (< 30 minutes prior to first daily application) and Day 35 (31 days after fourth daily application).~The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score is 5 questions relating to pain that the subject responds to using a 100mm visual analogue scale. The minimum score is 0 and the maximum score is 500. Reduction in pain is expressed as a difference from baseline to Study Day 35. Positive numbers indicate increases and negative numbers indicate decreases. ." (NCT03528369)
Timeframe: 35 days after the last dose of study drug on Day 4

Interventionunits on a scale (Mean)
CGS-200-1-130.7
CGS-200-5-159.7
CGS-200 Vehicle-99.0

[back to top]

Western Ontario and McMaster Universities Osteoarthritis (WOMAC) Index Total Scores (Pain, Stiffness and Function).

"Day 5, 19, 35, 64 and 94 Western Ontario and McMaster Universities Osteoarthritis (WOMAC) Index total scores (pain, stiffness and function) from Baseline.~The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) total score is 24 questions relating to pain, stiffness and physical function that the subject responds to using a 100mm visual analogue scale. The minimum score is 0 and the maximum score is 2400. Positive numbers indicate increases and negative numbers indicate decreases." (NCT03528369)
Timeframe: Day 5, 19, 35, 64 and 94 days after the last dose of study drug on Study Day 4

,,
Interventionunits on a scale (Mean)
Day 5 WOMAC Total Score Change from BaselineDay 19 WOMAC Total Score Change from BaselineDay 35 WOMAC Total Score Change from BaselineDay 64 WOMAC Total Score Change from BaselineDay 94 WOMAC Total Score Change from Baseline
CGS-200 Vehicle-288.1-285.3-435.8-317.2-345.9
CGS-200-1-548.8-582.8-544.5-330.6-491.9
CGS-200-5-716.1-820.9-737.5-745.2-710.8

[back to top]

Number of Subjects With Durability of Efficacy Response

Subjects who had a clinical response (i.e., reduction of at least 50% in WOMAC pain score) at the Day 5 visit and who remained at this reduction of pain score or lower at Days 19, 35, 64, and the Day 94 visit were considered to have a durable clinical response through Day 94. Subjects who had a clinical response at no more than one of the post Day 5 visits were considered to have a durable response through the last day at which reduction in WOMAC pain score is at least 50%. Subjects who had less than 50% WOMAC pain score reduction on two or more of the post Day 5 visits were considered to have failed to achieve a durable clinical response. (NCT03528369)
Timeframe: Days 35, 64 and 94 day after the last dose of study drug on Study Day 4

InterventionParticipants (Count of Participants)
Day 3572515815Day 3572515816Day 3572515817Day 64 Responders72515815Day 64 Responders72515816Day 64 Responders72515817Day 94 Responders72515815Day 94 Responders72515816Day 94 Responders72515817
Non-RespondersResponders
CGS-200-115
CGS-200-519
CGS-200 Vehicle11
CGS-200-125
CGS-200-522
CGS-200 Vehicle29
CGS-200-15
CGS-200-523
CGS-200 Vehicle9
CGS-200-135
CGS-200-518
CGS-200 Vehicle31
CGS-200-110
CGS-200 Vehicle10
CGS-200-130
CGS-200 Vehicle30

[back to top]

Western Ontario and McMaster Universities Osteoarthritis (WOMAC) Index Stiffness Scores.

"Day 5, 19, 35, 64 and 94 Western Ontario and McMaster Universities Osteoarthritis (WOMAC) Index Stiffness Scores.~The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) total score is 2 questions relating to stiffness that the subject responds to using a 100mm visual analogue scale. The minimum score is 0 and the maximum score is 200. Positive numbers indicate increases and negative numbers indicate decreases." (NCT03528369)
Timeframe: Day 5, 19, 35, 64 and 94 days after the last dose of study drug on Study Day 4

,,
Interventionunits on a scale (Mean)
Day 5 WOMAC Stiffness Score Change from BaselineDay 19 WOMAC Stiffness Score Change from BaselineDay 35 WOMAC Stiffness Score Change from BaselineDay 64 WOMAC Stiffness Score Change from BaselineDay 94 WOMAC Stiffness Score Change from Baseline
CGS-200 Vehicle-25.6-26.8-39.8-28.1-31.9
CGS-200-1-50.7-52.2-46.0-32.2-42.7
CGS-200-5-59.6-65.5-54.8-59.5-56.8

[back to top]

Western Ontario and McMaster Universities Osteoarthritis (WOMAC) Index Function Scores.

"Day 5, 19, 35, 64 and 94 Western Ontario and McMaster Universities Osteoarthritis (WOMAC) Index Function Scores.~The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Function score is 17 questions relating to physical function that the subject responds to using a 100mm visual analogue scale. The minimum score is 0 and the maximum score is 1700. Positive numbers indicate increases and negative numbers indicate decreases." (NCT03528369)
Timeframe: Day 5, 19, 35, 64 and 94 days after the last dose of study drug on Study Day 4

,,
Interventionunits on a scale (Mean)
Day 5 WOMAC Function Score Change from BaselineDay 19 WOMAC Function Score Change from BaselineDay 35 WOMAC Function Score Change from BaselineDay 64 WOMAC Function Score Change from BaselineDay 94 WOMAC Function Score Change from Baseline
CGS-200 Vehicle-198.1-192.1-296.9-213.7-233
CGS-200-1-385.0-398.7-367.8-218.9-337.5
CGS-200-5-499.0-583.7-523.0-515.9-506.5

[back to top]

Patient Reported Burning-Stinging Pain (BSP) During Application of Study Drug.

The average amount of burning-sting pain as reported by the subject using a 0 - 10 numerical rating scale (NRS). Higher scores indicate more pain. (NCT03528369)
Timeframe: 60 minutes after study drug application on Study Days 1,2,3,4

,,
Interventionunits on a scale (Mean)
Mean Burning-Stinging Pain on Day 1Mean Burning-Stinging Pain on Day 2Mean Burning-Stinging Pain Day 3Mean Burning-Stinging Pain Day 4
CGS-200 Vehicle0.360.490.220.20
CGS-200-11.360.750.700.56
CGS-200-52.701.711.531.47

[back to top]

Secondary Efficacy Endpoint #1: Extent of Change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Score From Baseline to Day 5, 19, 64 and 94.

"The extent of change in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score, relative to baseline, provided by once daily, one-hour application of CGS-200-0, CGS-200-1 and CGS-200-5 from Baseline to Day 5, 19, 64 and Day 94.~The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score is 5 questions relating to pain that the subject responds to using a 100mm visual analogue scale. The minimum score is 0 and the maximum score is 500. Positive numbers indicate increases and negative numbers indicate decreases." (NCT03528369)
Timeframe: Days 5, 19, 65 and 94 after the last dose of study drug on Day 4

,,
Interventionunits on a scale (Mean)
Day 5 WOMAC Pain Score Change from BaselineDay 19 WOMAC Pain Score Change from BaselineDay 64 WOMAC Pain Score Change from BaselineDay 94 WOMAC Pain Score Change from Baseline
CGS-200 Vehicle-64.5-66.475.4-80.1
CGS-200-1-113.1-131.8-79.5-111.8
CGS-200-5-157.5-171.7-169.8-147.6

[back to top]

"Mean Change From Baseline in KOOS Pain With Walking Single Question Score by Subject Type"

"The KOOS (KOOS = Knee Injury and Osteoarthritis Outcome Score) was developed as an extension of the WOMAC (Western Ontario and McMaster Universities Arthritis Index) to evaluate the dimensions of knee osteoarthritis associated pain and injury. It includes 5 separately scored subscales: Pain, Symptoms (including stiffness), Function (Daily Living), Function (Sports and Recreational Activities), and knee-related Quality of Life. Each subscale score is rated on a 5-point scale (i.e., 0 to 4). The previous week is the time period evaluated when answering the questions. A normalized score (100 indicating no symptoms and 0 indicating extreme symptoms) is calculated for each subscale. The KOOS Pain with Walking is a single question from the KOOS Pain subscale.~The KOOS was administered on Day 1 (Baseline) and Week 8.~Higher scores (or positive change from baseline) indicate improvement." (NCT03661996)
Timeframe: Baseline, Week 8

Interventionscore on a scale (Least Squares Mean)
Single Knee Injection (Unilateral Mod-Sev OA Knee Pain) INDEX KNEE21.08
Single Knee Injection (Non-Index Knee PJR/TJR) INDEX KNEE25.26
Bilateral Knee Injection (Bilateral Mod-Sev OA Knee Pain) INDEX KNEE25.85
Bilateral Knee Injection (Bilateral Mod-Sev OA Knee Pain) NON-INDEX KNEE23.34

[back to top]

"Mean Change From Baseline in KOOS Pain Subscale Score by Subject Type"

"The KOOS (KOOS = Knee Injury and Osteoarthritis Outcome Score) was developed as an extension of the WOMAC (Western Ontario and McMaster Universities Arthritis Index) to evaluate the dimensions of knee osteoarthritis associated pain and injury. It includes 5 separately scored subscales: Pain, Symptoms (including stiffness), Function (Daily Living), Function (Sports and Recreational Activities), and knee-related Quality of Life. Each subscale score is rated on a 5-point scale (i.e., 0 to 4). The previous week is the time period evaluated when answering the questions. A normalized score (100 indicating no symptoms and 0 indicating extreme symptoms) is calculated for each subscale.~The KOOS was administered on Day 1 (Baseline) and Week 8.~Higher scores (or positive change from baseline) indicate improvement." (NCT03661996)
Timeframe: Baseline, Week 8

Interventionscore on a scale (Least Squares Mean)
Single Knee Injection (Unilateral Mod-Sev OA Knee Pain) INDEX KNEE22.45
Single Knee Injection (Non-Index Knee PJR/TJR) INDEX KNEE23.90
Bilateral Knee Injection (Bilateral Mod-Sev OA Knee Pain) INDEX KNEE25.62
Bilateral Knee Injection (Bilateral Mod-Sev OA Knee Pain) NON-INDEX KNEE22.10

[back to top]

Mean Change From Baseline in Average Daily Pain With Walking NPRS (0-10) Score by Subject Type

"The pain with walking Numerical Pain Rating Scale (NPRS) (0-10, 0 being no pain, 10 being greatest pain) collected subjects' average pain with walking over the past 24 hours. Subjects recorded the pain in their target knee, either the index knee or additionally the non-index knee in the case of bilateral subjects. The NPRS was collected at Day 1 (Baseline) and Week 8.~Lower scores (or negative change from baseline) indicate improvement" (NCT03661996)
Timeframe: Baseline, Week 8

Interventionscore on a scale (Least Squares Mean)
Single Knee Injection (Unilateral Mod-Sev OA Knee Pain) INDEX KNEE-3.48
Single Knee Injection (Non-Index Knee PJR/TJR) INDEX KNEE-3.52
Bilateral Knee Injection (Bilateral Mod-Sev OA Knee Pain) INDEX KNEE-4.02
Bilateral Knee Injection (Bilateral Mod-Sev OA Knee Pain) NON-INDEX KNEE-3.72

[back to top]

"Mean Change From Baseline in KOOS Function (Sport and Recreational Activities) Subscale Score by Subject Type"

"The KOOS (KOOS = Knee Injury and Osteoarthritis Outcome Score) was developed as an extension of the WOMAC (Western Ontario and McMaster Universities Arthritis Index) to evaluate the dimensions of knee osteoarthritis associated pain and injury. It includes 5 separately scored subscales: Pain, Symptoms (including stiffness), Function (Daily Living), Function (Sports and Recreational Activities), and knee-related QOL. Each subscale score is rated on a 5-point scale (i.e., 0 to 4). The previous week is the time period evaluated when answering the questions. A normalized score (100 indicating no symptoms and 0 indicating extreme symptoms) is calculated for each subscale.~The KOOS was administered on Day 1 (Baseline) and Week 8.~Higher scores (or positive change from baseline) indicate improvement." (NCT03661996)
Timeframe: Baseline, Week 8

Interventionscore on a scale (Least Squares Mean)
Single Knee Injection (Unilateral Mod-Sev OA Knee Pain) INDEX KNEE25.17
Single Knee Injection (Non-Index Knee PJR/TJR) INDEX KNEE33.11
Bilateral Knee Injection (Bilateral Mod-Sev OA Knee Pain) INDEX KNEE27.80
Bilateral Knee Injection (Bilateral Mod-Sev OA Knee Pain) NON-INDEX KNEE24.80

[back to top]

"Mean Change From Baseline in KOOS Function (Daily Living) Subscale Score by Subject Type"

"The KOOS (KOOS = Knee Injury and Osteoarthritis Outcome Score) was developed as an extension of the WOMAC (Western Ontario and McMaster Universities Arthritis Index) to evaluate the dimensions of knee osteoarthritis associated pain and injury. It includes 5 separately scored subscales: Pain, Symptoms (including stiffness), Function (Daily Living), Function (Sports and Recreational Activities), and knee-related QOL. Each subscale score is rated on a 5-point scale (i.e., 0 to 4). The previous week is the time period evaluated when answering the questions. A normalized score (100 indicating no symptoms and 0 indicating extreme symptoms) is calculated for each subscale.~The KOOS was administered on Day 1 (Baseline) and Week 8.~Higher scores (or positive change from baseline) indicate improvement." (NCT03661996)
Timeframe: Baseline, Week 8

Interventionscore on a scale (Least Squares Mean)
Single Knee Injection (Unilateral Mod-Sev OA Knee Pain) INDEX KNEE20.86
Single Knee Injection (Non-Index Knee PJR/TJR) INDEX KNEE25.66
Bilateral Knee Injection (Bilateral Mod-Sev OA Knee Pain) INDEX KNEE25.57
Bilateral Knee Injection (Bilateral Mod-Sev OA Knee Pain) NON-INDEX KNEE22.26

[back to top]

Determination of Optimal Procedure for Administering CNTX-4975-05 With Regards to Pain, Participant Satisfaction, and Investigator's Satisfaction

"A composite score was calculated for each of the 5 treatment regimens by summing the scores of three assessments: (1) procedure pain 30 minutes after injection of CNTX-4975-05 on a 0-4 scale, 0 was best indicating no procedure pain, 4 was worst indicating severe procedure pain; (2) assessment of subjects' satisfaction with the regimen on a scale of 1 (completely dissatisfied) to 7 (completely satisfied), 1 was worst and 7 was best; and (3) assessment of investigators' satisfaction with the regimen on a scale of 1 (completely dissatisfied) to 7 (completely satisfied), 1 was worst and 7 was best.~The procedure pain at 30 minutes was reversed to a 1-7 scale so 7 was best indicating no procedure pain and 1 was worst indicating severe procedure pain. The three assessments were summed for a total score from 3-21, 3 being the worst outcome and 21 being the best outcome. The geometric mean of the scores was derived for each group.~All assessments were administered on Day 1 (Baseline)." (NCT03661996)
Timeframe: Day 1 assessments

Interventionscore on a scale (Geometric Least Squares Mean)
Group 1. Breg Cooling Control17.18
Group 2. Gel Pack Cooling18.26
Group 3. Shortened Gel Pack Cooling16.48
Group 4. Single Needle Injection Gel Pack Cooling - 2% Lidocaine17.40
Group 5. Single Needle Injection Gel Pack Cooling - 1% Lidocaine16.00

[back to top]

"Mean Change From Baseline in KOOS Symptoms Subscale Score by Subject Type"

"The KOOS (KOOS = Knee Injury and Osteoarthritis Outcome Score) was developed as an extension of the WOMAC (Western Ontario and McMaster Universities Arthritis Index) to evaluate the dimensions of knee osteoarthritis associated pain and injury. It includes 5 separately scored subscales: Pain, Symptoms (including stiffness), Function (Daily Living), Function (Sports and Recreational Activities), and knee-related Quality of Life. Each subscale score is rated on a 5-point scale (i.e., 0 to 4). The previous week is the time period evaluated when answering the questions. A normalized score (100 indicating no symptoms and 0 indicating extreme symptoms) is calculated for each subscale.~The KOOS was administered on Day 1 (Baseline) and Week 8.~Higher scores (or positive change from baseline) indicate improvement." (NCT03661996)
Timeframe: Baseline, Week 8

Interventionscore on a scale (Least Squares Mean)
Single Knee Injection (Unilateral Mod-Sev OA Knee Pain) INDEX KNEE17.15
Single Knee Injection (Non-Index Knee PJR/TJR) INDEX KNEE20.41
Bilateral Knee Injection (Bilateral Mod-Sev OA Knee Pain) INDEX KNEE20.05
Bilateral Knee Injection (Bilateral Mod-Sev OA Knee Pain) NON-INDEX KNEE18.40

[back to top]

"Mean Change From Baseline in KOOS Knee-Related Quality of Life Subscale Score by Subject Type"

"The KOOS (KOOS = Knee Injury and Osteoarthritis Outcome Score) was developed as an extension of the WOMAC (Western Ontario and McMaster Universities Arthritis Index) to evaluate the dimensions of knee osteoarthritis associated pain and injury. It includes 5 separately scored subscales: Pain, Symptoms (including stiffness), Function (Daily Living), Function (Sports and Recreational Activities), and knee-related QOL. Each subscale score is rated on a 5-point scale (i.e., 0 to 4). The previous week is the time period evaluated when answering the questions. A normalized score (100 indicating no symptoms and 0 indicating extreme symptoms) is calculated for each subscale.~The KOOS was administered on Day 1 (Baseline) and Week 8.~Higher scores (or positive change from baseline) indicate improvement." (NCT03661996)
Timeframe: Baseline, Week 8

Interventionscore on a scale (Least Squares Mean)
Single Knee Injection (Unilateral Mod-Sev OA Knee Pain) INDEX KNEE22.10
Single Knee Injection (Non-Index Knee PJR/TJR) INDEX KNEE16.75
Bilateral Knee Injection (Bilateral Mod-Sev OA Knee Pain) INDEX KNEE21.52
Bilateral Knee Injection (Bilateral Mod-Sev OA Knee Pain) NON-INDEX KNEE19.40

[back to top]